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Over the past two decades enormous progress in the comprehension of the 
pathogenesis of cancer has been made. Cancer is a lethal disorder 
characterized by the development of abnormalities in cells causing 
uncontrollable and fast growth and division due to a combination of mutagenic 
stages. As a consequence of these mutations, cancer cells get a battery of 
specific properties such as limitless proliferation potential, self-sufficiency in 
growth signals and resistance to growth inhibitory signals, as well as evasion 
from apoptotic cues, which, in a normal situation, would contain their growth. 
Besides, tumors have developed diverse methods to attain further support 
through interactions with surrounding stromal cells, promoting their 
angiogenesis, tissue invasion and metastasis to distant organs, along with 
evasion from immune detection.  
To date, the most common therapies in the fight against cancer are 
radiotherapy and chemotherapy. Although many advances have been achieved 
in conventional treatments, bioaccessibility of these drugs to tumor tissue is 
limited, large doses are required, leading to high toxicity to normal cells along 
with an increased incidence of MDR. Therefore, there has been an enormous 
interest in the research of more efficient therapeutic strategies that has 
prompted toward the development of novel cancer therapies over recent years.  
Nanotechnology offers a great opportunity in cancer treatment based on the 
concept that a drug formulated in NPs can alter its pharmacokinetics enhancing 
the treatment ability to target and kill cells of diseased tissues/organs while 
affecting as few healthy cells as possible. Depending on the properties of the 
carrier, large variations in drug pharmacokinetics with major clinical 
implications may occur. In particular, sterically stabilized nanocarriers with a 
biomimetic coating (stealth nanocarriers) show an increased blood circulation 
and potential to accumulate predominantly in pathological sites with 
compromised leaky vasculature. Defective vascular architecture coupled with 
poor lymphatic drainage is common to many kinds of solid tumors and has 
been exploited to promote drug accumulation in tumor site (the so-called “EPR 
effect”). The further development of the concept of pharmaceutical biomimetic 
nanocarriers implies exploitation of differences between cancer and normal 
cells. Surface engineering of nanocarriers with specific ligands able to interact 
with cell surface structures overexpressed in cancer cells (particular antigens, 
peptide receptors, folate, transferring and integrin surface receptors) or tumor 
vasculature is a fascinating option for improving the specificity of anticancer 
treatments. Another advantage of the NP-based approach relies on the 
prolongation of drug half-life in the circulation and at target site, which could 
in theory reduce the number of administrations with consequent improvement 
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of the patient compliance. It has been suggested also that drug accumulation 
and slow release inside tumor cells can be useful to circumvent MDR. With 
the aim to increase treatment efficacy, combination chemotherapy has long 
been adopted as the standard of care against many cancer types. It is generally 
acknowledged that through the proper drug combination the treatment can 
promote synergistic actions, improve target selectivity and reduce the 
development of MDR.  
PDT has emerged as a popular adjuvant therapy for cancer and has been 
approved as a primary treatment option for certain neoplastic conditions 
including inoperable esophageal tumors, head and neck cancers, and 
microinvasive endo-bronchial non-small cell lung carcinoma. PDT is also 
being investigated in preclinical and clinical studies for other cancer types 
including breast, prostate and ovarian cancers. PDT aims at selectively 
targeting neoplastic lesions by the combined action of a PS and visible light, 
which generally produces reactive oxygen species (mainly singlet oxygen). 
Selectivity is achieved partly by the accumulation of the PS in the malignant 
cells/tissue, and partly by restricting the application of the incident light to the 
desired area. PDT offers various treatment options in cancer management and 
has been used for localized superficial or endoluminal malignant and 
premalignant conditions. Its application has also been recently expanded to 
solid tumors. At present, regulatory approval for PDT has been obtained for 
selected tumors using for example Photofrin®, Foscan®, Levulan® and most 
recently Metvix®. There are several technical issues hampering the application 
of PDT in a wide range of diseases. First it is a difficult undertaking to prepare 
pharmaceutical formulations that enable parenteral administration of PS since 
most of them are hydrophobic and aggregate easily under physiological 
conditions. Secondly, the selective accumulation to diseased tissues is often 
not high enough for clinical use. In order to improve photodynamic-based 
treatments, several combination regimens, in which PDT has been associated 
with both traditional and innovative therapeutic approaches for cancer 
treatment have been proposed to increase the therapeutic effectiveness and to 
eradicate completely the tumor. 
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1.1 Nanotechnology in biomedical field 
Nanotechnology is defined by the National Nanotechnology Initiative 
(http://www.nano.gov) as research and technology development at the atomic, 
molecular, or macromolecular scale leading to the controlled creation and use 
of structures, devices, and systems with a length scale of approximately 100 
nm (Figure 1).  
 
 
Figure 1. Examples of nanotechnology platforms used in drug development1. 
 
The term "nanomedicine" refers to the application of nanotechnologies to the 
biomedical field for controlled drug delivery as well as for diagnostic 
purposes. In the past 30 years, the explosive growth of nanotechnology has 
burst into challenging innovations in pharmacology, which is in the process of 
revolutionizing the delivery of biologically active compounds. Thus, several 
reviews aimed to analyze and to discuss the impact of nanotechnology in 
pharmacology to improve treatments of various diseases considered as the 
major health threats (cancer, infections, metabolic diseases, etc.) have been 
published 2,3,4,5,6,7,8,9. Treatments of these severe diseases generally involve 
                                                           
1W. C. Zamboni, V. Torchilin, A. K. Patri, J. Hrkach, S. Stern, R. Lee, A. Nel, N. J. Panaro, and P. Grodzinski, 
"Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance," Clin.Cancer Res. 18, 
no. 12 (2012). 
2S. Bamrungsap, Z. Zhao, T. Chen, L. Wang, C. Li, T. Fu, and W. Tan, "Nanotechnology in therapeutics: a focus 
on nanoparticles as a drug delivery system," Nanomedicine.(Lond) 7, no. 8 (2012). 
3P. Couvreur and C. Vauthier, "Nanotechnology: intelligent design to treat complex disease," Pharm.Res. 23, no. 
7 (2006). 
4T. L. Doane and C. Burda, "The unique role of nanoparticles in nanomedicine: imaging, drug delivery and 
therapy," Chem.Soc.Rev. 41, no. 7 (2012). 
5O. M. Koo, I. Rubinstein, and H. Onyuksel, "Role of nanotechnology in targeted drug delivery and imaging: a 
concise review," Nanomedicine. 1, no. 3 (2005). 
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highly toxic compounds for healthy tissues, where the use of traditional 
pharmaceutical formulations is considerably limited by the occurrence of 
sometime dramatic side effects.  
Currently, several nanosized carriers, made of different materials such as 
lipids, polymers, metals, inorganic materials have been proposed in the 
biomedical field as diagnostic and therapeutic tools. In drug delivery 
technologies, nanocarriers are designed (i) to protect a drug from in vivo 
degradation; (ii) to enhance drug absorption by facilitating diffusion through 
epithelium; (iii) to modify pharmacokinetics and drug tissue distribution 
profile; (iv) to improve intracellular penetration and subcellular distribution. 
Furthermore, surface modification of pharmaceutical nanocarriers is normally 
used to control their biological fate in a desirable fashion and touse them 
simultaneously as therapeutic or diagnostic platform (theranostics). The most 
important results of such modification include an increased stability and half-
life of nanocarriers in the circulation, passive or active targeting into the 
required pathological zone, responsiveness to local physiological stimuli such 
as pathology-associated changes in local pH and/or temperature, and ability to 
serve as imaging/contrast agents for various imaging modalities.  
 
1.1.1 Nanocarriers as an emerging platform for cancer therapy 
Cancer is a major cause of mortality: more than ten million people are 
diagnosed with the disease annually. Cancer is known to develop via a 
multistep carcinogenesis process entailing numerous cellular physiological 
systems, making it a highly incomprehensible and complex disease 10 , 11 . 
Initially, cancers start as localized diseases, but they are prone to spread to 
distant sites within the body, which makes cancers still incurable in several 
occasions.  
                                                                                                                               
6Y. Liu, H. Miyoshi, and M. Nakamura, "Nanomedicine for drug delivery and imaging: a promising avenue for 
cancer therapy and diagnosis using targeted functional nanoparticles," Int.J.Cancer 120, no. 12 (2007). 
7J. Paradise, G. M. Diliberto, A. W. Tisdale, and E. Kokkoli, "Exploring emerging nanobiotechnology drugs and 
medical devices," Food Drug Law J. 63, no. 2 (2008). 
8R. A. Petros and J. M. Desimone, "Strategies in the design of nanoparticles for therapeutic applications," 
Nat.Rev.Drug Discov. 9, no. 8 (2010). 
9S. K. Sahoo and V. Labhasetwar, "Nanotech approaches to drug delivery and imaging," Drug Discov.Today 8, 
no. 24 (2003). 
10A. Gupta, P. Avci, M. Sadasivam, R. Chandran, N. Parizotto, D. Vecchio, W. C. de Melo, T. Dai, L. Y. 
Chiang, and M. R. Hamblin, "Shining light on nanotechnology to help repair and regeneration," Biotechnol.Adv. 
(2012). 
11A. Juarranz, P. Jaen, F. Sanz-Rodriguez, J. Cuevas, and S. Gonzalez, "Photodynamic therapy of cancer. Basic 
principles and applications," Clin.Transl.Oncol. 10, no. 3 (2008). 
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More harrowing is the fact that several significant achievements towards the 
treatment of the disease have failed to profoundly impact patient survival. The 
last century witnessed the maturation of chemotherapy as a viable, adjuvant 
therapeutic modality for the treatment of cancer. An enhanced understanding 
of the underlying mechanisms of tumorigenesis bursted the discovery and 
development of highly specific agents capable of exerting their effects on 
individual proteins or pathways either overexpressed or aberrant within 
tumors. 
Despite many advances in conventional treatment options such as 
chemotherapy, surgery and radiation, cancer therapy is still far from optimal 
because it is plagued by some drawbacks. Frequent challenges encountered by 
current cancer therapies include non specific systemic distribution of antitumor 
agents, inadequate drug concentrations reaching the tumor site, limited ability 
to monitor therapeutic responses and development of MDR. These sobering 
facts indicate that to make further progress, it is necessary to put an emphasis 
on other existing but still under appreciated therapeutic approaches.  
An increased interest is being focused on nanotechnological approaches in 
cancer treatment based on the concept that pharmacokinetics of an anticancer 
drug can be usefully altered in the body to promote drug accumulation 
predominantly in pathological sites12,13,14. Such a strategy is aimed to improve 
the treatment ability to target and to kill cells of diseased tissues/organs while 
affecting as few healthy cells as possible. Several reviews, indeed, have 
focused on the potential of nanotechnology in cancer and discussed how 
different nanoparticulate drug-delivery systems perform in this 
field15,16,17,18,19,20,21,22,23,24,25. 
                                                           
12J. R. Heath and M. E. Davis, "Nanotechnology and cancer," Annu.Rev.Med. 59 (2008). 
13K. K. Jain, "Advances in the field of nanooncology," BMC.Med. 8 (2010). 
14D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, "Nanocarriers as an emerging 
platform for cancer therapy," Nat.Nanotechnol. 2, no. 12 (2007). 
15Z. Gao, L. Zhang, and Y. Sun, "Nanotechnology applied to overcome tumor drug resistance," J.Control 
Release 162, no. 1 (2012). 
16N. T. Huynh, E. Roger, N. Lautram, J. P. Benoit, and C. Passirani, "The rise and rise of stealth nanocarriers for 
cancer therapy: passive versus active targeting," Nanomedicine.(Lond) 5, no. 9 (2010). 
17C. L. Waite and C. M. Roth, "Nanoscale drug delivery systems for enhanced drug penetration into solid 
tumors: current progress and opportunities," Crit Rev.Biomed.Eng 40, no. 1 (2012). 
18M. Talekar, J. Kendall, W. Denny, and S. Garg, "Targeting of nanoparticles in cancer: drug delivery and 
diagnostics," Anticancer Drugs 22, no. 10 (2011). 
19E. C. Dreaden, L. A. Austin, M. A. Mackey, and M. A. El-Sayed, "Size matters: gold nanoparticles in targeted 
cancer drug delivery," Ther.Deliv. 3, no. 4 (2012). 
20H. Zhang, "Multifunctional nanomedicine platforms for cancer therapy," J.Nanosci.Nanotechnol. 12, no. 5 
(2012). 
21S. P. Egusquiaguirre, M. Igartua, R. M. Hernandez, and J. L. Pedraz, "Nanoparticle delivery systems for cancer 
therapy: advances in clinical and preclinical research," Clin.Transl.Oncol. 14, no. 2 (2012). 
22M. Tiwari, "Nano cancer therapy strategies," J.Cancer Res.Ther. 8, no. 1 (2012). 
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The therapeutic effects of many anticancer drugs could be significantly 
improved if delivery of the drug occurs specifically to tumors (cancer cells) or 
preferably inside specific organelles inside cells and reduction of drug toxic 
side effects is achieved. In so doing, a multifunctional construct based on 
novel nanomaterials can be delivered directly to the tumor site and eradicate 
cancer cells selectively. An appropriate design allows nanoconstruct to 
improve drug efficacy (activity at lower doses) as compared with the free-drug 
treatment, which in turn gives a wider therapeutic window and lower side 
effects. Furthermore, NP carriers are also capable of addressing several drug 
delivery problems, which could not be effectively solved in the past and 
include overcoming MDR phenomenon and penetrating cellular barriers that 
may limit device accessibility to intended targets, such as the blood–brain 
barrier, among others. 
There has been intense interest in identifying NP characteristics that are best 
suited for oncology applications. Pharmacokinetics of the NPs is crucial and 
depends on several physiochemical characteristics of the carrier such as size, 
surface charge, shape, nature and density of coating, composition, stability, 
steric stabilization, deformability, dose and route of administration26,27. 
Regarding their composition and structure, nanocarrier platforms for cancer 
can be categorized as organic-based, inorganic-based or a hybrid combination 
of the aforementioned. Organic nanoplatforms include polymeric nanocarriers, 
lipid-based nanocarriers (e.g., liposomes and nanoemulsions), dendrimers, and 
carbon-based nanocarriers (e.g., fullerenes and carbon nanotubes). Inorganic 
nanoplatforms include metallic nanostructures, silica NPs, and QDs.  
 
1.1.2 Polymeric nanomedicines for cancer 
Over the past few decades, several polymer-based nanocarriers have been 
developed as effective drug delivery devices28. The drug of interest is either 
dissolved, entrapped, adsorbed, covalently attached or encapsulated in the 
                                                                                                                               
23C. Heneweer, S. E. Gendy, and O. Penate-Medina, "Liposomes and inorganic nanoparticles for drug delivery 
and cancer imaging," Ther.Deliv. 3, no. 5 (2012). 
24R. Misra, S. Acharya, and S. K. Sahoo, "Cancer nanotechnology: application of nanotechnology in cancer 
therapy," Drug Discov.Today 15, no. 19-20 (2010). 
25S. Kolhe and K. Parikh, "Application of nanotechnology in cancer: a review," Int.J.Bioinform.Res.Appl. 8, no. 
1-2 (2012). 
26M. Wang and M. Thanou, "Targeting nanoparticles to cancer," Pharmacol.Res. 62, no. 2 (2010). 
27S. E. Gratton, P. A. Ropp, P. D. Pohlhaus, J. C. Luft, V. J. Madden, M. E. Napier, and J. M. Desimone, "The 
effect of particle design on cellular internalization pathways," Proc.Natl.Acad.Sci.U.S.A 105, no. 33 (2008). 
28A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Maincent, Y. Kawashima, and C. M. 
Lehr, "Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease," 
J.Pharmacol.Exp.Ther. 299, no. 2 (2001). 
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nanocarrier. The advantages of using polymer-based nanocarriers for drug 
delivery result from their two main basic properties. First, the use of 
biodegradable materials for nanocarrier preparation allows an improved 
stability in the body and sustained drug release within the target site over a 
period of days or even weeks. Second, because of their small size, nanocarrier 
can penetrate through smaller capillaries and be taken up by cells, thus 
allowing efficient drug accumulation at the target sites. 
Biodegradable polymers are materials widely used in the preparation of 
controlled release systems intended for innovative parenteral dosage forms. 
Their wide application in this field is due to their extensive degradation by 
chemical or enzymatic processes in water-soluble low molecular weight 
compounds that enter the normal metabolic pathways of the organism. 
Polymeric nanomedicines such as polymeric NPs, polymer micelles, 
polymersomes and polymer-drug conjugates currently developed for solid 
tumor treatment have proved to be efficacious cancer therapeutics (Figure 2).  
 
 
 
 
 
 
 
Figure 2. Polymeric nanoplatforms for drug delivery29. 
Polymeric NPs may be defined as colloidal systems generally made of 
polymers (biodegradable or not). According to the process used for the 
preparation of NPs, nanospheres or nanocapsules can be obtained (Figure 3).  
Nanocapsules differ from nanospheres in that they are vesicular systems with  
reservoir structure, which is liquid or semisolid at room temperature. In the 
case of nanocapsules, the core is composed of oil hence allowing a high 
payload of a hydrophobic drug whereas nanocapsules with an aqueous core 
                                                           
29F. Alexis, E. M. Pridgen, R. Langer, and O. C. Farokhzad, "Nanoparticle technologies for cancer therapy," 
Handb.Exp.Pharmacol., no. 197 (2010). 
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enable to encapsulate water-soluble compounds. Generally, the polymer shell 
surrounding the liquid core is formed either due to polymerization taking place 
at the interface between the dispersed and continuous phase of the emulsion or 
by precipitation of a preformed polymer at the surface of emulsion droplets. 
Nanospheres are matrix particles, i.e. particles where entire mass is solid. To 
remain well dispersed in a liquid, NPs, like all types of colloids, need to be 
stabilized using amphiphilic molecules or colloid protecting agents. Drugs can 
be either entrapped inside the NPs or adsorbed on their surface.  
 
 
Figure 3. The two main types of polymeric NPs known as nanosphere (matrix system) and 
nanocapsule (reservoir system) with different drug-loading modalities. 
 
Biodegradable NPs can be prepared from a variety of materials such as 
proteins, polysaccharides and synthetic biodegradable polymers, depending on 
many factors such as i) size of the desired NPs, ii) properties of the drug to be 
encapsulated (aqueous solubility, stability, etc.), iii) surface characteristics and 
functionality, iv) degree of biodegradability and biocompatibility, and v) drug 
release profile of the final product. The methods to prepare NPs can be 
classified in 1) dispersion of preformed polymers, 2) polymerization of 
monomers and 3) ionic gelation method for hydrophilic polymers. Production 
of NPs have been recently reviewed in the light of pharmaceutical technology 
by Benoit et al 30  especially focusing on the formation of NPs on nano-
emulsion templates. Today, numerous examples of original methods to form 
NPs entrapping lipophilic and hydrophilic molecules are available31,32. For 
                                                           
30N. Anton, J. P. Benoit, and P. Saulnier, "Design and production of nanoparticles formulated from nano-
emulsion templates-a review," J.Control Release 128, no. 3 (2008). 
31C. Perez, A. Sanchez, D. Putnam, D. Ting, R. Langer, and M. J. Alonso, "Poly(lactic acid)-poly(ethylene 
glycol) nanoparticles as new carriers for the delivery of plasmid DNA," J.Control Release 75, no. 1-2 (2001). 
32A. Taden, K. Landfester, and M. Antonietti, "Crystallization of dyes by directed aggregation of colloidal 
intermediates: a model case," Langmuir 20, no. 3 (2004). 
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example, working on the intrinsic solubility and melting point (Tm) of a 
polymer without the use of an organic solvent, a new method named ‘MeSo’ 
has been developed in our laboratories33. The method consists in the nano-
emulsification of a fluid, non water-miscible copolymer at T >Tm by sonication 
in water. Cooling at room temperature then hardens the copolymer and, 
spherical non-aggregated particles are formed. 
Micelles are self-assembling nanosized colloidal particles which form 
spontaneoulsy under certain concentrations and temperatures from amphiphilic 
or surface-active molecules, which consist of two clearly distinct regions with 
opposite affinities towards a given solvent. The formation of micelles is driven 
by the decrease of free energy in the system because of the removal of 
hydrophobic fragments from the aqueous environment and the re-establishing 
of hydrogen bond network in water. Hydrophobic segments of amphiphilic 
molecules form the core of a micelle, while hydrophilic fragments form the 
micelle shell. When used as drug carriers in aqueous media, micelles solubilize 
molecules of poorly soluble non polar pharmaceuticals within the micelle 
core34. Micelles based on biodegradable polyesters are now considered as a 
very promising injectable delivery system. 
Polymersomes are polymer-based vesicular shells that form upon hydratation 
of amphiphilic block copolymers. As the nanocapsules, polymersomes are 
indeed vesicular systems in which the drug is confined to a reservoir or within 
a cavity surrounded by a polymer coating. In particular, the core of this vesicle 
is an aqueous phase while the surrounding coating is a polymer bilayer 
composed of amphiphilic copolymers. Accurate selection of polymer MW, 
hydrophilic/hydrophobic ratio and chemistry impart polymersomes with a 
broad and tunable range of carrier properties. These systems are capable of 
encapsulating a large range of therapeutically water soluble active molecules 
and biomolecules, with considerable work being done to engineer the release 
of those encapsulants at the desired place and time35.  
Finally, polymer–drug conjugates are macromolecular prodrugs where a drug 
is covalently bound to a water soluble polymeric carrier, normally via a 
biodegradable linker. Amphiphilic polymer-drug conjugates in aqueous 
                                                           
33F. Quaglia, L. Ostacolo, Rosa G. De, M. I. La Rotonda, M. Ammendola, G. Nese, G. Maglio, R. Palumbo, and 
C. Vauthier, "Nanoscopic core-shell drug carriers made of amphiphilic triblock and star-diblock copolymers," 
Int.J.Pharm. 324, no. 1 (2006). 
34V. P. Torchilin, "Micellar nanocarriers: pharmaceutical perspectives," Pharm.Res. 24, no. 1 (2007). 
35D. E. Discher and F. Ahmed, "Polymersomes," Annu.Rev.Biomed.Eng 8 (2006). 
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solution can form micelles or micelle-like nanoassemblies in which the 
lipophilic drug is confined in the internal core of the system36.  
 
1.1.3 Administration routes for nanoparticles 
Multiple biological barriers exist for drugs to successfully reach their intended 
target in the body 37 . Oral drugs need to have high stability in the 
gastrointestinal tract and the ability to penetrate intestinal epithelium to 
achieve high systemic bioavailability. Similarly, skin, nasal, and pulmonary 
drug delivery requires efficient transport of drugs across the epithelium. While 
most new drug formulations for small molecules are intended for the oral 
route, with drug chemistry directed towards optimization of absorption extent, 
intravenous (iv) administration remains the most direct and efficient route to 
deliver drugs like peptides, proteins, large molecules, and fragments of nucleic 
acids. 
Several nanocarrier systems have been designed and developed as 
pharmaceutical formulations for different administration routes. For example, 
significant research has been done using NPs as oral38 and pulmonary39 drug 
delivery vehicles. Oral delivery of peptides and proteins using NPs has been 
shown to be far superior to the delivery of free drugs in terms of 
bioavailability, residence time, and biodistribution. The bioavailability of these 
molecules is limited by the epithelial barriers of the gastrointestinal tract and 
they may also be susceptible to gastrointestinal degradation by digestive 
enzymes. For this reason, the advantage of using polymeric NPs is to allow 
encapsulation of bioactive molecules and protect them against enzymatic and 
hydrolytic degradation. The administration of small peptides can occur also 
through the nasal route. This is due to the greater permeability and lower 
enzymatic activity of the nasal mucosa as compared to the intestinal mucosa. 
However, as in the case of the oral route, the transport of particles across the 
nasal epithelium has been considered as a defence event, strictly related to the 
nose-associated lymphoid tissue. Nevertheless, the activity generated over the 
last few years in the design of transmucosal drug carriers has led to the 
conclusion that the surface composition of NPs affects the crossing of  the 
                                                           
36X. Hu and X. Jing, "Biodegradable amphiphilic polymer-drug conjugate micelles," Expert.Opin.Drug Deliv. 6, 
no. 10 (2009). 
37A. Chrastina, K. A. Massey, and J. E. Schnitzer, "Overcoming in vivo barriers to targeted nanodelivery," 
Wiley.Interdiscip.Rev.Nanomed.Nanobiotechnol. 3, no. 4 (2011). 
38EP. Herrero , MJ. Alonso , N. Csaba, “Polymer-based oral peptide nanomedicines,” Ther Deliv. (2012). 
39F. Ungaro , I. d'Angelo , A. Miro , MI. La Rotonda , F. Quaglia, “Engineered PLGA nano- and micro-carriers 
for pulmonary delivery: challenges and promises,” J Pharm Pharmacol.(2012). 
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epithelium and the intensity of this transport40. For example, it was recently 
demonstrated that chitosan NPs accumulate in the first layers of the epithelium 
from where they can release their cargo41.  
In the treatment of specific disease, such as cancer, the field of injectable 
nanocarriers has matured to include a wide range of strategies incorporating 
many different materials. Taking advantages of the abnormal organization and 
structure of the tumor vasculature, that will be described in the following, a 
great part of the research efforts in the field of advanced pharmaceutical 
technologies were focused on the design of an enormous number of 
nanoscopic delivery systems for iv administration, in order to improve efficacy 
and specificity of anticancer treatments.  
 
1.1.4 Injectable nanoparticles  for cancer 
Injectable nanocarriers have received much attention due to their vast range of 
structures and ability to contain multiple functional groups, both within the 
bulk material and on the surface of the particles. In general, an effective 
nanomedicine should have high therapeutic loading, controlled drug release 
along with efficient targeting ability. Nevertheless, multiple obstacles must be 
overcome in order to have an effective injectable drug delivery system42. The 
major challenges include overcoming clearence in the body, increasing cellular 
uptake into target tissue/cells, and endosomal escape that is especially 
important for nucleic acid fragments. 
 
1.1.4.1 Elimination by renal clearance and RES 
Natural elimination processes include both renal clearance and MPS uptake.  
Renal clearance of intravascular agents is a process involving glomerular 
filtration, tubular secretion and finally elimination of the molecule through 
urinary excretion. Filtration of particles through the glomerular capillary wall 
is highly dependent on molecule size and is referred to as the filtration-size 
threshold. Molecules with a diameter of less than 6 nm are typically filtered, 
while those more than 8 nm are not typically capable of glomerular filtration43. 
                                                           
40N. Csaba , M. Garcia-Fuentes , MJ. Alonso, “ Nanoparticles for nasal vaccination,”Adv Drug Deliv Rev. 
(2009). 
41
 M. Garcia-Fuentes , MJ. Alonso, “Chitosan-based drug nanocarriers: where do we stand?,” J Control Release. 
(2012). 
42D. M. Webster, P. Sundaram, and M. E. Byrne, "Injectable nanomaterials for drug delivery: Carriers, targeting 
moieties, and therapeutics," Eur.J.Pharm.Biopharm. (2013). 
43H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, Ipe B. Itty, M. G. Bawendi, and J. V. Frangioni, "Renal 
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MPS uptake proceeds quickly and must be avoided in order to have an 
acceptable circulation time for nanocarrier. The MPS, also referred to as the 
RES, is the main natural clearance system for particles not filtered by the 
kidneys acting via phagocytosis. Recognition by the MPS is aided by 
opsonization, which consists in the binding of blood opsonins to nanocarrier 
surface thus inducing its phagocytosis and accumulation in the liver (Kuppfer 
cells). The liver acts as a reservoir toward nanocarriers conditioning their rapid 
first-phase disappearance from the blood and, in case of biodegradable 
systems, their second-phase release in the body under degraded and excretable 
form. This biodistribution can be of benefit for the chemotherapeutic treatment 
of MPS localized tumors (e.g. hepatocarcinoma or hepatic metastasis arising 
from digestive tract or gynecological cancers, bronchopulmonary tumors, 
myeloma and leukemia). Multiple methods have been investigated to avoid 
opsonin binding, thus increasing circulation time and increasing the carrier’s 
ability to reach its target cell for internalization. Ideally, an injectable NP has 
to be smaller than 100 nm to avoid internalization by the MPS. The surface 
charge also helps increase cellular uptake and avoid self-aggregation between 
NPs, also resulting in lowered MPS recognition (-10 mV to +10 mV). Particles 
with hydrophobic surfaces, in fact, will preferentially be taken up by the liver, 
followed by the spleen and lungs, while particles with longer circulation times 
should be 100 nm or less in diameter and have a hydrophilic surface in order to 
reduce clearance by macrophages44.  
 
1.1.4.2 Long circulating nanocarriers (Stealth) 
In order to overcome the opsonization of nanocarriers, a number of widely 
used and effective methods have been investigated to make nanocarriers 
“invisible” to the immune system, creating long-circulating NPs, known also 
as stealth NPs (Figure 4). Interestingly, by coating the NP surface with 
hydrophilic polymers, such as PEG, poloxamers, or hydrophilic 
polysaccharides, it is possible to create a hydrated water barrier that provides 
good steric hindrance to the attack of phagocytes. Indeed, the presence of such 
macromolecules allows the prevention of opsonization thanks to this protective 
hydrophilic and flexible layer, preventing their interaction with blood 
components 45 , 46 . Furthermore, a steric stabilization limits also aggregation 
                                                           
44 D. E. Owens, III and N. A. Peppas, "Opsonization, biodistribution, and pharmacokinetics of polymeric 
nanoparticles," Int.J.Pharm. 307, no. 1 (2006). 
45S. M. Moghimi and J. Szebeni, "Stealth liposomes and long circulating nanoparticles: critical issues in 
pharmacokinetics, opsonization and protein-binding properties," Prog.Lipid Res. 42, no. 6 (2003). 
46S. M. Moghimi, A. C. Hunter, and J. C. Murray, "Long-circulating and target-specific nanoparticles: theory to 
practice," Pharmacol.Rev. 53, no. 2 (2001). 
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between particles themselves in the blood and contribute to system stability in 
biological environments. In so doing, NPs exhibit decreased levels of uptake 
by the MPS and, consequently, an increased circulation time in the blood, and 
accumulate in solid tumors passing through their leaky vasculature (passive 
targeting). In particular, it was demonstrated that NPs decorated with PEG can 
circulate for a longer time as compared to non-pegylated NPs, and normally 
exhibit a circulation half-life of 2-24h in mice and rats, and as long as 45h in 
humans. PEGylation simply refers to the decoration of a particle surface by the 
covalent surface grafting, or adsorption of PEG chains. Some research has 
directly shown that particles with covalently bound PEG chains exhibit longer 
blood circulation half-lives than similar particles with only surface adsorbed 
PEG. 
Gref et al47were the first to report the advantages of PEGylation on PLGA-
PEG NPs, resulting in a substantial increase in blood residence time. The chain 
length, shape, and density of PEG on the particle surface have been shown to 
be the main parameters affecting NP surface hydrophilicity and phagocytosis. 
Most research indicates that a PEG chain with molecular weight of 2000 Da or 
greater is required to achieve increased MPS-escape. This minimum MW is 
most likely due to the loss in flexibility of shorter PEG chains. Also, it has 
been shown that as molecular weight is increased above 2000, the blood 
circulation half-life of the PEGylated particles is also increased, which may be 
due in part to the increased chain flexibility of higher MW PEG polymers. In 
addition to chain molecular weight, surface chain density and conformation are 
also critical factors to achieve improved stealth characteristics, although these 
two aspects are much more interrelated 48 . For instance, at low surface 
coverage, the PEG chains have a larger range of motion and will typically take 
on what is termed a “mushroom” configuration, where on average they will be 
located closer to the surface of the particle. Very low surface coverage can also 
lead to gaps in the PEG protective layer where opsonins can freely bind to the 
NP surface. On the other hand, at high surface coverage the PEG chains range 
of motion will be greatly restricted and they will most often exhibit a semi-
linear or “brush” configuration. Although a high surface coverage ensures that 
the entire surface of NP is covered, this method also decreases the mobility of 
the PEG chains and thus decreases the steric hindrance properties of the PEG 
                                                           
47
 R. Gref , M. Lück , P. Quellec , M. Marchand , E. Dellacherie , S. Harnisch , T. Blunk , RH. Müller, “Stealth' 
corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain 
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Colloids Surf B Biointerfaces. (2000). 
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layer. Interestingly, a threshold of 1-2 nm space between the PEG chains was 
estimated for minimal protein absorption. 
 
 
Figure 4. Schematic diagrams of PEG configurations on the upper hemisphere of a polymeric NP. 
In (a), the low surface coverage of PEG chains leads to the “mushroom” configuration where most 
of the chains are located closer to the particles surface. In (b), the high surface coverage and lack 
of mobility of the PEG chains leads to the “brush” configuration where most of the chains are 
extended away from the surface49. 
 
1.1.5 Principles of drug targeting to tumors 
Ideally, for anticancer drugs to be effective in cancer treatment, they should 
first (after administration) be able to reach the desired tumor tissues through 
the penetration of barriers in the body with minimal loss of activity in the 
bloodstream. Second, after reaching the tumor tissue, drugs should have the 
ability to selectively kill tumor cells without affecting normal cells and extend 
their effect along time. These two basic strategies are also associated with 
improvements in patient survival and quality of life, by simultaneously 
increasing the intracellular concentration of drugs and reducing dose-limiting 
toxicities. In principle, NP delivery of anticancer drugs to tumor tissues can be 
achieved by either passive or active targeting (Figure 5). 
Passive targeting refers to the accumulation of a drug or a drug carrier system 
at a desired site owing to physico-chemical or physiological factors. It takes 
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advantage of the size of NPs and the unique properties of tumor vasculature 
and microenvironment. 
For further growth and enlargement, tumors need to form new blood vessels, 
via the angiogenesis process, in order to obtain nutrients and sustain their 
growth. 
 
Figure 5. Passive vs active targeting. (Right) NPs tend to passively (by their biophysicochemical 
properties) extravasate through the inflammated vasculature; (Left) Once NPs have extravasated in 
the target tissue, the presence of targeting ligands (e.g. proteins) on the NP surface can result in 
active targeting of NPs to receptors that are present on target cell or tissue resulting in enhanced 
accumulation and cell uptake through receptor-mediated endocytosis50. 
 
Tumor vessels are generally abnormal and have aberrant branching, blind 
loops of twisted shape, which are characterized by architectural defectiveness 
and a high degree of vascular density. The newly formed tumor blood vessels 
usually present an abnormal architecture too, including defective endothelial 
cells with wide fenestrations, irregular vascular alignment, lack of a smooth 
muscle layer or innervation, wide lumen and impaired functional receptors for 
AT-II. Blood flow behavior, such as direction of blood flow, is also irregular 
or inconsistent in these vessels. When compared with normal vessels, tumor 
vessels are “leaky”, owing to basement membrane abnormalities and a 
decreased number of pericytes lining the rapidly proliferating endothelial cells. 
Indeed, the pore size of tumor vessels varies from 100 nm to almost 1 mm in 
diameter, depending upon the anatomic location of the tumors and the stage of 
tumor growth. In comparison, the tight endothelial junctions of normal vessels 
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are tipically of 5-10 nm in size. The leaky and defective architecture of tumor 
vasculature might be due to elevated levels of vascular mediators such as 
bradykinins, nitric oxide, VEGF, basic fibroblast growth factor, prostaglandins 
and so on. Moreover, solid tumors are also characterized by an impaired and 
lack lymphatic network that decreases the clearance of macromolecules giving, 
consequently, extended retention times in the tumor interstitium 51 , 52 . The 
unique pathophysiologic characteristics of tumor vessels coupled with poor 
lymphatic drainage (Figure 6) induces the EPR effect, which enables 
macromolecules, including NPs, to extravasate through these gaps into 
extravascular spaces and accumulate inside tumor tissues.  
 
 
Figure 6. Differences between normal and tumor tissues that explain the passive targeting of 
nanocarriers by the EPR. A. Normal tissues contain linear blood vessels maintained by pericytes. 
Collagen fibres, fibroblasts and macrophages are in the extracellular matrix. Lymph vessels are 
present. B. Tumor tissues contain defective blood vessels with many sac-like formations and 
fenestrations. The extracellular matrix contains more collagen fibres, fibroblasts and macrophages 
than in normal tissue. Lymph vessels are lacking53. 
 
The EPR effect reported by Matsumura and Maeda in 198654 was commented 
by Torchilin55 as a molecular weight-dependent phenomenon: particles larger 
than 40 kDa, which is the threshold for renal clearance, show a prolonged 
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circulation time (thus, a much increased half-life) and hence very slow 
clearance from the body, with a higher AUC. Thus, these molecules permeate 
gradually tumors in a selective fashion. 
In addition, accumulated macromolecular drugs remain in tumors for a 
relatively long time (e.g., several days). Molecular weight is not the only 
determinant of the EPR effect; other factors such as the surface charge and an 
in vivo surveillance system for macromolecules (i.e., scavenger receptors of 
the RES) are quite important. The vascular endothelial luminal surface is 
known to carry a negative charge, so basic proteins with positive charges or 
cationic polymers rapidly bind to vascular endothelial cells, which results in a 
lower AUC, shorter plasma half-life, and a consequently reduced tumor drug 
accumulation by means of the EPR effect. Acidic or neutral particles are thus 
expected to have a longer plasma half-life. However, the RES in the liver and 
spleen showed faster uptake of negatively charged NPs than that of neutral 
particles.  
PEGylation thus benefits EPR-based targeting of drugs to tumors. Certain 
PEG-modified particles are also now understood to have a slower uptake into 
tumor cells than non-PEGylated molecules. Developing suitable PEGylation 
strategies to achieve a longer plasma half-life, as well as better intracellular 
trafficking, is of utmost importance. The EPR effect will drive the particles 
into tumor tissue but the ultimate goal is access of active drugs to target sites. 
Therefore, the release rate of the drug from the carrier at the target must be 
optimal (e.g., 3–10% per day), because too slow a release results in insufficient 
concentrations of active drugs at sites of action. Release that is too rapid would 
lead to a high concentration of free drug in circulation but no drug 
accumulation in the tumor, the results thus being a considerably lower 
therapeutic effect and undesired systemic toxicity.  
On the basis of this scenario, the vast majority of nanomedicines developed for 
drug targeting to tumors rely on the EPR effect. These primarily include long-
circulating liposomes, polymers and micelles. Examples of passively targeted 
nanomedicines approved for clinical use are Myocet®, Doxil®, Daunoxome®, 
Abraxane® and Genexol-PM®. Several additional passively tumor-targeted 
nanomedicines are currently in clinical trials, and a large number of other ones 
are in early- and late-stage preclinical development. 
Targeting cancer cells using the EPR effect is not feasible in all tumors 
because the degree of tumor vascularization and porosity of tumor vessels can 
vary with the tumor type and status. One approach to overcome this limitation 
is to attach targeting moieties to the NP surfaces, thus forming an “active 
nanocarrier”. Active targeting of nanomedicines provides the additional 
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targeting mechanism of receptor-mediated binding of NPs to surface receptors 
expressed on tumor cells or blood vessels, such as αβ-integrins, folic acid, and 
prostate-specific membrane antigen. Research has been conducted on several 
targeting ligands, including antibodies, aptamers, peptides, and small 
molecules. Efficient binding and internalization requires that receptors are 
expressed exclusively on target sites relative to normal cells. At present, 
several targeted delivery systems are under clinical trials, such as transferrin 
receptor targeted cytotoxic platinum-based oxaliplatin in a liposome (MBP-
426), transferrin receptor targeted cyclodextrin-containing NPs with siRNA 
payload (CALAA-01), or PSMA targeted polymeric NPs containing DTX 
(BIND-014). To date, however, in spite of significant advances made at the 
preclinical level with regard to active targeting, only antibody-based 
nanomedicines, such as Zevalin, Mylotarg, Ontak and Bexxar have been 
approved for clinical use. 
The observation that actively targeted ‘classical’ nanomedicines so far largely 
failed to demonstrate benefit at the preclinical level can likely be mostly 
attributed to the fact that after leaving the highly leaky tumor vasculature, there 
are quite a number of anatomical and physiological barriers that need to be 
overcome before antibody- or peptide-targeted formulations can bind to (and 
enter) cancer cells. These include the presence of pericyte-, smooth muscle 
cell- and fibroblast-based cell layers between endothelial and tumor cells, the 
high cellular density within solid malignancies, and the high interstitial fluid 
pressure that is typical of tumors. Therefore, and also because of the binding-
site barrier, which further limits the penetration of actively targeted 
nanomedicines into the tumor interstitium, actively targeted nanomedicines 
tend to have problems finding their target cells, and they generally fail to 
demonstrate an advantage over passively targeted formulations56. 
The possibility to engineer a NP surface with a wide range of functional 
groups allowed to design and develop multifunctional nanostructures (Figure 
7). Multifunctional nanocarriers can combine a specific targeting agent 
(usually an antibody or peptide) with NPs for imaging (such as QDs or 
magnetic NPs), a cell-penetrating agent (e.g. the polyArg peptide TAT), a 
stimulus-sensitive element for drug release, a stabilising polymer to ensure 
biocompatibility (PEG most frequently) and two or more therapeutic 
compounds. This approach can be used for example for simultaneously tumor 
imaging, diagnosis and treatment. Combining diagnosis and therapy in one 
process is an emerging biomedical method referred to as theranostic. Several 
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recent reviews have discussed engineering designs, physiochemical 
characteristics and biomedical applications of magnetic NPs that can 
simultaneously act as diagnostic molecular imaging agents and as drug 
carriers57,58,59. 
 
 
 
Figure 7. Example of multifunctional nanoplatform.  
 
1.1.6 PEGylated nanocarriers in clinical use 
As previously described, the circulation time of nanocarriers intended for iv 
administration and directed passively to solid tumors is widely increased by 
the inclusion of surface bound hydrophilic molecules such as PEG. Whereas 
free drugs are usually cleared from circulation within minutes of iv 
administration, PEGylated nanostructures can circulate for hours and 
accumulate in sites of leaky vasculature, carrying along the entrapped drug. 
The use of PEG has been shown to increase circulation times of different 
nanocarriers such as liposomes and polymeric NPs. To date, several stealth and 
PEGylated nanocarriers or drugs are already on the market and others are still 
under clinical trials and studied in animals. Table 1 summarizes the most 
relevant examples. 
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Table 1. PEGylated nanomedicines for cancer approved or under clinical and 
preclinical research. 
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1.1.7 Amphiphilic block copolymers 
In the field of injectable PEGylated nanomedicines for cancer, amphiphilic 
block copolymers have attracted a great deal of attention due to their ability to 
form various types of self-assembling NPs. These polymers are obtained by 
the polymerization of more than one type of monomer, typically one 
hydrophobic and one hydrophilic, so that the resulting molecule is composed 
of regions that have opposite affinities for an aqueous solvent. These materials 
are generally composed of biocompatible, biodegradable hydrophobic polymer 
blocks such as polyesters covalently bound to a biocompatible hydrophilic 
block, typically PEG. To date, numerous block copolymers have been 
synthesized, not only with a variety of block combinations, but also varying 
hydrophilic and hydrophobic block lengths. 
Block copolymers are classified into several types by sequential arrangement 
of component segments (Figure 8).  
 
 
Figure 8. Types of block copolymers: a) AB type diblock, b) ABA type triblock, c) ABn type 
multiblock, d) (AB)n star block. 
 
The simplest block copolymer is AB-type block copolymer, which is 
composed of one segment of homopolymer A linked to one segment of 
homopolymer B. In the second type of copolymer, both terminals of B unit is 
connected at the terminal of A unit, and thus, it is referred to as an ABA type 
block copolymer. In the third type of block copolymers, A and B segments are 
connected n times and referred to as a multiblock copolymer. The fourth type 
of block copolymer has a star block architecture. In this last family, unit A has 
multi-arm functionality and copolymerizes with B blocks giving a star-like 
n
a b
c d
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shape. The number of arms of the star block copolymer depends on the number 
of functional groups on block A.  
The literature abounds with studies using amphiphilic block copolymers of 
different compositions that produce,by different preparation techniques, core-
shell nanoassemblies referred to as micelles (spherical, worm-like, crew-cut), 
nanospheres, nancapsules and polymersomes.  
The selection of an appropriate hydrophobic core-forming material is 
considered of utmost importance in order to attain a physically stable delivery 
system. Poly(alpha-hydroxesters), such as PDLLA, PGA, and PCL, remain the 
most widely employed polymers for core-shell nanostructures to target 
hydrophobic drugs, given their biocompatibility and biodegradability.  
 
1.1.7.1 Poly-ε-caprolactone 
PCL (Figure 9) is an aliphatic polyester of considerable interest in the design 
of amphiphilic block copolymer. 
*
O
*
O
n
 
 
Figure 9. PCL. 
 
PCL is a semi-crystalline polymer with a low glass transition temperature (Tg -
60 °C) and a melting temperature between 59 and 64 °C related closely to the 
crystalline nature of the material. It is slowly biodegradable in vivo by 
chemical and enzymatic reactions. It was used for the preparation of sustained 
release systems of oral contraceptives (Capronor®)60. Recently, the process of 
degradation in vivo was studied by implanting the low molecular weight 
poly(ε-caprolactone14C) in rats and by measuring the radioactivity in urine, 
feces, exhaled air and the residual activity in the implant site. A complete 
bioabsorption was observed in 60 days and the presence of ε-hydroxycaproic 
acid, produced by complete hydrolysis of the polymer, as well as tritiated 
water as metabolites. While studying the mechanism of bioabsorption, studied 
by electron microscopic analysis of the tissue at the implantation site, the 
presence of intracellular polymeric particles was detected, demonstrating the 
                                                           
60C. G. Pitt, M. M. Gratzl, G. L. Kimmel, J. Surles, and A. Schindler, "Aliphatic polyesters II. The degradation 
of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo," Biomaterials 2, no. 4 (1981). 
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role of phagocytosis in the final stage of polymer degradation61. The cell and 
tissue biocompatibility of PCL was demonstrated but also an extensive 
inflammatory reaction in the muscle probably due to increased vascularity of 
the tissue and a larger amount of implanted material was evidenced. The 
inflammation may be due to a high local concentration of degradation products 
and to a potential transport of the polymer with subsequent activation of 
neutrophils. The rapid activation of neutrophils by microsphere-based PCL, 
after intramuscular injection, was confirmed from the measurement of the 
superoxide anion generated from the material. Finally, studies of flow 
cytometry to assess the effect of PCL microspheres on apoptosis and cell 
cycles were conducted. Results revealed that the material exhibits excellent 
cytocompatibility62.  
Due to its high reactivity and ability to polymerize in not drastic conditions for 
the presence of the terminal -OH groups, PCL represents an excellent 
candidate for the synthesis of amphiphilic block copolymers. Furthermore, due 
to a marked lipophilic character PCL is considered an excellent material to 
prepare self-assembling systems, being prone to form a lipophilic core where 
poorly water-soluble drugs can be entrapped. 
 
1.1.7.2 Amphiphilic block copolymers of PCL-PEG and anticancer drugs 
PCL-PEG copolymers are important biomedical materials with amphiphilicity, 
controlled biodegradability and good biocompatibility. They have great 
potential in the fields of nanotechnology, tissue engineering, pharmaceutics, 
and medicinal chemistry. 
Generally, amphiphilic block copolymers composed of hydrophilic and 
hydrophobic segments can form a micelle-like structure with a hydrophobic 
inner core and a hydrophilic outer shell in selective solvent63,64. In PCL-PEG 
polymeric micelles, hydrophobic core formed by PCL is surrounded by water-
soluble polar groups of PEG that extend into an aqueous medium. Therefore, 
drugs with a hydrophobic character can be easily incorporated into NP core by 
                                                           
61V. R. Sinha, K. Bansal, R. Kaushik, R. Kumria, and A. Trehan, "Poly-epsilon-caprolactone microspheres and 
nanospheres: an overview," Int.J.Pharm. 278, no. 1 (2004). 
62Q. Luo, J. Chen, and K. Dai, "[Study on the cytocompatibility of biodegradable poly(epsilon-caprolactone) 
microspheres in vitro]," Sheng Wu Yi.Xue.Gong.Cheng Xue.Za Zhi. 20, no. 1 (2003). 
63D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman, and P. Maincent, "Stability study of 
nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide)," Biomaterials 
17, no. 22 (1996). 
64E. Piskin, "Biodegradable polymers as biomaterials," J.Biomater.Sci.Polym.Ed 6, no. 9 (1995). 
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covalent binding or non-covalent hydrophobic interactions in aqueous 
media65,66,67. 
Micro/NPs from PCL-PEG copolymers are successfully employed to improve 
the aqueous solubility of hydrophobic drugs. With this purpose, micelles 
containing small drugs such as indomethacin 68 , rapamycin 69 , honokiol 70 , 
cyclosporine A 71 and fenofibrate 72  were prepared. Spontaneously self-
assembled micelles encapsulating ketoprofen and furosemide were obtained 
using PCL-PEG modified with trimethylene carbonate PEG-P(CL-co-TMC)73 
whereas micelles containing risperidone were studied for oral delivery 74 . 
Invaluable insight in the delivery of hydrophobic drugs for cancer 
chemotherapy has been gained through the research on polymeric NPs. 
Hydrophobic drugs such as hydroxycamptothecin75, paclitaxel76 and DTX77,78 
                                                           
65Y. I. Jeong, M. K. Kang, H. S. Sun, S. S. Kang, H. W. Kim, K. S. Moon, K. J. Lee, S. H. Kim, and S. Jung, 
"All-trans-retinoic acid release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene 
glycol) diblock copolymer," Int.J.Pharm. 273, no. 1-2 (2004). 
66J. Ryu, Y. I. Jeong, I. S. Kim, J. H. Lee, J. W. Nah, and S. H. Kim, "Clonazepam release from core-shell type 
nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) triblock 
copolymers," Int.J.Pharm. 200, no. 2 (2000). 
67 S. Singh and M. S. Muthu, "Preparation and characterization of nanoparticles containing an atypical 
antipsychotic agent," Nanomedicine.(Lond) 2, no. 2 (2007). 
68K. Letchford, R. Liggins, and H. Burt, "Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-
block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations," 
J.Pharm.Sci. 97, no. 3 (2008). 
69J. A. Yanez, M. L. Forrest, Y. Ohgami, G. S. Kwon, and N. M. Davies, "Pharmacometrics and delivery of 
novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin," Cancer 
Chemother.Pharmacol. 61, no. 1 (2008). 
70C. Gong, X. Wei, X. Wang, Y. Wang, G. Guo, Y. Mao, F. Luo, and Z. Qian, "Biodegradable self-assembled 
PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization," 
Nanotechnology. 21, no. 21 (2010). 
71H. M. Aliabadi, A. Mahmud, A. D. Sharifabadi, and A. Lavasanifar, "Micelles of methoxy poly(ethylene 
oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A," 
J.Control Release 104, no. 2 (2005). 
72K. K. Jette, D. Law, E. A. Schmitt, and G. S. Kwon, "Preparation and drug loading of poly(ethylene glycol)-
block-poly(epsilon-caprolactone) micelles through the evaporation of a cosolvent azeotrope," Pharm.Res. 21, no. 
7 (2004). 
73D. J. Latere, L. Rouxhet, M. E. Brewster, V. Preat, and A. Arien, "Spontaneously self-assembled micelles from 
poly(ethylene glycol)-b-poly(epsilon-caprolactone-co-trimethylene carbonate) for drug solubilization," 
Pharmazie 63, no. 3 (2008). 
74F. Mathot, Beijsterveldt L. van, V. Preat, M. Brewster, and A. Arien, "Intestinal uptake and biodistribution of 
novel polymeric micelles after oral administration," J.Control Release 111, no. 1-2 (2006). 
75J. Zhang, L. Q. Wang, H. Wang, and K. Tu, "Micellization phenomena of amphiphilic block copolymers based 
on methoxy poly(ethylene glycol) and either crystalline or amorphous poly(caprolactone-b-lactide)," 
Biomacromolecules. 7, no. 9 (2006). 
76 M. Shahin and A. Lavasanifar, "Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) 
based drug conjugates and nano-containers for paclitaxel delivery," Int.J.Pharm. 389, no. 1-2 (2010). 
77Q. Liu, R. T. Li, H. Q. Qian, M. Yang, Z. S. Zhu, W. Wu, X. P. Qian, L. X. Yu, X. Q. Jiang, and B. R. Liu, 
"Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded 
poly(ethylene glycol)-poly(varepsilon-caprolactone) nanoparticles," Int.J.Nanomedicine. 7 (2012). 
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were formulated into NPs with high encapsulation efficiency and kept stable in 
aqueous media. In addition, PCL-PEG NPs containing hydrophilic drug such 
as doxorubicin were also prepared to modulate drug release profile 79 . 
Noticeably, some published work relies on the attachment of folate groups as 
targeting moiety for NPs80. Superparamagnetic iron oxide and doxorubicin 
were also co-encapsulated within folate-conjugated PCL-PEG micelles81. 
Other specific applications of PCL-PEG NPs such as multimodal carriers for 
drugs and imaging agents were reported. PCL-PEG NPs co-encapsulating a 
hydrophobic vitamin (beta-carotene) and an inorganic colloid for imaging (Au) 
were obtained82. PCL-PEG copolymers were also intensively studied for their 
potential in non-viral gene carriers83,84 and for their ability to self-assemble in 
polymersomes for hydrophilic drugs85.   
                                                                                                                               
78F. Ungaro, C. Conte, L. Ostacolo, G. Maglio, A. Barbieri, C. Arra, G. Misso, A. Abbruzzese, M. Caraglia, and 
F. Quaglia, "Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, 
antiproliferative activity and in vivo toxicity," Nanomedicine. 8, no. 5 (2012). 
79 A. K. Yadav, P. Mishra, S. Jain, P. Mishra, A. K. Mishra, and G. P. Agrawal, "Preparation and 
characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin," J.Drug 
Target 16, no. 6 (2008). 
80 E. K. Park, S. Y. Kim, S. B. Lee, and Y. M. Lee, "Folate-conjugated methoxy poly(ethylene 
glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery," 
J.Control Release 109, no. 1-3 (2005). 
81X. Yang, W. Deng, L. Fu, E. Blanco, J. Gao, D. Quan, and X. Shuai, "Folate-functionalized polymeric micelles 
for tumor targeted delivery of a potent multidrug-resistance modulator FG020326," J.Biomed.Mater.Res.A 86, 
no. 1 (2008). 
82 M. E. Gindy, A. Z. Panagiotopoulos, and R. K. Prud'homme, "Composite block copolymer stabilized 
nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures," Langmuir 24, no. 1 
(2008). 
83 T. K. Endres, M. Beck-Broichsitter, O. Samsonova, T. Renette, and T. H. Kissel, "Self-assembled 
biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and 
nanoparticles designed for drug and gene delivery," Biomaterials 32, no. 30 (2011). 
84T. Kanazawa, K. Sugawara, K. Tanaka, S. Horiuchi, Y. Takashima, and H. Okada, "Suppression of tumor 
growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL 
nanomicelles," Eur.J.Pharm.Biopharm. 81, no. 3 (2012). 
85D. E. Discher and F. Ahmed, “Polymersomes,” Annu Rev Biomed Eng. (2006). 
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1.2 Photodynamic Therapy 
With advances in the early diagnosis of cancer and increased interest in the 
conservation of normal tissue during cancer surgery, the rising demands for 
non-invasive or minimally invasive therapeutic methods for cancer have led to 
the accelerated development of medical technologies such as radiation therapy, 
ultrasound treatment, cryotherapy and PDT. PDT is a clinically approved, 
minimally invasive procedure that can exert a selective cytotoxic activity 
toward malignant cells. The procedure involves administration of a PS 
followed by irradiation at a wavelength corresponding to an absorbance band 
of the PS. In the presence of oxygen, a series of events lead to direct tumor cell 
death, damage to the microvasculature, and induction of a local inflammatory 
reaction. Clinical studies reveal that PDT can be curative, particularly in early 
stage tumors, can prolong survival in patients with inoperable cancers and 
significantly improve quality of life. Minimal normal tissue toxicity, negligible 
systemic effects, greatly reduced long-term morbidity, lack of intrinsic or 
acquired resistance mechanisms and excellent cosmetic as well as organ 
function-sparing effects of this treatment make it a valuable therapeutic option 
for combination treatments. With a number of recent technological 
improvements, PDT has the potential to become integrated into the mainstream 
of cancer treatment. 
 
1.2.1 Principles of PDT 
Photodynamic effectiveness is based on photochemical reactions between light 
and tumor tissue with exogenous PS. These components, tolerated singly by 
the diseased cells, generate cytotoxic oxygen-based molecular species in 
proper dosage and concentration. Mechanistically it consists in three phases: 
excitation of PS, generation of toxic oxygen and cell death (Figure 10). In the 
first phase, irradiated light of an appropriate wavelength, usually visible or 
near-infrared, excites the PS molecules in the ground or singlet state, 
characterized by two electrons with opposite spins in a low energy molecular 
orbital. Following the absorption of light in the form of photons, one of these 
electrons is boosted into a high-energy orbit, but keeps its spin from the first 
short-live excited singlet state. The light is usually chosen to coincide with the 
maximum absorption wavelength of the drug molecules. In common with 
many other fluorescent molecules, PS can, at this stage, decay to the native 
state with concomitant emission of light in the form of fluorescence. However, 
the excited singlet state PS may also undergo a process known as intersystem 
crossing whereby the spin of the excited electron inverts to form a relatively 
                                                                                                                           Introduction 
36 
 
more stable and long-lived excited triplet-state that has electrons which spin in 
a parallel conformation. A high quantum efficiency for this transition is a key 
characteristic of a good PS. The PS in triplet state can either decay radiation to 
the ground state or transfer its energy to molecular oxygen (O2) in the 
surroundings, which is unique in being a triplet in its ground state. This step 
leads to the formation of singlet oxygen (1O2), which initiates oxidation of 
susceptible substrates, and the reaction is referred to as a Type II process. A 
Type I process can also occur whereby the PS reacts directly with an organic 
molecule in a cellular microenvironment, acquiring a hydrogen atom or 
electron to form a radical. Subsequent autoxidation of the reduced PS produces 
a superoxide anion radical (O-2). Dismutation or one electron reduction of O-2 
gives hydrogen peroxide (H2O2), which in turn can undergo one-electron 
reduction to a powerful and virtually indiscriminate oxidant hydroxyl radical 
(HO-).  
 
 
Figure 10. Schematic illustration of a photodynamic reaction. The PS initially absorbs a photon 
that excites it to the short-lived singlet state. This can lose energy by fluorescence, internal 
conversion to heat, or by intersystem crossing to the long-lived triplet state. This triplet PS can 
interact with molecular oxygen in two pathways, type 1 and type 2, leading to the formation of 
ROS and singlet oxygen (1O2) respectively86. 
 
Both Type 1 and Type 2 reactions can occur simultaneously and competitively, 
and the ratio between these processes depends on the type of PS used, as well 
as the concentrations of substrate and oxygen. Type II reaction, however, 
appears to play a central role in cytotoxicity, because of the highly efficient 
interaction of the 1O2 species with various biomolecules. Singlet oxygen, in 
                                                           
86A. Gupta, P. Avci, M. Sadasivam, R. Chandran, N. Parizotto, D. Vecchio, W. de Melo, T. Dai, L. Y. Chiang, 
M. R. Hamblin, “Shining light on nanotechnology to help repair and regeneration,” Biotechnology Advances, 
(2012). 
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fact, is believed to be the main cytotoxic agent in PDT 87 .Singlet oxygen 
species have a lifetime of less than 3.5 µs and can diffuse only 0.01 to 0.02 µm 
during this period. Therefore, the initial extent of the damage is limited to the 
site of concentration of the PS.This is usually the mitochondria, plasma 
membrane, Golgi apparatus, lysosomes, endosomes and ER. The nucleus and 
nuclear membrane are usually spared and DNA damage is rare.  
In addition to direct damage to neoplastic cells, vascular damage plays an 
important role in tumor eradication. In PDT, oxygen radicals induce changes in 
both tumor and surrounding normal vasculature, decreasing the barrier 
function of endothelial cells and depriving neoplastic cells of nutrients88.  
 
1.2.2 Light sources and Light Delivery 
No single light source is ideal for all PDT indications, even with the same PS. 
The choice of light source should therefore be based on PS absorption, disease, 
cost, and size. Furthermore, the clinical efficacy of PDT is dependent on 
complex dosimetry: total light dose, light exposure time, light delivery mode 
(single vs fractionated or even metronomic) and fluence rate (intensity of light 
delivery).  
The effective excitation light magnitude is determined by the combination of 
optical absorption and scattering properties of the tissue. Absorption is largely 
due to endogenous tissue chromophores such as hemoglobin, myoglobin and 
cytochromes (Figure 11). The optical scattering of tissue decreases with 
wavelength. For the spectral range of 450–1,750 nm, tissue scattering is, in 
general, more prevalent than absorption, although for the range of 450–600 
nm, melanin and hemoglobin provide significant absorption, while water plays 
a similar role for l > 1,350 nm. Therefore, the optimal optical window for 
PDT, as well as for optical imaging, is in the near-infrared spectral region 
(600–1,300 nm), where the scattering and absorption by tissue are minimized 
and, therefore, the longest penetration depth can be achieved. Within this 
optical window, the longer the wavelength is, the deeper is the penetration 
depth. However, light up to only approximately 800 nm can generate 1O2, 
because longer wavelengths have insufficient energy to initiate a 
photodynamic reaction89. 
                                                           
87P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, 
A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B. C. Wilson, and J. Golab, 
"Photodynamic therapy of cancer: an update," CA Cancer J.Clin. 61, no. 4 (2011). 
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The light source for PDT must exhibit suitable spectral characteristics that 
coincide with the maximum absorption wavelength range of the PS applied in 
order to generate enough ROS to produce a cytotoxic effect. Currently 
approved PS absorb in the visible spectral regions below 700 nm, where light 
penetration into the skin is only a few millimeters, clinically limiting PDT to 
treating topical lesions. Different light sources have been usedin clinical and 
experimental PDT. Laser systems are widely used for treatment of 
dermatological conditions90. 
The gold vapor laser (628 nm), the argon ion-pumped dye laser (630 or 635 
nm), and the copper vapor-pumped dye laser constitute the most popular 
systems.These systems allow the selection of a wavelength that has a maximal 
effective tissue penetration of approximately 10 mm, and have been used in 
combination with all types of PS.The laser beams can be launched into an 
optical fiber applicator, enabling light to be delivered directly into internal 
tumors. However, these techniques are relatively expensive, require 
specialized supporting staff and are space-consuming. 
 
 
 
Figure 11. Optical absorption coefficients of principal tissue chromophores in the human body91. 
 
It is probable that such systems will eventually be replaced by laser diode 
arrays which are very convenient since they can be easily moved, require only 
a single phase supply and also being relatively inexpensive. Commercially 
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available incoherent light sources, such as incandescent or arc lamps, have 
been used in topical PDT by several groups mainly for treatment of large 
lesions92. Because coherence of light is not necessary for PDT, such sources 
offer the advantage of being less expensive and easier to handle. The most 
popular of them is the filtered slide projector, which excludes light below 600 
nm with glass filters, minimizing the emission of shorter wavelengths, which 
by being strongly absorbed by hemoglobin, could lead to the production of 
heat-induced erythema. Despite this, unfiltered white light has also been 
employed, and recently, professional incoherent lamp like PDT 1200 lamp has 
been developed for PDT.  
 
1.2.3 Photosensitizing agents 
Most of the PS used in cancer therapy are based on a heterocyclic tetrapyrrole 
structure, similar to that of the protoporphyrin contained in hemoglobin. 
There are many properties which an ideal PS should possess: 
 stable composition; 
 easily synthesized or readily available; 
 minimal self-aggregation tendency; 
 not highly hydrophobic or encapsulated inside appropriate carriers; 
 non-toxic in the absence of light exposure; 
 photostable; 
 absorbance in the red region of spectrum with high extinction molar 
coefficient; 
 target specificity; 
 quickly cleared from the body. 
Each of the currently commercially available PS has specific characteristics, 
but none of them is an ideal agent. For example, most of the PS are 
hydrophobic and can aggregate very easily in aqueous media which can affect 
their photophysical, chemical and biological properties93. 
PS are generally classified as porphyrins and non-porphyrins. Amid porphyrin-
based PS first, second, and third generation PS are reported. 
The first generation agent, Hp, was isolated from hemoglobin of dried blood 
using concentrated sulfuric acid in 1841 by Scherer. Purification and 
solubilization of Hp are the chemical processes leading to the preparation of 
HpD, a very complex mixture of several components, of which approximately 
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50% is identifiable as oligomeric ematoporphyrins and protoporphyrins, which 
have a low in vivo photosensitizing activity. Further chemical purification 
yielded to the preparation of porfimer sodium (Photofrin®), a lyophilized 
concentrated form of monomeric and oligomeric ematoporphyrin derivatives, 
clinically approved in the treatment of early- and late-stage lung cancers, 
esophageal cancer, bladder cancer, malignant and nonmalignant skin diseases 
and early-stage cervical cancer. It is also being considered as a potential 
therapy against Kaposi’s sarcoma, Barrett’s esophagus with high-grade 
dysplasia, psoriasis and cancers of the head, brain, neck and breast.  
Photofrin® is characterized by an absorption maximum of 630 nm 
(corresponding to a penetration of about 5–10 mm) and a low molar extinction 
coefficient which in turn demands high concentrations of Photofrin® and light 
to obtain an adequate tumor eradication, and a long half-life of 452 h, causing 
long-lasting photosensitivity. The time delay between drug delivery and the 
time it takes to maximize the tumor to normal cell uptake within the target 
tissue determines the correct time for light application. Photofrin®-mediated 
PDT involves iv administration of PS followed by irradiation (100– 200 J/cm2 
of red light) 24-48 h later. During this period Photofrin is cleared from a 
number of tissues and remains concentrated at target site94. 
Various chemical modifications of the tetrapyrrolic ring of the porphyrins 
characterize the different groups of the ‘second-generation’ PS. They have 
high absorption coefficients and quantum yields as well as absorption peaks in 
the far red (660–700 nm) or near infrared (700–850 nm) regions. The serum 
half-life of the second-generation PS is short and tissue accumulation is 
selective and quick (within 1–6 h after injection). Thus the treatment can be 
carried out on the same day as the administration of the drug. In addition, the 
risk of burns by accidental sun exposure is low because clearance from normal 
tissues is rapid. Toxicity to skin and internal organs in the absence of light (so-
called ‘dark’ toxicity) is absent or minimal. Many PS currently under 
investigation belong to two chemical groups: the chlorins and the cyanines. 
The joining of four benzenes or naphthalene rings to the β-pyrrolic positions of 
porphyrins and the substitution of the methine-bridge carbons with nitrogen 
produce phthalocyanines and naphthalocyanines, respectively. The presence of 
aluminium, zinc(II), silicon(IV) and other ions gives hexacoordination and 
guarantees a satisfactory yield of singlet oxygen generation. 
Chlorins are reduced porphyrins such as NPe6 and chlorin e6, hydrophilic 
compounds with some amphiphilicity and similar photobiological properties. 
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They have been found effective in treating BCC and SCC. SnET2 and m-
THPC are hydrophobic and their use for dermatological indications has been 
investigated extensively. Finally, bacteriochlorins might be particularly useful 
for the PDT of pigmented tumors.  
Phthalocyanines are second-generation PS, containing a diamagnetic metal 
ion, which have shown high photodynamic efficiency in the treatment of 
animal tumors, as well as reduced phototoxic side effects. AlPcS are 
chemically stable, readily soluble in water, and have a strong absorption in the 
red part of the spectrum. ALPcTS has been used in clinical studies of BCC, 
Kaposi’s sarcoma and lung cancer. In addition, other PS with different 
modifications of the porphyrin structure are available. Porphycenes, synthetic 
porphyrins, and isomers of porphines, are efficient generators of singlet 
oxygen and of tumor regression. ATMPn is a chemically pure substance with 
fast pharmacokinetics and superior photodynamic properties in vitro and in 
vivo as compared to Photofrin II®. Texaphyrins are synthetic, water-soluble 
expanded-ring porphyrin analogues, in which a phenyl ring replaces one 
pyrrole ring. They can be easily complexed with large metal cations, such as 
Ln(III) or Lu(III), to give metal complexes that are photoactive in vivo with 
high selectivity and an efficient generation of 1O2 with an absorption peak near 
732 nm. The lack of significant persistent skin phototoxicity is another 
outstanding characteristic of these compounds. Photosensitivity lasts up to 6 
weeks but strict avoidance of sunlight is needed only for the first 2 weeks. 
TPPS is a hydrophilic substituted porphyrin that is 25–30 times more effective 
than HpD and Photofrin95,96. 
Second generation PS show lower toxicity, but most of them exhibit poor 
solubility in aqueous media, preventing iv delivery into the bloodstream and 
affecting their efficacy and tumor selectivity. Thus, it becames important to 
develop more performing compounds with improved deliverability. Currently, 
research efforts have been focused on the development of third generation PS, 
characterized by more specificity to the target cells, resulting in minimized 
accumulation in healthy tissues. Conjugating a targeting component, such as 
an antibody (directed against the tumour antigens), PS allows the drug to 
localize, accumulate and bind selectively at the diseased site 97 , 98 . The PS 
                                                           
95 A. E. O'Connor, W. M. Gallagher, and A. T. Byrne, "Porphyrin and nonporphyrin photosensitizers in 
oncology: preclinical and clinical advances in photodynamic therapy," Photochem.Photobiol. 85, no. 5 (2009). 
96 P. G. Calzavara-Pinton, M. Venturini, and R. Sala, "Photodynamic therapy: update 2006. Part 1: 
Photochemistry and photobiology," J.Eur.Acad.Dermatol.Venereol. 21, no. 3 (2007). 
97R. Hudson, M. Carcenac, K. Smith, L. Madden, O. J. Clarke, A. Pelegrin, J. Greenman, and R. W. Boyle, "The 
development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for 
photoimmunotherapy," Br.J.Cancer 92, no. 8 (2005). 
                                                                                                                           Introduction 
42 
 
bioconjugate is then able to (specifically) photodynamically inactivate in 
tumour cells expressing the tumour-associated antigen, minimizing healthy cell 
localization and concomitant damage. An alternative approach would be to use 
a colloidal carrier such as a liposome or targeted NPs. For example BPD-MA, 
also known as Verteporfin (Visudyne®, Novartis AG), is a semisynthetic 
porphyrin derived from protoporphyrin. It has poor water solubility but can be 
formulated successfully either in liposomes or emulsions. 
Non-porphyrin derivates include hypericin, a naturally occurring compound 
from Hypericum plants that shows maximum absorption in the ultraviolet (330 
nm) and visible (550 and 588 nm) light range, high singlet oxygen production, 
minimal dark toxicity, and high clearance from the body, after administration. 
Hypocrellins, methylene blue, azure C, methylene violet, thionine, methylene 
green, Nile blue A, and rhodamine 123 are potential PS for PDT. 
 
1.2.4 Changes in cell signaling after PDT 
PDT treatment is connected to the modification of different signal transduction 
cellular pathways, in relation to calcium expression levels, lipid metabolism 
effects, tyrosine kinase expression, cell adhesion molecules and cytokines. In 
particular, there is an acute stress reaction leading to changes in cellular 
metabolism following PDT treatment which may result in apoptosis, necrosis 
or cell survival.  
 
1.2.4.1 Calcium and lipid metabolism 
PDT performed on cancer cells in vitro has been shown to raise the levels of 
total intracellular calcium via the influx of Ca2+ through ion channels, release 
of Ca2+ stored in internal stores in the endoplasmic reticulum and 
mitochondria, and/or activation of ion exchange mechanisms, and this has 
been associated with cell death, and in certain occasions and conditions, with 
cell survival99. In many cases, the rapid release of arachidonic acid metabolites 
due to the activation of phospholipase A2 (a membrane enzyme activated by 
Ca2+) and the increase of intracellular ceramide levels after PDT treatment 
have been observed. Ceramide has been shown to activate a number of 
enzymes involved in stress signaling cascades including both protein kinases 
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and phosphatases regulating diverse cellular processes including apoptosis, cell 
senescence, cell cycle, and cellular differentiation. 
 
1.2.4.2 Tyrosine kinases 
The MAPK signaling pathways play an important role in signal transduction 
within eukaryotic cells, whereby they modulate many cellular events including 
ERK-1/2. It has been found that after PDT treatment of cells, ERK’s 
expression is significantly decreased in relation to an increase in cell death and 
so it can be assumed that the two processes are connected. Furthermore, many 
studies on cancerous cell lines have found that PDT can induce the complete 
loss of the EGFR on the cell membrane, inducing anti-proliferative responses 
and apoptosis. 
 
1.2.4.3 Cellular adhesion and cytokines 
PDT causes the damage of adhesion molecules located within the cell 
membranes, such as integrins, immunoglobulin G superfamily, selectins, 
cadherins, ICAM-1 and VCAM-1. For this reason, the alterations in the 
attachment of cancer cells to the substratum induces a decrease in cellular 
adhesion as well as a decrease in their metastatic potential. Moreover, it was 
widely demonstrated that in most cases PDT may induce over- or under-
expression of cytokines, which often relates to tumor regression and possible 
eradication. 
 
1.2.4.4 Hypoxia and angiogenesis 
Tumor hypoxia is associated with malignant progression, resistance to 
chemotherapy, PDT and radiotherapy together with increased metastasis and 
poor prognosis. There are some current reports that suggest that  hypoxia 
derived from antiangiogenic effects might promote the selection of aggressive 
tumor cell phenotypes and that therefore these treatment do not result always 
in clinical benefits100. The HIF is a master transcriptional activator of oxygen-
regulated genes, which are involved in anaerobic energy metabolism, 
angiogenesis, cell survival, cell invasion, and MDR. Since PDT is capable of 
rapidly consuming significant amounts of tissue oxygen and also shutting 
down blood that delivers oxygen supply to the tumor region, the treatment 
itself may produce severe levels of hypoxia. Therefore, high levels of HIF 
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expression are often associated with a poor overall cellular response to PDT 
treatment, so further investigation is warranted in order to understand and 
overcome this phenomenon101.  
 
1.2.5 Pathways of PDT-mediated tumor destruction 
Three distinct mechanisms have been recognized which contribute to the 
observed reduction (and frequent disappearance) of tumors when treated with 
PDT (Figure 12).  
 
 
 
Figure 12. Consequences of PDT.  Damage to endothelial cells activates a cascade of events that 
lead to local  inflammation, vessel dilatation and platelet aggregation102.  
 
In the first case, the ROS that is generated by PDT can kill tumor cells directly 
by apoptosis and/or necrosis if the PS has been taken up by tumor cells. 
Alternatively, PDT also damages the tumor-associated vasculature, which can 
lead to tumor death via lack of oxygen and nutrients. Lastly, the acute 
inflammation and release of cytokines and stress response proteins induced in 
the tumor by PDT can lead to an invasion of leukocytes that can both 
contribute to tumor destruction as well as stimulate the immune system to 
recognize and destroy tumor cells even at isolated locations. These three 
mechanisms can also influence each other. The relative importance of each 
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mechanism for the overall tumor response is yet to be defined and so requires 
further research. It is clear, however, that the combination of all these 
components in PDT is required for optimum long-term tumor regression, 
especially of tumors that may have metastasized. 
 
1.2.5.1 Mechanisms of cell death in PDT 
Although PDT can induce many cellular and molecular signaling pathway 
events in cells, its main purpose is to induce cell death. In particular, PDT can 
evoke the three main cell death pathways: apoptotic, necrotic, and autophagy-
associated cell death (Figure 13).  
 
 
 
Figure 13. Three Major Cell Death Morphotypes103. 
 
The concentration, physiochemical properties and subcellular location of the 
PS, the concentration of oxygen, the appropriate wavelength and intensity of 
the light, as well as the cell type specific properties may all influence the mode 
and extent of cell death. In general, it is believed that lower doses of PDT lead 
to more apoptotic cells, while higher doses lead to proportionately more 
necrotic cells.  
Apoptosis is a generally major cell death modality in cells responding to PDT 
for the activation of the pro-apoptotic family of proteins Bcl. MOMP after 
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photodynamic injury is controlled by Bcl-2 family members and thought to be 
largely p53-independent. 
With mitochondria-associated PS, photodamage to membrane-bound Bcl-2 can 
be a permissive signal for MOMP and the subsequent release of caspase 
activators such as cytochrome c and Smac/DIABLO, or other proapoptotic 
molecules, including AIF. 
High proportions of cell death occur after PDT when there is strong evidence 
of caspase 3 and 9 being present within the cell lysate, indicating that PDT 
must activate them within the cellular death pathway. Lysosomal membrane 
rupture and leakage of cathepsins from photo-oxidized lysosomes induces Bid 
cleavage and MOMP. 
Phototoxicity is not propagated only through caspase signaling but involves 
other proteases, such as calpains, as well as non apoptotic pathways. Typically, 
inhibition orgenetic deficiency of caspases only delays phototoxicity or shifts 
the cell death modality toward necrotic cell death. The molecular mechanisms 
underlying programmed necrosis are still elusive, but certain events including 
activation of RIP kinase, excessive mitochondrial ROS production and 
lysosomal damage are recurrently involved. Severe inner mitochondria 
membrane photodamage or intracellular Ca2þ overload could promote 
mitochondrial permeability transition, an event that may favor necrotic rather 
than apoptotic phototoxicity. It has been suggested that apoptosis and necrosis 
share common initiation pathways and that the final outcome is determined by 
the presence of an active caspase. This implies that apoptosis inhibition re-
orients cells to necrosis, so that cells sufficiently damaged by PDT are 
destroyed, regardless of the mechanism involved. 
Photodamage of cells can also lead to the stimulation of macroautophagy 
(hereafter referred to as autophagy) by various stress signals including 
oxidative stress. This process can have both a cytoprotective and a pro-death 
role after cancer chemotherapies, including those involving ROS as primary 
damaging agents. Recent studies delineate autophagy as a mechanism to 
preserve cell viability after photodynamic injury104. PS that photodamage the 
lysosomal compartment may compromise completion of the autophagic 
process, causing incomplete clearance of the autophagic cargo. Accumulation 
of ROS-damaged cytoplasmic components may then potentiate phototoxicity 
in apoptosis-competent cells. A better understanding of the interplay between 
autophagy, apoptosis, and necrosis and how these processes lead to improved 
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tumor response will be a requisite to devise better therapeutic strategies in 
PDT105. 
 
1.2.5.2 Cytoprotective mechanisms 
Numerous publications have reported cytoprotective mechanisms that cancer 
cells exploit to avoid the cytotoxic effects of PDT such as the production in 
cancer cells of antioxidant molecules (eg, some amino acids, 
glutathione,vitamin E) and the expression of enzymes that can detoxify ROS. 
For example, SOD overexpression or treatment with SOD mimetics have been 
shown to counteract the cytotoxic effect of PDT. The third cytoprotective 
mechanism involves proteins whose encoding genes are themselves induced by 
PDT. Many categories can be specified but most of them are part of signaling 
pathways that can regulate PDT-induced apoptosis or participate in the repair 
of lesions induced by oxidative stress. NFκB inhibition by overexpression of 
the Basuper-repressor or by the use of pharmacological inhibitors strongly 
sensitizes cancer cells to apoptosis induced by PDT. Other stress-related 
transcription factors induced by PDT include AP-1, HIF, or Nrf2. PDT was 
shown to upregulate heme oxygenase-1 expression, and the mechanism is 
dependent on Nrf2 nuclear accumulation and on p38 MAPK and 
phosphoinositide 3-kinase activities. PDT was found to induce expression of 
various HSPs for which a protective role in PDT has been described106. For 
example, transfection of tumor cells with the HSP gene increased the survival 
of tumor cells after PDT. Similarly, increased HSP60 and HSP70 levels are 
inversely correlated with sensitivity to the photodynamic treatment. The 
simplest explanation for these observations is the ability of HSPs to bind to 
oxidatively damaged proteins. Moreover, the intracellular function of HSPs is 
not only restricted to protein refolding. Many HSPs ‘‘client’’ proteins play a 
critical role in the regulation of prosurvival pathways. PDT also leads to 
increased ubiquitination of carbonylated proteins, thereby tagging them for 
degradation in proteasomes, which prevents the formation of toxic protein 
aggregates. 
 
1.2.5.3 Antivascular Effects of PDT 
PDT has been known to cause microvasculature collapse leading to severe 
tissue hypoxia, eventual complete blood flow stasis, hemorrhage, and, in some 
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larger vessels, the formation of platelet aggregates (Figure 14). The vascular 
effects of PDT can differ greatly based on the different PS and the drug-light 
interval administered. For example, PDT with Photofrin® changes vessel 
constriction and permeability, vessel leakage and leukocyte adherence, certain 
phthalocyanine derivatives cause vascular leakage and NPe6 results in blood 
flow stasis. Although microvascular damage and hypoxia after PDT 
contributes to greater tumor response, reduction in oxygen during treatment 
can limit tumor control by inducing the production of proangiogenic markers 
such as VEGF, COX-2, MMPs and other cytokines, creating enhanced 
environment for tumor recurrence. Many reports directly implicate the 
endothelium as a primary target for PDT in vivo; this stimulated research into 
the relative sensitivity of endothelial cells to PDT and the responses of 
endothelial cells that could initiate the various phenomena at the vessel level.  
 
 
Figure 14. Tumor endothelial responses after PDT leading to blood flow stasis. (A) Tumor blood 
vessel before PDT. (B-E) Magnification of the junction of the tumor vessel. (B) Before PDT 
endothelial cells are tightly attached to the basement membrane of the vessel wall, lining the blood 
vessel. Endothelial cells are connected through tight junctions. (C) After injection of a PS and light 
exposure, cellular stress inside the endothelial cells results in disruption of tight junctions, partial 
retraction and detachment from the vessel wall. (D) Blood gets in contact with the vessel wall 
collagen and the clotting cascade is initiated, ultimately leading, through the interaction with 
fibrinogen, to the formation of a stabilized thrombus, leading to obstruction of the vessel. (E) Due 
to the angiogenic switch, endothelial cell proliferation, migration and sprout formation is 
observed107.  
Exponentially growing endothelial cells were significantly more sensitive than 
similarly proliferating tumor cells, and the difference in sensitivity was 
accompanied by greater PS accumulation in the endothelial cells. Endothelial 
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cell responses to sublethal doses of PDT may also contribute to vascular 
changes observed in tissue108,109,110. 
 
1.2.6 PDT and the Immune Response 
Numerous preclinical and clinical studies have demonstrated that PDT can 
influence the adaptive immune response in different ways; some regimens 
result in potentiation of adaptive immunity, whereas others lead to 
immunosuppression. The precise mechanism leading to potentiation versus 
suppression is unclear; however, it appears as though the effect of PDT on the 
immune system is dependent upon the treatment regimen, the area treated, and 
the PS type. Recent reports have shown that clinical antitumor PDT also 
increases antitumor immunity111.  
First of all, PDT frequently provokes a strong acute inflammatory reaction 
observed as localized edema at the targeted site (Figure 15). This reaction 
starts with the generation of important alarm/danger signals, also called 
DAMPs or CDAMPs, at the treated site that can be detected by the innate 
immunity. As consequence, PDT induce oxidative stress which triggers a vast 
array of signal pathways via TLRs. This includes expression of HSPs, 
transcription factors such as NF-κB and AP-1. NF-κB and AP-1 can then 
induce expression of immunoregulatory and proinflammatory proteins such as 
IL (-1α, -1β, -2, -6, -8, -11, -12, -15), TNF, chemokines and IFN-α/β. Further, 
photooxidative degradation of membrane lipids and generation of arachidonic 
acid metabolites are themselves potent inflammatory mediators that cause a 
rapid and strong inflammatory reaction. These processes together with the 
release of histamine and serotonin from damaged vasculature cause infiltration 
of the tumor site by diverse populations of immune cells (neutrophils, mast 
cells and macrophages) that become activated and engaged in tumor cell 
destruction. However, a key event appears to be PDT induced complement 
activation. 
Photosensitization induces the innate immunity response with subsequent 
development of adaptive immunity. In particular, PDT activates both humoral 
and cell-mediated antitumor immunity. PDT-induced acute local and systemic 
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inflammation is postulated to culminate in the maturation and activation of 
DCs. Activated DCs then migrate to tumor draining lymph nodes, where they 
stimulate T-cell activation. Generation of CD8+ effector and memory T cells is 
frequently, but not always, dependent upon the presence and activation of 
CD4+T cells. PDT-induced antitumor immunity may or may not depend on 
CD4+ T cells and may be augmented by natural killer cells. Nevertheless, in 
some cases, certain PDT regimens have been shown to systemically suppress 
immune reactivity112.  
 
 
Figure 15. PDT induces an anti-tumor immunity response. PDT-treated dying cells produce 
danger signals including the expression of HSPs, cytokines, adhesion molecules, co-stimulatory 
molecules and immunologically important genes. These processes together with the release of 
histamine and serotonin from damaged vasculature induce an activation of complement, sequential 
arrival of neutrophils. DCs are activate by PDT sensing endogenous danger signals release by 
dying tumor cells, then they migrate to the tumor-draining lymph nodes and stimulate T-cell 
activation113.  
 
It was demonstrated for example that the cutaneous Photofrin-PDT and ALA-
PDT cause suppression of the contact hypersensitivity reaction and the 
increase in levels of IL-10 expression in the sera of treated animals. It is 
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known that IL-10 suppresses cell-mediated immune response via its ability to 
inhibit activation of Th1 cells by APC. Nevertheless, the major effector cell in 
CHS is the IFN-γ secreting CD8+ (Tc1) cell. Therefore, it is possible that PDT 
induces a defect in thedevelopment of Th1 and Tc1 cells. Another potential 
suppressor of Th1 and Tc1 development, and thus CHS, is IL-4, often inducted 
by PDT treatment114. 
1.2.7 Clinical PDT for cancer 
PDT has been utilized for pre-neoplastic and neoplastic diseases in a wide 
variety of organ systems, including skin, genitourinary, esophagus, prostate, 
bile duct, pancreas, head and neck, and brain. Several medicines have been 
approved or are currently in clinical trials (table 2). 
Several types of skin cancers and precancers are among the first to be studied 
in PDT due to their accessibility to PS and external light. In the definitive 
setting, PDT is currently approved for the treatment of AK, BCC and SCC. 
Successful results for PDT of nonhyperkeratotic AK have been achieved with 
systemically administered porfimer sodium as well as topically applied ALA 
and methyl-ALA (MAL). Twenty-eight RCTs that reported the use of PDT in 
the treatment of AK have been identified115 and aggregated data indicate better 
rates of complete response and better cosmetic results with PDT than with the 
other treatments116. 
Thirteen RCTs on superficial and nodular BCC have been reported, comparing 
ALA-PDT with surgical excision, cryotherapy or placebo. In particular, for 
superficial BCC, the outcome after PDT appears similar to surgery or 
cryotherapy, whereas for nodular (deep) BCC, PDT is less effective than 
surgery for lesion clearance. Finally, PDT can substantially reduce the size of 
large SCC tumors reducing morbidity and increasing overall curative 
response117. 
Regarding ophthalmic disease, the only clinically PDT treatment is 
Verteporfin (Visudyne®) approved for AMD worldwide since 2000. Its 
                                                           
114S. O. Gollnick, B. Owczarczak, and P. Maier, "Photodynamic therapy and anti-tumor immunity," Lasers 
Surg.Med. 38, no. 5 (2006). 
115D. Fayter, M. Corbett, M. Heirs, D. Fox, and A. Eastwood, "A systematic review of photodynamic therapy in 
the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head 
and neck, lung, oesophagus and skin," Health Technol.Assess. 14, no. 37 (2010). 
116C. A. Morton, S. B. Brown, S. Collins, S. Ibbotson, H. Jenkinson, H. Kurwa, K. Langmack, K. McKenna, H. 
Moseley, A. D. Pearse, M. Stringer, D. K. Taylor, G. Wong, and L. E. Rhodes, "Guidelines for topical 
photodynamic therapy: report of a workshop of the British Photodermatology Group," Br.J.Dermatol. 146, no. 4 
(2002). 
117G. Jeremic, M. G. Brandt, K. Jordan, P. C. Doyle, E. Yu, and C. C. Moore, "Using photodynamic therapy as a 
neoadjuvant treatment in the surgical excision of nonmelanotic skin cancers: prospective study," 
J.Otolaryngol.Head Neck Surg. 40 Suppl 1 (2011). 
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therapy involves iv administration of verteporfin followed by activation 
through an ophthalmoscope equipped with a 690 nm diode laser while the PS 
is still in the general circulation. Several RCTs are currently under way to 
evaluate the efficacy of AMD PDT for use with other PS, such as SnET2, 
motexafin lutetium, and Npe6118.  
In the field of head and neck cancer, over 1500 patients have been treated with 
PDT119 with Photofrin, 5-ALA, Foscan and Photoclor by systemic delivery; in 
particular, Foscan® was approved in Europe in 2001 for the palliative 
treatment of patients with advanced head and neck cancer who have exhausted 
other treatment options. Furthermore, various formulations of porfimer 
sodium, ALA and temeporfin are  currently undergoing intensive clinical 
investigation as an adjunctive treatment for brain tumors, such as glioblastoma 
multiforme, anaplastic astrocytoma, malignant ependymomas or meningiomas, 
melanoma and lung cancer brain metastasis, and recurrent pituitary 
adenomas 120 . Currently, PS are being evaluated both as intraoperative 
diagnostic tools by means of PD and FGR as well as during PDT as an 
adjunctive therapeutic modality. The most recently published trials that 
employed PD, FGR, and PDT provided additional encouraging results, but the 
initial delay in tumor progression did not translate to extended overall 
survival121. PDT is increasingly being used to treat cancers of the airways and 
other tumors in the thoracic cavity, especially NSCLC122 . Different RCTs 
based on talaporfin or porfimer sodium-mediated PDT showed good results 
and complete response rate in patients with early stage lung cancer or for 
whom surgery is not feasible123.  
 
                                                           
118J. I. Lim, "Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials," 
Ophthalmol.Clin.North Am. 15, no. 4 (2002). 
119
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120H. Kostron, "Photodynamic diagnosis and therapy and the brain," Methods Mol.Biol. 635 (2010). 
121 S. Eljamel, "Photodynamic applications in brain tumors: a comprehensive review of the literature," 
Photodiagnosis.Photodyn.Ther. 7, no. 2 (2010). 
122C. B. Simone, J. S. Friedberg, E. Glatstein, J. P. Stevenson, D. H. Sterman, S. M. Hahn, and K. A. Cengel, 
"Photodynamic therapy for the treatment of non-small cell lung cancer," J.Thorac.Dis. 4, no. 1 (2012). 
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Another interesting application of PDT is in the MPM124. 
In gastroenterology, endoscopically accessible premalignant or malignant 
lesions located within the esophagus, the stomach, the bile duct, or the 
colorectum with a high surgical risk have become suitable targets of 
endoscopic PDT 125 . Photofrin-PDT has been approved for obstructing 
esophageal cancer, early-stage esophageal cancer, and Barrett's esophagus in 
several countries, as an alternative to esophagectomy because these are 
superficial and large mucosal areas that are easily accessible for light. Recent 
pilot studies have demonstrated that endoscopic Photofrin-PDT is also 
effective in the palliative treatment of hilarcholangiocarcinoma126, PDT for 
early duodenal and ampullary cancers and advanced adenomas. 
Due to advances in light applicators, the interstitial PDT is now becoming a 
practical option for solid lesions, including those in parenchymal organs such 
as the liver and pancreas127. Talaporfin-mediated PDT may have efficacy in 
treating hepatocellular carcinoma, whereas Foscan looked promising  in the 
treatment of pancreatic cancer 128 . In the case of prostate cancer, Foscan, 
Tookad, and Lutex looked minimally-invasive alternatives to surgery or 
radiotherapy, reducing the risk of the post-surgical side effects of incontinence 
and impotence. Bladder cancer tends to be a superficial condition, and for this 
reason it is proposed that a superficial treatment mediated with ALA or its 
ester derivatives, by intravesical instillation, may be a preferable means for 
local therapy129. 
The last PDT application is based on the treatment of gynecological cancers. 
For cervical intraepithelial neoplasia, PDT based on chlorine e6 (Fotolon) or 
hexyl-ALA offers a nonscarring alternative to cone biopsy. For vulvar 
intraepithelial neoplasia, use of Foscan or ALA may ameliorate the need for 
radical mutilating surgery. Similarly, penile intraepithelial neoplasia and anal 
intraepithelial neoplasia have been treated with ALA-based PDT, sometimes 
                                                           
124 J. S. Friedberg, "Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?," 
Expert.Rev.Respir.Med. 5, no. 1 (2011). 
125M. W. Wiedmann and K. Caca, "General principles of photodynamic therapy (PDT) and gastrointestinal 
applications," Curr.Pharm.Biotechnol. 5, no. 4 (2004). 
126M. A. Ortner, "Photodynamic therapy for cholangiocarcinoma," Lasers Surg.Med. 43, no. 7 (2011). 
127T. J. Vogl, K. Eichler, M. G. Mack, S. Zangos, C. Herzog, A. Thalhammer, and K. Engelmann, "Interstitial 
photodynamic laser therapy in interventional oncology," Eur.Radiol. 14, no. 6 (2004). 
128S. G. Bown, A. Z. Rogowska, D. E. Whitelaw, W. R. Lees, L. B. Lovat, P. Ripley, L. Jones, P. Wyld, A. 
Gillams, and A. W. Hatfield, "Photodynamic therapy for cancer of the pancreas," Gut 50, no. 4 (2002). 
129 A. P. Berger, H. Steiner, A. Stenzl, T. Akkad, G. Bartsch, and L. Holtl, "Photodynamic therapy with 
intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-
center study," Urology
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with complete clearance. Extramammary Paget’s disease responds to PDT 
with porfimer sodium or ALA130. 
 
1.2.8 Combined PDT 
At present, combination of different chemotherapeutic drugs in a 
chemotherapy regimen is an attractive strategy for effective anticancer 
treatment. In a clinical setting the treated patients were found to fail the 
experiences of single agent chemotherapy, because it is limited to act on 
specific cancer survival pathways and showed low response rates and relapse 
of tumor. The major limiting factors associated with poor prognosis of cancer 
following single agent chemotherapeutic treatment in cancer patients are: 
MDR, significant toxicity and undesirable side effects. To improve the 
therapeutic potential of cancer chemotherapy, it is essential to establish an 
alternative approaches that could provide a solution to the problems involved 
in single drug chemotherapy. To this end, much attention has been given to 
combination approaches for a better long-term prognosis and to decrease side 
effects associated with high doses of single drug treatment. Unlike single agent 
therapy, combination therapy can modulate different signaling pathways, 
maximizing the therapeutic effect by overcoming toxicity and, moreover, can 
overcome the mechanisms of MDR associated with cancer treatment. The use 
of combination therapy for cancer treatment has been well established in recent 
years and its advantages applied to cancer therapy are illustrated below. One of 
the prime benefits of combination therapies is the potential for providing 
synergistic effects. In combination therapy the overall therapeutic benefit of 
the drugs in combination were found to be greater than the sum of the effects 
of the drugs individually. These advantages have driven drug discovery efforts 
toward the search for combination therapies. The best drug combination with 
maximal antitumor efficacy can be calculated by multiple drug 
effect/combination index isobologram analysis, an effective way to 
demonstrate that drugs are working synergistically. The prime mechanism of 
synergistic effect following combinational drug treatment could act on the 
same or different signaling pathways to achieve more-favorable outcomes at a 
lower dose with equal or increased efficacy131,132. Combinations of various 
                                                           
130S. Anand, B. J. Ortel, S. P. Pereira, T. Hasan, and E. V. Maytin, "Biomodulatory approaches to photodynamic 
therapy for solid tumors," Cancer Lett. 326, no. 1 (2012). 
131P. Parhi, C. Mohanty, and S. K. Sahoo, "Nanotechnology-based combinational drug delivery: an emerging 
approach for cancer therapy," Drug Discov.Today 17, no. 17-18 (2012). 
132J. Lehar, A. S. Krueger, W. Avery, A. M. Heilbut, L. M. Johansen, E. R. Price, R. J. Rickles, G. F. Short, III, 
J. E. Staunton, X. Jin, M. S. Lee, G. R. Zimmermann, and A. A. Borisy, "Synergistic drug combinations tend to 
improve therapeutically relevant selectivity," Nat.Biotechnol. 27, no. 7 (2009). 
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therapeutic modalities with non overlapping toxicities are among the 
commonly used strategies to improve the therapeutic index of treatments in 
modern oncology. Two general approaches may increase the antitumor 
effectiveness of PDT: 1) sensitization of tumor cells to PDT and 2) 
interference with cytoprotective molecular responses triggered by PDT in 
surviving tumor or stromal cells. Any interactions between PDT and PDT-
sensitizing agents will be confined to the illuminated area. Therefore, the 
potentiated toxicity of the combinations is not systemic. This should be of 
special importance in elderly or debilitated patients who tolerate more 
intensive therapeutic regimens poorly. Moreover, considering its unique 1O2-
dependent cytotoxic effects, PDT can be safely combined with other antitumor 
treatments without the risk of inducing cross-resistance133. There have been 
few studies on combinations of PDT with standard antitumor regimens 
published to date. PDT can be used in combination with surgery as a 
neoadjuvant, adjuvant, or repetitive adjuvant treatment, preferably image-
guided fluorescence to confine illumination to the most suspicious lesions. 
PDT has also been successfully combined with radiotherapy and 
chemotherapy134,135. 
Another approach to promote PDT efficacy involves increased PS delivery or 
impaired loss from tumor cells. The first approach involves conjugation of PS 
to various tumor-targeting molecules. This may be important in the treatment 
of tumors where large surface areas are illuminated and hence increased tumor 
selectivity is desired. The use of compounds that impair PS efflux has also 
been demonstrated to effectively sensitize tumor cells to PDT, although such 
approaches seem to be limited to those PS that are the substrates of outward 
transport systems such as ABCG2136. The development of novel target-specific 
antitumor drugs has enabled examination of a number of concept-based 
combinations that in various molecular mechanisms sensitize tumor cells to the 
                                                           
133 D. Kessel and C. Erickson, "Porphyrin photosensitization of multi-drug resistant cell types," 
Photochem.Photobiol. 55, no. 3 (1992). 
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136W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, and A. R. Oseroff, "The 
tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting 
ABCG2," Clin.Cancer Res. 13, no. 8 (2007). 
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cytotoxic effects of PDT. Proteins are major targets for oxidative reactions 
because they constitute nearly 70% of the dry weight of cells. Oxidized 
proteins can be refolded by molecular chaperones such as HSPs. Inefficient 
restoration of their structure leads to accumulation of misfolded proteins and 
their aggregation, which precipitates cell death. Accumulation of damaged or 
misfolded proteins within ER triggers a process called ER stress, which can be 
ameliorated by unfolded protein response or can lead to cell death. Therapeutic 
approaches that interfere with refolding or removal of oxidized proteins can be 
used to sensitize tumor cells to PDT. For example, modulation of HSP 
function with geldanamycin, a HSP90 inhibitor, sensitizes tumor cells to 
PDT137. Bortezomib, a proteasome inhibitor successfully used in the treatment 
of hematological disorders, potentiates the cytotoxic effects of PDT by 
aggravation of ER stress. Moreover, several apoptosis-modulating factors such 
as rapamycin, Bcl-2 antagonists, ursodeoxycholic acid, or ceramide analogues 
have been shown to increase PDT-mediated cancer cell death138(table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
137A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer, "Survivin, a member of the inhibitor of apoptosis 
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1.3 NPs in PDT 
A PDT treatment can be considered to be selective in that the toxicity to tumor 
tissue is induced by the local activation of the PS, while normal tissue not 
exposed to light are spared. In spite of this, several drawbacks limit the clinical 
application of PDT. 
Firstly, several organs or tissues exposed to environmental light can suffer 
some phototoxicity following PS administration. For example, patients treated 
with PDT using porphyrins as PS exhibit some degree of cutaneous 
photosensitivity on exposure to solar radiation which persists for several 
weeks. This side effect is caused by the accumulation and prolonged retention 
of the PS in the skin. Secondly, the low extinction coefficients of PS require 
the administration of relatively large amounts of drug to obtain a satisfactory 
therapeutic response. Furthermore, the adsorption maximum is at a relatively 
short wavelength leading to a poor tissue penetration of light. Finally, most of 
the PS are hydrophobic. This lipophilic nature may be an important factor 
affecting the preferential accumulation in cellular hydrophobic loci since these 
molecules must be able to get into the cells by crossing lipid membranes. 
However, due to their minute solubility in water, iv treatment is greatly 
hampered. Thus, it is necessary to develop suitable delivery systems such as 
oil-dispersions, liposomes, polymeric NPs or hydrophilic polymer-PS 
conjugates.  
The ideal drug delivery system should enable the selective accumulation of the 
PS within the diseased tissue and the delivery of therapeutic concentrations of 
PS to the target site with little or no uptake by non-target cells. The carrier 
should be able also to incorporate the PS without loss or alteration of its 
activity. Another reason for using vehicles is to provide an environment where 
the PS can be administered in a monomeric form. In fact, due to their chemical 
structure, most PS tend to aggregate in aqueous media. This state is one of the 
determining factors, which can hinder the efficacy of the drug in vivo by 
decreasing its bioavailability and limiting its capacity to absorb light.  
Nanocarriers for the delivery of PS for PDT can be divided into passive and 
active based on the presence or the absence of a targeting molecule on the 
surface. Passive carriers can be sub-classified by material composition into 
biodegradable polymer-based NPs and non-polymer based NPs. Active NPs 
can be sub-classified by mechanism of activation.  
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1.3.1 Passive NPs 
1.3.1.1 Biodegradable NP carriers 
Biodegradable polymeric NPs have received tremendous attention as a 
possible means of delivering antineoplastic conventional agents, as well as PS 
for their capacity to lie in high drug loading, the possibility of controlling the 
drug release, and the existence of a large variety of materials and 
manufacturing processes. Investigation into biodegradable polymeric NPs for 
use in PDT began as early as 1990 with efforts to enhance carrier capacity and 
control drug release.  
In 1991, Labib et al reported the encapsulation of ZnPcS4 or AlPc into 
poly(isobutylcyanoacrylate) or poly(ethylbutylcyanoacrylate) ‘nanocapsules’ 
or ‘nanospheres’139. Almost all subsequent research have utilized PLA/PLGA 
NPs. In a series of studies p-THPP was encapsulated into sterile sub-150nm 
biodegradable NPs based on PLGA and PLA140,141.                                                                                                                             
At the same time, m-THPP was incorporated in biodegradable modified 
chitosan NPs and in vitro photocytotoxicity and cellular uptake investigated142. 
In order to further investigate these p-THPP loaded PLGA NPs, the efficacy of 
the encapsulated drug was assessed on the chick embryo CAM model143. It 
was proven that PDT-induced vascular occlusion of p-THPP is enhanced when 
encapsulated into NP delivery systems, due to a longer residence time inside 
the vasculature. In another study, the in vitro and in vivo photodynamic 
activities of verteporfin-loaded PLGA NPs intended to be intravenously 
injected were investigated144. In particular, two types of verteporfin loaded 
PLGA NPs (167 and 370 nm in diameter) were prepared. A higher 
photocytotoxic effect was evident in the case of smaller sized NPs for their 
higher intracellular uptake. Furthermore, in vivo studies on 
                                                           
139A. Labib, V. Lenaerts, F. Chouinard, J. C. Leroux, R. Ouellet, and J. E. van Lier, "Biodegradable nanospheres 
containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy," Pharm.Res. 8, no. 
8 (1991). 
140Y. N. Konan, M. Berton, R. Gurny, and E. Allemann, "Enhanced photodynamic activity of meso-tetra(4-
hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles," Eur.J.Pharm.Sci. 18, no. 3-4 (2003). 
141Y. N. Konan, R. Cerny, J. Favet, M. Berton, R. Gurny, and E. Allemann, "Preparation and characterization of 
sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy," 
Eur.J.Pharm.Biopharm. 55, no. 1 (2003). 
142Saboktakin M. Reza, R. M. Tabatabaie, A. Maharramov, and Ramazanov M. Ali, "Synthesis and in vitro 
studies of biodegradable modified chitosan nanoparticles for photodynamic treatment of cancer," 
Int.J.Biol.Macromol. 49, no. 5 (2011). 
143A. Vargas, B. Pegaz, E. Debefve, Y. Konan-Kouakou, N. Lange, J. P. Ballini, H. van den Bergh, R. Gurny, 
and F. Delie, "Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation 
using chick embryos," Int.J.Pharm. 286, no. 1-2 (2004). 
144Y. N. Konan-Kouakou, R. Boch, R. Gurny, and E. Allemann, "In vitro and in vivo activities of verteporfin-
loaded nanoparticles," J.Control Release 103, no. 1 (2005). 
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rhabdomyosarcoma-bearing DBA/2 mice demonstrated that verteporfin-loaded 
small NPs effectively controlled tumour growth for 20 days in the mice with 
early light irradiation times following drug administration. In yet another study 
based on PLGA NPs, Ricci-Junior et al reported the preparation, 
characterization and results of the phototoxicity assay of PLGA NPs 
containing ZnPc for PDT use. This system showed a strong phototoxicity on 
P388-D1 cells145. Following, another PLGA nanosystem entrapping ZnPc was 
developed and tested on tumor-bearing mice 146 . Other PS that have been 
experimented include ICG 147and Hypericin 148 . These compounds have the 
potential to be used for both diagnostic and therapeutic purposes. In particular, 
ICG-entrapped PLGA NPs and hypericin-loaded PLA-NPs were  investigated. 
Recently, hypocrellin was entrapped in PLGA NPs and used for PDT 
treatment of SCCVII growing subcutaneously in syngeneic mice 149 . 
Temoporfin-loaded core-shell PEG-PLGA NPs were prepared and in vivo 
activity assessed on athymic nude-Foxn1 mice150. Another novel drug delivery 
system for hydrophobic PS was accomplished using PEG–PCL micelles 
containing protoporphyrin IX151. 
 
1.3.1.2 Non-biodegradable NP carriers 
Non-biodegradable NPs have a different role in PDT than the biodegradable 
ones. They are not traditionally used for drug delivery because of their 
inability to degrade and release drugs in controlled amounts. However, unlike 
other drugs, PS are not by themselves toxic to the targeted cells; rather, they 
act like catalysts to create toxic products from non-toxic dissolved oxygen. 
Like catalysts, they are themselves not destroyed by the process, and can be 
used repeatedly with proper activation. In such a scenario, non-biodegradable 
                                                           
145E. Ricci-Junior and J. M. Marchetti, "Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic 
therapy use," Int.J.Pharm. 310, no. 1-2 (2006). 
146M. Fadel, K. Kassab, and D. A. Fadeel, "Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for 
photodynamic therapy in tumor-bearing mice," Lasers Med.Sci. 25, no. 2 (2010). 
147V. Saxena, M. Sadoqi, and J. Shao, "Polymeric nanoparticulate delivery system for Indocyanine green: 
biodistribution in healthy mice," Int.J.Pharm. 308, no. 1-2 (2006). 
148 M. Zeisser-Labouebe, N. Lange, R. Gurny, and F. Delie, "Hypericin-loaded nanoparticles for the 
photodynamic treatment of ovarian cancer," Int.J.Pharm. 326, no. 1-2 (2006). 
149M. Korbelik, R. Madiyalakan, T. Woo, and A. Haddadi, "Antitumor efficacy of photodynamic therapy using 
novel nanoformulations of hypocrellin photosensitizer SL052," Photochem.Photobiol. 88, no. 1 (2012). 
150M. Rojnik, P. Kocbek, F. Moret, C. Compagnin, L. Celotti, M. J. Bovis, J. H. Woodhams, A. J. Macrobert, D. 
Scheglmann, W. Helfrich, M. J. Verkaik, E. Papini, E. Reddi, and J. Kos, "In vitro and in vivo characterization 
of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy," Nanomedicine.(Lond) 
7, no. 5 (2012). 
151B. Li, E. H. Moriyama, F. Li, M. T. Jarvi, C. Allen, and B. C. Wilson, "Diblock copolymer micelles deliver 
hydrophobic protoporphyrin IX for photodynamic therapy," Photochem.Photobiol. 83, no. 6 (2007). 
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carriers can be used as carriers to circumvent problems of usage of the free 
drug. To be effective, NPs must be small enough to have a volume of 
distribution roughly parallel to that of the free drug. This requires stringent 
control on size, with a maximum allowable diameter less than 100 nm, and 
preferably in the sub-50 nm range. 
Ceramic-based NPs, non-covalently doped with PS, hold several advantages 
over organic polymeric particles like ambient temperature conditions in the 
preparative processes, stability, exquisite control over size, shape and porosity, 
very low sizes (less than 50 nm), immunity to changes in pH and microbial 
attack. Possibly, the first paper on the use of ceramic-based NPs as a novel 
drug-carrier system for PDT used silica-based spherical particles encapsulating 
the anticancer drug HPPH 152 . Covalent bonding of the PS molecules into 
organically modified silica (ORMOSIL) NPs creates more stable 
formulations153 . ORMOSIL was also used later by this group for TP dye 
encapsulation154. Wieder et al reported the development of a delivery system 
based on gold NPs, whereby a phthalocyanine is bound to the surface of the 
NP. In this study a significant improvement in PDT efficiency was evident as 
compared to the free PS155. TP dyes have received attention lately because of 
their ability to convert absorbed low-energy radiation to higher energy 
emissions. Dyes which can direct by transfer the higher energy to molecular 
oxygen for generation of singlet oxygen can be very useful in PDT because 
they can be activated in deep tissues. The first report in this direction used 
microemulsion to incorporate the TP dye porphyrin TMPyP into 
polyacrylamide NPs156 . Organically modified silica NPs were used to co-
encapsulate HPPH and an excess amount of BSA and TP sensitization of 
singlet oxygen in an aqueous dispersion was demonstrated. NPs were taken up 
by tumor cells and cytotoxic effect under TP irradiation was demonstrated.  
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1.3.2 Active NPs 
1.3.2.1 Quantum dots 
QDs are nanoparticulate imaging probes with high quantum yields, high 
photostability and fluorescent emission properties which can be tunable by 
size. QDs can transfer energy to surrounding O2, with consequent toxicity to 
cells. Several recent papers have explored their potential as PS in their own. In 
probably the first paper to mention this possibility, while investigating the two-
step energy-transfer mechanism from CdSe QDs to the attached PS. The 
authors discovered that semiconductor QDs alone can generate 1O2 without a 
mediating PS molecule in toluene probably because of the intercalation of 
dissolved O2 molecules with the TOPO layer at the QD surface 157 . To 
circumvent the inefficiency of QDs alone to generate singlet oxygen, several 
attempts have been made to covalently conjugate PSs to CdSe/ZnS via organic 
bridges 158 or by electrostatic interactions. For example, recently, AlPcSs, 
conjugated with amine-dihydrolipoic acid coated QDs by an electrostatic 
binding,was able to destroy the most cancer cells via FRET mediated PDT159. 
 
1.3.2.2 Self-lighting NPs 
Self Lighting PDT is a new approach to cancer treatment through a 
combination of radiation therapy and PDT. Upon exposure to ionising 
radiation such as X-rays, scintillation luminescence will emit from the NPs and 
activate the PS; as a consequence, singlet oxygen is produced to enhance the 
killing of cancer cells by ionizing radiation. Supplementing conventional 
radiation therapy (that can damage healthy tissues as well) with PDT will 
enable the use of lower doses of radiation. When the NPs have persistence 
luminescence, e.g. BaFBr:Eu+, Mn+ NPs, short X-ray exposures are followed 
by prolonged PS excitation. The period of afterglow is increased in vivo 
because of higher ambient temperatures 160 . However, direct application in 
biological systems have not been reported yet. 
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159L. Li, J. F. Zhao, N. Won, H. Jin, S. Kim, and J. Y. Chen, "Quantum Dot - Aluminum phthalocyanine 
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1.3.2.3 Upconversion NPs 
Luminescent materials with triplet excitation states (phosphors) emit light of 
higher energy than exciting radiation (Anti-Stokes emission) by different 
mechanisms, including upconversion and simultaneous TP absorption 161 . 
Simultaneous TP absorption requires a single entity where the transition from 
ground to an excited electronic state is brought about by simultaneous 
absorption of two low energy photons whose combined energy is sufficient to 
induce the transition. Quantum mechanically, this takes place through the 
attainment of a virtual intermediate state on absorption of the first photon. 
Upconversion relies on sequential discrete absorption and luminescence steps 
where at least two metastable entities (usually ions) are involved, the first 
serving as an excitation reservoir, and the second as the emitting state. It is 
generally a more efficient process, does not require coherent radiation and 
involves real (as opposed to virtual) intermediate states. Anti-Stokes emissions 
for upconversion processes are found to exceed excitation energies by 10–100 
times kT. Since both the mechanisms allow excitation with low energy light 
and since this is known to penetrate tissues deeply, NPs excited by each 
process have been used to activate PS. The common advantage is in extending 
the reach of PDT to tumor sites several centimeters below the skin/mucosal 
surface. The role of the NPs here can be likened to a nanotransducer. NPs are 
by themselves unable to generate singlet oxygen species from dissolved 
oxygen, and require the attachment of an appropriate PS with an excitation 
band matching the emission of the NPs. Upconversion NPs are modified 
nanometer-sized composites which generate higher energy light from lower 
energy radiation, usually near-infrared or infrared, through the use of transition 
metal, lanthanide, or actinide ions doped into a solid state host. A variety of 
core materials and dopants have been demonstrated for upconversion particles 
with actual/possible biological applications.  
The first reported use of upconversion NPs in PDT used NaYF4:Yb3+, Er3+ 
NPs coated with a porous, thin layer of silica doped with merocyanine-540 PS 
and functionalized with a tumor targeting antibody162 . Then, upconversion 
ZnPc/PEI/NaYF4 NPs were developed. The ability to observe the emission 
from the NPs to some depth within tissues can have enormous impact on the 
diagnosis and monitoring of some tumors. NIR light, for example, can 
penetrate to a considerable extent in soft fibro-fatty tissues like breast, and the 
                                                           
161F. Auzel, "Upconversion and anti-Stokes processes with f and d ions in solids," Chem.Rev. 104, no. 1 (2004). 
162P. Zhang, W. Steelant, M. Kumar, and M. Scholfield, "Versatile photosensitizers for photodynamic therapy at 
infrared excitation," J.Am.Chem.Soc. 129, no. 15 (2007). 
                                                                                                                           Introduction 
67 
 
upconversion NPs can potentially be used for therapy as well as monitoring of 
tumors over time. 
 
1.3.3 NPs in combined PDT 
The idea to combine two drugs with different mechanism of action and 
pharmacokinetics in a nanocarrier with well-tailored properties can allow a 
control over anticancer drug/PS biological fate and promote co-localization in 
the same area of the body163. This approach is rather recent and demonstrated 
to be a promising strategy to overcome tumor drug resistance in a mouse tumor 
model treated with doxorubicin in combination with the PS methylene blue164. 
In particular, surfactant-polymer hybrid NPs formulated using an anionic 
surfactant, Aerosol-OT, and a naturally occurring polysaccharide polymer, 
sodium alginate, were used for synchronized delivery of the two drugs. Balb/c 
mice bearing syngeneic JC tumors (mammary adenocarcinoma) were used as a 
drug-resistant tumor model. NP-mediated combination therapy significantly 
inhibited tumor growth and improved animal survival. NP-mediated 
combination treatment resulted in enhanced tumor accumulation of both 
doxorubicin and methylene blue, significant inhibition of tumor cell 
proliferation, and increased induction of apoptosis. Moreover,  a study of 
combination of PDT with chemotherapy using as a model tumor mammary 
adenocarcinoma was conducted; the results showed that this combination may 
result in a decrease in resistance of the tumor . 
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The goal of the project was to design and develop biodegradable nanocarriers 
for the combined delivery of a conventional cytotoxic drug and a PS for PDT 
with the aim to potentiate anticancer effect and attenuate toxicity profile of 
both drugs. To this purpose, we developed iv nanoassemblies with different 
structures and able to deliver both hydrophilic and hydrophobic molecules. 
The knowledge of the state of the art has encouraged us to focus on 
nanocarriers based on amphiphilic PCL-PEO block copolymers developed 
from the group of Prof. Maglio at Department of Chemistry - University of 
Napoli Federico II. PCL-PEO block copolymers with different architectures 
were synthesized according to well established procedures and by novel “core 
first” - “coupling onto” strategies based on ROP polymerization followed by 
coupling of different segments performed with condensation or “click” 
chemistry reactions.  
DTX and the highly lipophilic phtalocyanine ZnPc were selected as 
conventional chemotherapeutic and PS, respectively, to obtain “the proof of 
concept”.  
DTX, a semisynthetic taxane (Figure 16) analogue of Paclitaxel, is one of the 
most widely used chemotherapeutic agents in solid tumors, with efficacy 
against advanced breast, non-small lung cancers, head and neck, ovary, 
prostate, stomach and urothelium cancers165,166. The anticancer mechanism of 
DTX as a potent inhibitor of cancer cell replication is related to its ability to 
block cancer cells in the late G2-mitotic phase of the cell cycle by stimulating 
microtubule polymerization and suppressing their dynamics. In analogy to 
many other anticancer drugs, DTX suffers for severe toxicity related to 
myelosuppression whereas neutropenia is usually considered as dose-limiting 
factor. Nevertheless, asthenia and peripheral neuropathy can limit continued 
administration of weekly DTX167. Furthermore, DTX is sparingly soluble in 
water and thus difficult to formulate in dosage forms intended for iv delivery.  
In recent years, a conspicuous number of controlled release systems were 
developed to deliver DTX, improving its antitumor activity as well as reducing 
its toxicity profile (see table 1).  
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166S. J. Clarke and L. P. Rivory, "Clinical pharmacokinetics of docetaxel," Clin.Pharmacokinet. 36, no. 2 (1999). 
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Figure 16. Chemical structure of DTX. 
ZnPc is a second generation PS, not yet approved in therapy, able of producing 
cytotoxic singlet oxygen with high yield 168 , 169 . Structurally related to 
porphyrins (Figure 17), it is characterized by a high molar extinction 
coefficient (25000 M-1cm-1) and a maximum absorption peak between 670 and 
770 nm in the red region of the spectrum. The presence of the central atom of 
Zn provides a high yield of singlet oxygen with long half-life of the triplet 
state. This highly hydrophobic molecule localizes exclusively in mitochondria 
and after irradiation induces direct damage to cellular organelles. It was 
demonstrated that ZnPc is able to bind lipoproteins and serum albumin 
depending on the vehicle used for administration. Hydrophobic character of 
ZnPc hinders its systemic administration but, on the contrary, facilitates its 
encapsulation in many drug delivery systems as liposomes170,171, polymeric 
micelles172,173 and NPs174. 
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Figure 17
 
Specific tasks of the work can be outlined as follow:
 
T1) Development of PCL-PEO 
molecules 
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PEO block copolymers to self
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T3) Development of multifunctional nanoparticles entrapping ZnPc and 
DTX for combined photodynamic and conventional therapy of 
cancer 
Nanocarriers were developed with the aim to combine two drugs with 
different pharmacokinetics in a nanocarrier with well-tailored properties 
which can allow a control over anticancer drug/PS biological fate and 
promote their co-localization in the same area of the body. Combined 
NPs containing both DTX and ZnPc were prepared again by MeSo 
employing the same amphiphilic materials. Overall properties, stability, 
and in vitro biological behavior of NPs as well as fluorescence behavior 
were evaluated. Cell culture studies aimed to clarify the cellular biofate 
encompassing both mechanisms involved in cellular uptake and 
molecular events controlling cellular response were carried out. Finally, 
in vivo activity of these systems in an ortothopic mice model of 
amelanotic melanoma was investigated. 
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Abstract 
Well-defined amphiphilic Y-shaped miktoarm star block copolymers of PEO 
and PCL were synthesized by ring opening polymerization of ε-caprolactone 
initiated by a PEO bound lysine macroinitiator. The copolymers were 
characterizedby 1H NMR, SEC, DSC, and WAXD techniques. Separate PCL 
and PEO crystalline phases occur in melt-crystallized copolymers when their 
segmental lengths were comparable and the PCL content was ≤80 wt %. Self-
assembling of these copolymers in aqueous medium led to nanoaggregates 
with low critical aggregation concentration values (0.35 to 1.6 mg·L−1) and 
size depending on composition. Despite the fact that copolymers were not 
prone to self-organize in vesicles, once processed by a novel w/o emulsion-
melting/sonication technique, they gave nanocapsules with a water core and a 
hydrophilic surface. A macromolecular fluorescent dye was effectively loaded 
and released at sustained rate by optimizing nanocapsule formulation. The 
results demonstrate that amphiphilic block copolymers can be assembled in 
different kinds of nanomorphologies independently of their 
hydrophilic/hydrophobic balance and architecture through specifically 
designed preparation techniques. 
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Introduction 
Materials, such as protein, oligonucleotides (ODNs) and siRNA represent 
forthcoming treatments of cancer and viral infections. Thus, for optimal 
activity, the ideal carrier system would be hydrophilic molecules entrapped 
within the internal core of polymeric nanocapsules wall [1] or polymersomes 
[2-4] in order to mask them and to protect them from interactions with 
proteins. 
Amphiphilic block copolymers (ABCs) have received increasing interest 
because they can aggregate in aqueous medium, leading to different 
nanomorphologies, mainly dictated by block copolymer composition and 
molecular geometry1,2. 
Much interest has concerned miktoarm star-block copolymers, branched 
systems with three or more arms, at least two of which are chemically 
different. Their structure is thereby characterized by the presence of different 
building blocks linked to the same junction point.3-8 Several synthetic 
strategies such as atom transfer or nitroxide-mediated radical polymerization 
(ATRA, NMP), reversible addition−fragmentation chain transfer (RAFT), and 
“click chemistry” reactions have been successfully employed in the synthesis 
of miktoarm star-block copolymers with well-defined macromolecular 
building blocks and architecture9-13. Many ABCs contain as hydrophilic 
component blocks of poly(ethylene oxide) (PEO) that impart structure stability 
and biomimetic properties to formed nanostructures14. Poly(ε-caprolactone) 
(PCL) has been frequently used to form the core of self-assembling ABC 
systems owing to its high hydrophobicity, propensity to aggregation, as well as 
low glass transition temperature that ensures a partial rubbery core. PEO-PCL 
copolymers are currently investigated as base materials for different drug 
delivery systems15,16 although the most promising application remains in the 
field of anticancer drug delivery17,18. In fact, nanocontainers of PEO-PCL with 
core-shell structures consisting in a core of hydrophobic blocks surrounded by 
an hydrated flexible fringe of hydrophilic blocks have been intensively 
investigated in the past few years as delivery system for lipophilic drugs19-23. 
Linear di- and triblock systems have been extensively employed as drug 
nanocarriers; also, branched PCL-g-PEO and multiarm star-shaped PEO-PCL 
diblock copolymers have attracted attention and synthetic procedures to obtain 
star architectures with different numbers have been developed24-30. 
Nevertheless, it has been recognized that hydrophilic/lipophilic balance is a 
key factor controlling the type of aggregate formed (micelle, worm,vesicles) as 
well as stability in biological media31-33. Much more complicated is to obtain 
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nanostructures based on PEO-PCL copolymers able to deliver hydrophilic 
compounds. In this research area, some work has been done to develop tailor 
made ABC able to self-organize in vesicles, that is, the so-called 
polymersomes34,35. Again, hydrophobic−hydrophilic balance inspires the 
organization and morphology of the ABCs, and the nature and the length of the 
blocks determine their stability, size, drug-loading capacity, and release rate.32 
Nevertheless, PEO-PCL polymersomes spontaneously evolve to micelles in an 
aqueous environment, rapidly delivering their drug cargo.36 Prompted by these 
considerations, here we try to design PEO-PCL NPs able to entrap efficiently 
hydrophilic molecules and release them at sustained rates. To this purpose, we 
developed a novel emulsion/melting-sonication technique based on copolymer 
hardening on a w/o emulsion template. Both linear and Y-shaped 3-miktoarm 
star-block PEO-PCL copolymers were employed in the study to understand the 
suitability of the technique on different PEO-PCL architectures. Miktoarm 
copolymers were obtained through a straightforward synthetic strategy based 
on the combination of coupling reactions and ring-opening polymerization 
(ROP) using lysine as a core molecule. Self-organization properties were 
investigated and compared with those of a linear diblock PEO-PCL copolymer 
of similar composition, with the aim to evaluate the influence of copolymer 
architecture on self-aggregation both in aqueous environment and using the 
emulsion-melting sonication technique. Rhodamine-dextran was selected as a 
model hydrophilic macromolecule and its encapsulation in and release from 
nanocapsules investigated. Finally, toxicity toward red blood cells and 
melanoma cell lines was tested. 
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Experimental part 
Materials 
α-OCH3,ω-NH2 poly(ethylene oxide) with Mn =2.0 kDa (mPEO2.0k-NH2, 
Aldrich) was dried by distillation of the water−toluene azeotrope. ε-
Caprolactone (CL, Aldrich) was dried over CaH2 at room temperature for 48 h 
and then distilled under vacuum before use. Stannous-(2-ethylhexanoate)2 
(Sn(oct)2, Aldrich) and pyridine (Fluka) were purified by vacuum distillation 
before use. N-Hydroxysuccinimide (NHS) and succinic anhydride (SA) 
(Fluka) were dried under high vacuum. N,N-diisopropylethylamine (DIPEA), 
Nα,Nε-di-Z-lysine (di-Z-lys), N,N′-dicyclohexylcarbodiimide (DCCI), and 4-
dimethylaminopyridine (DMAP), all provided by Fluka, and Pd/C (Pd 10 wt % 
by Aldrich) were used without further purification. Potassium phosphate 
dibasic and potassium phosphate monobasic,sodium azide, sodium chloride, 
Span 80, polyethylene glycol (PEG, Mw 400 Da), rhodamine B isothiocyanate-
Dextran (RhDex, Mw 10kDa), and 3-[4,5-dimethyltiazol-2yl]-2,5 diphenyl 
tetrazolium bromide (MTT) were from Sigma-Aldrich. Sodium hydroxide was 
from Delchimica Scientific Glassware. Miglyol 812 
(capryl/caprylictriglycerides) was from Farmalabor (Italy). Normal hexane, 
methylenechloride (DCM), and chloroform (CHCl3) of analytical grade were 
purchased from Carlo Erba Reagenti (Milan, Italy). Analytical grade DCM and 
CHCl3 were dried according to literature methods. 
 
Synthesis of the macroinitiator Lys-mPEO2.0 k (1). A two-steps procedure 
was used in the synthesis of the macroinitiator after a preliminary activation of 
the –COOH group of di-Z-Lys with NHS, performed in a CHCl3 solution using 
DCCI as condensing agent and DMAP as catalyst.  
(a) A solution of mPEO2.0k-NH2 (1.02 g, 0.51 mmol) and activated di-Z-Lys 
(0.255 g, 0.50 mmol) in 12 mL of DCM was stirred at r.t. for 24 h. The crude 
product recovered removing the solvent was washed with a diethyl 
ether/methanol mixture (3:1 v:v), then purified by column chromatography on 
silica gel to eliminate unreacted mPEO2k-NH2 using a CHCl3/CH3OH mixture 
as eluent, with a linear gradient of 2, 4, 8 wt% of CH3OH. Di-Z-Lys-mPEO2.0k 
was recovered removing the solvents under vacuum (1.01 g,70% yield): 1H–
NMR (CDCl3, ppm): 7.35 (10H, aromatic H of Z group); 5.40 (1H, -CH2-NH-
CO-O-CH2-∅ ); 5.20-5.00 (5H, -CO-O-CH2-∅ + -CH-NH-CO-O-CH2-∅ ); 
3.70-3.60 (176H, -CH2OCH2-); 3.45 (2H, -CO-NH-CH2-PEO); 3.36 (3H, -
OCH3 ); 3.20 (2H, -CH2-CH2-NH-CO-O-∅); 2.00-1.00 (6H, -CH-(CH2)3-CH2-
NH-CO-O-CH2-∅).  
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(b) Pd/C (0.266 g) was added to a solution of di-Z-Lys-PEO2.0k (1.498 g) in 35 
mL of methanol and hydrogen was bubbled for 6 h at 30°C. The reaction 
mixture was then centrifuged to eliminate Pd/C and the supernatant solution 
was filtered through a celite layer. Methanol was removed under vacuum to 
give 1.11 g (85% yield) of Lys-mPEO2.0k (1) (ηinh 0.15 dL·g-1, 80 % yield). 1H–
NMR (CDCl3, ppm): 3.70-3.60 (176H, -CH2OCH2-); 3.45 (2H, -Lys-CO-NH-
CH2-PEO); 3.36 (3H, -OCH3); 3.20 (2H, -CH-CH2-CH2-CH2-CH2-NH-Z); 1.0-
2.0 (6H,-CH-(CH2)3-CH2-NH-Lys. 
 
Synthesis of (Lys-mPEO2.0 k)-(PCL2.1 k)2 (2a) and (Lys-mPEO2.0 k)-(PCL6.15 
k)2(2b), AB2 block copolymers (A=PEO, B=PCL). A 50 mL flask was 
charged under nitrogen with (1) (0.94 g, 0.45 mmol) and CL (1.90 g, 16.7 
mmol). The mixture was stirred at 80 °C for 24 h, then Sn(Oct)2 (3.7 mg, 9.1 
µmol) was added to the mixture and the polymerization was carried out at 120 
°C for 24 h. After cooling, the product was dissolved in 6 mL of CHCl3 and 
precipitated in chilled diethylether (300 mL). The precipitate was collected and 
dried in a vacuum oven to give 2.41 g of (2a). (ηinh = 0.18 dL·g-1, 85% yield, 
Mw/Mn = 1.48). 1H–NMR (CDCl3, ppm): 4.05 (72H, -CH2-OCO-, PCL); 3.65 
(178H, -CH2-O-, PEO, + 4H, -CH2-CH2-OH, PCL); 3.45 (2H, -Lys-CO-NH-
CH2-, PEO);3.36 (3H, -OCH3, PEO); 2.3 (72-CH2-CO-, PCL); 1.8-1.3 (224H, -
O-CH2-[CH2-]3-CH2CO-, PCL, + -[CH2]3-CH2-NH-, Lys). (Lys-mPEO2.0k)-
(PCL6.15k)2 , (2b), was obtained according to the above procedure using a 
monomer to initiator molar ratio of 112. (ηinh = 0.30 dL·g-1, 87% yield, 
Mw/Mn = 1.64). 
 
Synthesis of the A(BA)2 block copolymer (Lys-PEO2.0.k)-(PCL6.15 k-PEO2.0 
k)2. The synthesis was carried out through a two-steps procedure: 
(a) (Lys-PEO2.0k-(PCL6.15k)2 , (2b), (1.55 g, 0.11 mmol) dissolved in 8 mL of 
CHCl3 was reacted with 0.068 g (0.68 mol) of SA and 0.004 g of pyridine 
(50.6 mmol) for 48 h at 60 °C. The solution was poured in 400 mL of a 
diethylether/methanol mixture (5:2 v:v) and the precipitated (Lys-PEO2.0 k)-
(PCL6.15 k-COOH )2 was collected and dried in a vacuum oven (1.41 g, 90% 
yield). (b) NHS (21 mg, 0.18 mmol), DCC (37 mg, 0.18 mmol) and DMAP 
(4.0 mg, 3.3 mmol) were added to a solution of (Lys-PEO2.0k)-(PCL6.15k-
COOH)2 (0.643g, 45.0 µmol) in 6 mL of CH2Cl2. The reaction was carried out 
for 24 h at r.t. under stirring. Then, after filtration to remove the precipitated 
dicyclohexylurea, the solution was poured in 300 mL of a 
diethylether/methanol mixture (5:2 v:v). The precipitate was collected and 
dried under vacuum at 30°C (0.579 . Activated (Lys-PEO2.0k)-(PCL6.15k-
                                                                                                                              Chapter 2 
82 
 
COOH)2 (0.579 g 0.04 mmol) and 0.217 g (0.11 mmol) of mPEO2.0k-NH2 were 
dissolved in 10 mL of DCM. After addition of DIPEA (0.021 g, 0.23 mmol), 
the reaction was carried out at r.t. for 24 h. The reaction mixture was poured in 
300 mL of a diethylether/methanol mixture (5:2 v:v) and the precipitate was 
collected and dried under vacuum (0.685 g, 86% yield, ηinh = 0.36 dL·g-1, 
Mw/Mn =1.48). 
 
Synthesis of the AB diblock copolymer PEO2.0k-PCL4.3k. A linear AB 
diblock copolymer was prepared by ROP of CL at 120 °C for 24 h using α-
methoxy,ω-hydroxyl-PEO (Mn = 2.0 kD) as initiator and Sn(Oct)2 as catalyst; 
CL: initiator molar ratio = 38 (ηinh = 0.28 dL·g-1, 88% yield, Mw/Mn = 1.16). 
 
Polymer Characterization 
1H NMR spectra were recorded at 25 °C on a Varian-Gemini spectrometer at 
200 MHz using CDCl3 as asolvent and TMS as internal reference. Differential 
scanning calorimetry (DSC) analyses were carried out under nitrogen on 5 to 6 
mg samples using a Mettler-Toledo 30 instrument with a 2 °C·min−1 scanning 
rate in the temperature range 0−80 °C. Inherent viscosities were measured at 
25 °C in CHCl3 using an Ubbelhode viscometer (c = 0.5 g·dL−1). Wide-angle 
X-ray diffraction spectra (WAXS) were recorded with a Philips PW-1711 
diffractometer using a Ni-filtered Cu K α radiation; the crystallinity degree 
was evaluated subtracting the contribution of the amorphous part from the total 
scattering. Size-exclusion chromatography (SEC) was performed on a Jasco 
PU-1580 system equipped with a refractive index detector, using polystyrene 
standards as reference. Samples were eluted in tetrahydrofuran at 25 °C 
through three Polymer Laboratories  Phenogel columns connected in series. 
 
Copolymers Self-Assembly 
Critical aggregation concentration (CAC) of the copolymers was determined 
by a fluorescence spectroscopy method, as previously reported.29 In brief, 
copolymers were stirred for 24 h in water at 60 °C. The dispersion was cooled 
at room temperature and filtered to eliminate undissolved polymer. Polymer 
solubility was assessed by weighing the sample after freeze-drying. A pyrene 
solution in acetone was added in 2 mL flasks to provide a final concentration 
of 6 × 10−7 M. Acetone was evaporatedand replaced with aqueous polymer 
solutions at different concentrations ranging from 0.084 to 42 µg/mL for AB to 
0.23−615 µg/mL for Y-shaped copolymers. Samples were heated to 65 °C for 
1 h,cooled to room temperature, and analyzed at 25°C on a Shimadzu RF-1501 
                                                                                                                              Chapter 2 
83 
 
spectrofluorimeter. Excitation spectra were registered at λem = 390 nm, and the 
ratio I334/I331 was plotted against polymer concentration. CAC was 
extrapolated from the linear part of the graph. The size of aggregates was 
evaluated on the above samples and determined by photon correlation 
spectroscopy using a N5 submicrometer particle size analyzer (Beckman-
Coulter). Dispersion was diluted in Milli-Q water at the intensity between 104 
and 106counts/s, and measurements were performed at 25 °C on 90° angle. 
 
Nanocapsule Preparation 
Nanocapsules with an inner aqueous core were prepared by an emulsion-
melting/sonication procedure. A vial containing 10 mg of copolymer and 2 mL 
of a 2% (w/v) solution of Span 80 in Miglyol 812 was placed in a water bath 
heated to 75 ± 1°C to allow copolymer melting. Then, 0.2 mL of water or a 
water/PEG400 1:1 v/v solution containing RhDex (0.2 mg) was added to the 
previously warmed mixture and allowed to equilibrate at the same temperature. 
The sample was sonicated for 10 min at 3W (Sonicator 3000, Misonix) by a 
microtip probe. Nanocapsules were finally cooled and allowed to harden under 
magnetic stirring at room temperature. Nanocapsules were washed four times 
(twice with hexane and twice with distilled water) by ultracentrifugation at 
137,000 g for 30 min to remove the external oily phase and the unloaded 
molecules. Then, nanocapsules were freeze-dried without the help of 
cryoprotectant and kept at 4 °C. Recovery yield of nanocapsules was 
evaluated, weighting the solid residue after freeze-drying. Results are 
expressed as the ratio of the actual nanoparticles weight to the theoretical 
polymer weight × 100. 
 
Nanocapsule Characterization  
The hydrodynamic diameter and polydispersity index of nanocapsules were 
determined by photon correlation spectroscopy (PCS) using a N5 
submicrometer particle size analyzer (Beckman-Coulter). Nanocapsules 
dispersion was dilutedin Milli-Q water at the intensity between 104 and 106 
counts/s, and measurements were performed at 25 °C on 90° angle. Each 
sample was analyzed in triplicate. Zeta potential was determined by analyzing 
a dispersion of nanocapsules in water on a Zetasizer Nano Z (Malvern 
Instruments). Results are reported as the mean of three separate measurements 
on three different batches ± standard deviation. 
The morphology of nanocapsules was assessed by TEM on a Leo 912 AB 
microscope (Zeiss). A dispersion of nanocapsules in water was placed on a 
copper grid and stained with uranile acetate (2% w/v). 1H NMR spectra of a 
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nanocapsule dispersion in D2O were recorded at 25 °C on a Varian-Gemini 
spectrometer at 200 MHz. 
 
RhDex Loading and Release from Nanocapsules 
RhDex loading inside nanocapsules was assessed by treating 1 mg of freeze-
dried nanocapsules in 1 mL of methylene chloride and extracting RhDex in 1 
mL of water under vortex mixing. Phase separation was accomplished by 
centrifugation at 5000 rpm and 4 °C for 1 min (Universal 16R, Hetting 
Zentrifugen). The amount of RhDex in the aqueous phase was measured by 
spectrofluorimetry at λex = 556 nm and λem= 573 nm (RF-1501, Shimadzu). To 
verify a possible interference of copolymers, we treated an amount of unloaded 
nanocapsule by the same method and analyzed it. The linearity of response 
was verified in the concentration range 0.1 to 2 µg/mL (R2 =0.996, LOD = 
0.001 µg/mL, LOQ = 0.002 µg/mL). Results are expressed as actual loading 
percent (mg of RhDex encapsulated per 100 mg of nanocapsules) and 
encapsulation efficiency (ratio of actual to theoretical loading). 
Release profile of RhDex from nanocapsules was evaluated by placing 0.5 mL 
of a nanocapsule dispersion (2 mg/mL) in a dialysis sac (molecular weight 
cutoff 50 000 Da, Spectra/Por), which was placed in 5 mL of a 10 mM 
phosphate buffer at pH 7.4 and 37 °C. At predetermined intervals, 1 mL of 
medium was withdrawn and replaced by the same amount of fresh buffer. As a 
control, the release profile of free RhDex was evaluated. RhDex in the release 
medium was quantified according to the previously described method. 
 
Hemolysis 
Human blood freshly collected in EDTA-containing tubes was washed three 
times with isotonic 10 mM phosphate buffer saline (PBS) solution (pH 7.4) by 
centrifugation at 880g for 5 min (Universal 320R, Hettich Zentrifugen), and 
the pellet, containing red blood cells (RBCs), was finally diluted 1:10 v/v with 
10 mM PBS. RBC suspension (0.1 mL) was added to 0.9 mL of a 
nanocapsuledispersion at concentration ranging from 0.01 to 1.0 mg/mL of 
copolymer. After incubation at 37 °C for 30 min, the sample wascentrifuged at 
1000g for 10 min to remove nonlysed RBC. The supernatant was collected and 
analyzed for hemoglobin release by spectrophotometric determinations at 416 
nm. To obtain 0 and 100% hemolysis, 0.1 mL of RBC suspension was added 
to 0.9 mL of PBS and distilled water, respectively. The degree of hemolysis 
was determined by the following equation: hemolysis (%) =(ABS − 
ABS0)/(ABS100− ABS0) × 100, where ABS100 and ABS0 are the absorbances of 
the solution at 100 and 0% hemolysis, respectively. 
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Cytotoxicity Assay 
The human melanoma cell lines A375 and the normal human epidermal 
melanocytes (NHEMs) (PromoCell, Germany) were tested. NHEMs were 
grown in melanocyte growth medium 2 (PromoCell), whereas A375 were 
grown in complete Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 25 mM 
HEPES, 100 units/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a 
humidified incubator under 5% CO2. Cell proliferation was measured by the 
MTT assay.35 The cells were seeded on 96-well plates (1 × 104cells/well) and 
treated with nanocapsules (0.1 to 1 mg/mL) for 24−48 h before adding 25 µL 
of MTT (5 mg/mL in saline). Cells were thus incubated for additional 3 h at 37 
°C. After this time interval, cells were lysed, and dark-blue crystals were 
solubilized with a solution containing 50% (v/v) N,N-dimethyl formamide and 
20% (w/v) sodium dodecylsulfate with a pH adjusted to 4.5. The OD of each 
well was measured with a microplate spectrophotometer (Titertek Multiskan 
MCC/340) equipped with a 620 nm filter. 
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Results and Discussion 
Synthesis and Characterization of Copolymers 
Well defined miktoarm star-block AB2 and A(BA)2 copolymers (A=PEO, 
B=PCL) were synthesized via a combination of segment coupling and ROP of 
CL. Nα,Nε-di-Z-lysine (di-Z-lys) was used as a multifunctional core molecule 
with a carboxyl group and two carbobenzyloxy (Z)-protected functional amino 
groups available for sequential reactions. The reaction pathway is displayed in 
Scheme 1.  
 
 
 
Scheme 1. Synthetic Pathways for Miktoarm Y-Shaped PEO-PCL Block Copolymers. 
 
First, α-methoxy,ω-amino-PEO with Mn=2 kDa (mPEO2.0k-NH2) was reacted 
with a di-Z-Lys previously activated with NHS converting the carboxyl group 
into a succinimidylester group. Then, deprotection of the amino groups by 
catalytic hydrogenation leads to product (1), containing a single mPEO chain 
and two −NH2 groups, which was used as a macroinitiator of the bulk ROP of 
CL in the presence of a catalytic amount of Sn(oct)2. The molecular weight of 
PCL blocks was controlled varying the CL/initiator molar ratio in the feed. 
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Two different Mn values, 2.0 and 6.0 kDa, were selected for the PCL 
segments, yielding two AB2 copolymers, mPEO2.0k-(PCL2.1k−OH)2 (2a) and 
mPEO2.0k-(PCL6.15k−OH)2 (2b). The copolymer (3), with the A(BA)2 
architecture, was obtained by coupling of two mPEO2k-NH2 chains to the PCL 
segments of 2b, after conversion of PCL hydroxyl end groups into carboxyl 
groups subsequently activated by NHS. The molecular structures of the 
macroinitiator and copolymers were investigated by 1H NMR spectroscopy. 
The coupling of mPEO2k-NH2 to di-Z-Lys was detected monitoring the 
appearance in the spectrum of 1 of a resonance at 3.46 ppm attributed to 
−O−CH2−CH2−NH−CO−end groups of linked PEO chains (Supporting 
Information, Figure S1). A reaction degree ≥90% was estimated by comparing 
the resonance integral of −CH2−O−CH2− units of PEO at 3.6 to 3.7 ppm with 
those relative to CH2 and aromatic −CH− protons of benzyl-protecting groups 
of di-Z-Lys at 5.20 and 7.35 ppm, respectively. The quantitative deprotection 
of −NH2 groups in the Lys moiety by hydrogenation was assessed, monitoring 
the disappearance of the resonances due to the Z group. The average PCL 
chain length in the AB2 copolymers was evaluated from the relative intensity 
of the α-hydroxy methylene protons of −CH2−OH chain ends at 3.64 ppm and 
the inner methylene protons −CH2−O−CO− of the main chain at 4.07 ppm 
(Supporting Information, Figure S2). The experimental Mn values found by 1H 
NMR were close to those calculated from the monomer/initiator molar ratio in 
the feed. Unimodal and rather sharp molecular weight distributions were found 
by SEC analysis (Supporting Information, Figure S3). Direct evidence of the 
successful coupling of two mPEO2.0k segments to mPEO2.0k-(PCL6.15k-OH)2 in 
the synthesis of the A(BA)2 copolymer was found evaluating by 1H NMR the 
enrichment of PEO in the (3) copolymer compared with the (2B) precursor. 
Accordingly, the SEC diagram of (3) displays a single sharp peak (PDI = 1.48) 
with a shift toward higher molecular weight with respect to that of 
A2.0k(B6.15k)2, as shown in Figure 1. A corresponding increase in the inherent 
viscosity was also observed.  
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Figure 1. Molecular weight distributions of A2k(B6.1k)2 (solid line) andA2k(B6.1k-A2k)2 (dashed line) 
obtained by SEC. 
 
 
The characterization results for the Y-shaped copolymers are reported in Table 
1, together with those of a linear mPEO2.0k-PCL4.3k. diblock copolymer having 
the same composition and molecular weight of mPEO2.0k(PCL2.1k)2, for the 
sake of comparison. A lower viscosity was found for the latter copolymer, as 
expected because of the branched architecture. The slightly broader molecular 
weight distributions observed for Y-shaped copolymers are likely related to the 
multistep synthetic procedures. 
 
 
Table 1. Characterization data of a linear AB and Y-shaped miktoarm PCL-PEO block 
copolymers (A=PEO, B=PCL). 
 
Copolymer PCL (wt-%) Mn
a
 
(kDa) 
Mwb 
(kDa) 
PDI c 
 
ηinh d 
(dL·g-1) 
A2k-B4.3k 68 6.3 10.9 1.16 0.28 
A2k(B2.1k)2 68 6.2 7.9 1.48 0.18 
A2k(B6.1k)2 86 14.2 16.4 1.64 0.33 
A2k(B6.1k-A2k)2 67 18.2 19.6 1.48 0.36 
a
 Number average molecular weight evaluates by 1H-NMR. 
b Molecular weight obtained by SEC. 
c Molecular weight polydispersity index obtained by SEC. 
d Inherent viscosity in CHCl3 at 25°C, c = 0.5 g/dL. 
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Crystallization Behavior 
DSC and WAXS techniques were used to gain insight into the self-
organization and the crystallization behavior of the copolymers in bulk. Since 
PCL and PEO have close melting temperatures, the melt crystallization 
behavior is rather complex, especially underdynamic conditions, because 
coincident crystallization of both components may occur and the 
crystallization of one block may affect the crystallization of the second 
block.37,38A low scanning rate (2 °C/min) in the cooling run may promote the 
formation of well-separate exotherms for different blocks, provided that the 
crystallization from the melt occurs in the presence of a microphase-separated 
structure.39 Thermograms relative to crystallization from the melt and to 
second melting runs are shown in Figure 2, and the results are summarized 
inTable 2. 
 
 
 
Figure 2. DSC thermograms of A2k(B2.1k)2 (red), A2k(B6.1k)2 (green),and A2k(B6.1k-A2k)2 (blue) 
copolymers. 
 
 
Single melting and crystallization peaks were observed in the DSC traces of 
A2.0k(B6.15k)2. Because the competition in crystallization between PCL and 
PEO blocks mainly depends on the PEO-PCL weight ratio as well as on the 
relative segmental lengths,40,41 the peaks were attributed to the PCL component 
considering the low weight fraction of PEO and the high segmental length of 
PCL blocks (6.15 kDa) compared with the PEO block (2.0 kDa). The powder 
WAXS diagram of A2.0k(B6.15k)2 displayed characteristic diffraction maxima of 
crystalline PCL at 2θ= 21.5°, 23.9°, whereas those related to PEO at 2θ=19.2°, 
23.4° were not detected, in agreement with the DSC results (Supporting 
Information, Figure S4). 
                                                                                                                              Chapter 2 
90 
 
Table 2. Thermal behaviour and crystallinity of a linear AB and Y-shaped miktoarm 
PCL-PEO block copolymers (A=PEO, B=PCL). 
 
 
Tm a,b 
(°C) 
∆Hm a,b 
(J·g-1) 
∆Hc a 
(J·g-1) 
Tca 
(°C) 
Χc 
 c
 
(%) 
Copolymer A B A B A B A B A B 
A2kB4.3k 46.6 53; 57 11 50 16 52 26.8 34.3 18 (15) 
47 
(52) 
A2k(B2.1k)2 43.0 47.9 20 42 15 40 20.0 30.5 20 (25) 
40 
(42) 
A2k(B6.1k)2 - 56.4 - 62 - 58 - 38.8 - 55 (51) 
A2k(B6.1kA2k)2 - 54.2 - 48 - 47 - 38.3 - 40 (43) 
a
 Crystallization and melting temperatures determined by DSC. 
b
 Second heating run.  
c
 % crystallinity calculated from WAXS spectra and from ∆Hm (in brackets).  
 
The crystallization of PCL chains as first, in fact, provides strong restrictions 
to PEO chains that hinder their crystallization. Evidence of a PEO crystalline 
phase was not found, both by DSC and WAXS analyses, also for A2k(B6kA2k)2, 
despite the higher content of PEO (35% by wt). Tm and Tc of PCL were not 
affected by the increased PEO content, while lowering of melting and 
crystallization enthalpies were found. These findings emphasize the relevance 
of segment length in the organization of separate crystalline domains. The 
double melting endotherms of PCL may be ascribed to a melting 
recrystallization process of less-ordered crystallites and reflects a more 
complex crystallization process related to the increased number of outer short 
PEO blocks. In the case of PEO2k(PCL2k)2 and PEO2k(PCL4k), with identical 
length of PEO segments and 2:1 PCL/PEO weight ratio, the coexistence of two 
crystalline phases was suggested by the presence of well separate 
crystallization and melting peaks. The WAXS diagrams displayed 
characteristic diffraction maxima for both PCL and PEO crystalline phases, in 
agreement with a double-crystalline morphology suggested by DSC. The 
relative intensities of the PCL and PEO crystalline diffraction peaks support 
the attribution to PCL of high-temperature crystallization and melting peaks 
with crystallization of PEO blocks occurring inside a preformed crystalline 
PCL environment. The crystallinity degree of PCL and PEO evaluated by 
WAXS are consistent with the melting enthalpies found by DSC, evidencing in 
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the branched copolymer a limited Xc lowering for PCL blocks balanced by a 
corresponding increase in Xc for PEO blocks. 
 
Self-Assembly in Aqueous Solution  
The aggregation of ABCs in aqueous environment is an enthalpy-driven 
process resulting from replacement of unfavorable water/hydrophobic-B-block 
contacts in the unimer dispersed state with favorable B−B contacts within the 
solvent-free core in core−shell structures. Therefore, the aggregate stability, 
assessed by low CACs and negative free-energy values, ∆G° = RT ln(XCAC) 
(XCAC = ABC molar fraction at CAC), is mainly controlled by the chemical 
nature and length of hydrophobic block. Self-assembly of copolymers in 
aqueous environment was followed by a steady-state fluorescent spectroscopic 
method using pyrene as a probe (Figure 3). The CAC and ∆G° values are 
reported in the table inserted in Figure 3. The low CAC values are indicative of 
a fair thermodynamic stability in aqueous medium. With respect to the linear 
diblock A2k-B4.3k, the star-block A2k(B2.1k)2 counterpart showed a small free-
energy penalty associated with the localization of 3 arms in A-B junctions at 
the core/corona interface with consequent loss of conformational freedom. As 
expected, the size of aggregates formed by block copolymers with low MW is 
smaller than 100 nm (DH for A2kB4.3k and A2k(B2.1k)2 were 40 and 67 nm, 
respectively), whereas larger DH, in the rangeof 180−200 nm, with broad size 
distributions was found for aggregates based on high MW copolymers. 
Therefore, A2kB4.3k and A2k(B2.1k)2 were selected as model ABCs for the 
preparation of nanocapsules. 
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Copolymer CAC (mg⋅L-1) 
CAC 
(mol⋅L-1) 
∆G° 
(kJ⋅mol-1) 
A2k-B4.3k 0.30 4.76·10-8 -52.1 
A2k(B2.1k)2 0.69 1.11·10-7 -49.6 
A2k(B6.1k)2 3.50 2.46·10-7 -47.6 
A2k(B6.1k-A2k)2 0.41 2.25·10-8 -53.9 
 
Figure 3. I334/I331 of pyrene in aqueous copolymer solutions at different concentrations. In the 
table, calculated CAC and ∆G° are reported. 
 
Preparation and Characterization of RhDex-Loaded Nanocapsules  
Assembly of ABCs of PCL is generally suited to deliver lipophilic drugs with 
the advantage to improve greatly their water solubility and to exert a spatial 
and temporal control over the delivered drug dose. The efficient delivery of 
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hydrophilic drugs is indeed much more complicate to attain. As expected, 
RhDex, selected as a model hydrophilic macromolecule,could not be 
efficiently entrapped during copolymer self-assembly through conventional 
methods reported in the literature such as dialysis or melting-sonication in 
water27,42 (encapsulation efficiency of RhDex was <2%). This suggested that 
spontaneous organization of copolymers in nanostructures able to entrap 
hydrophilic molecules as a consequence of slow solvent removal (dialysis) or 
hardening in water from a melted phase (melting-sonication) was not a suitable 
strategy. Therefore, we tried to design a general procedure suitable to give 
nanocapsules with the aim to: (i) employ materials with different architectures 
not necessarily designed to form vesicles; (ii) efficiently entrap hydrophilic 
compounds; and (iii) release them at controlled rates. 
Options available in the literature to prepare nanocapsules with an aqueous 
core from preformed copolymers are very scarce.43 This prompted us to 
develop an alternative method of preparation based on the idea that copolymer 
hardening can occour at the interface of a w/o emulsion nanotemplate. In fact, 
it has been recently demonstrated that PEO-PCL diblock copolymers can act as 
an emulsifier and stabilize o/w emulsions forming a polymeric interface.44 The 
technique developed in this study, indicated as emulsion/melting-sonication 
(EMeSo), consists of (i) melting the copolymer in Miglyol 812 at a 
temperature about 10 °C higher than copolymer Tm; (ii) adding the aqueous 
inner phase with the dissolved active principle, which may or may not contain 
a stabilizer (PEG400); (iii) apply sonication to generate a w/oemulsion; and (iv) 
cool the mixture at room temperature to promote copolymer hardening. In this 
way, molten copolymer forms a skin around aqueous droplets, giving 
nanocapsules with an inner aqueous core. The oily nanocapsules suspension is 
then purified by washing with hexane and then redispersed in water to allow 
freeze-drying. Two copolymer architectures and different formulation 
conditions were employed to prepare nanocapsules, as reported in Table 3. 
PEG400 was added in the aqueous phase of the emulsion to promote phase 
separation of PEO-PCL nanocapsule wall. In all the experimental conditions 
tested, nanocapsules were formed except for ABA copolymer, where the 
absence of PEG400 destabilizes the formulation causing copolymer 
precipitation. Recovery yield was similar and satisfactory for all formulations. 
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AB-WP AB2-WP
Table 3.  Properties of RhDex-loaded nanocapsules. 
 
Formulation codea AB-W AB-WP AB2-W AB2-WP 
Copolymer A2kB4.3k A2kB4.3k A2k(B2.1k)2 A2k(B2.1k)2 
Yield(% ± SD) 80±1 85±1 82±2 80±1 
Mean DH(nm ± SD) 110±5 100±2 100±1 201±1 
P.I. 0.347 0.206 0.369 0.177 
Zeta Potential 
(mV ± SD) -30±0.3 -16.3±1 -30±0.8 -18±1 
RhDex actual loadingb 
(mg/100 mg  
nanocapsules ± SD) 
0.882±0.010 1.175±0.035 0.799±0.036 1.141±0.028 
RhDex enc. efficiencyc 
(% ± SD) 45±1.0 59±2.2 40±0.7 57±1.4 
 
a
 Code W refers to nanocapsules with water as aqueous core whereas code WP refers to nanocapsules with 
water/PEG400 1:1 by wt as aqueous core. 
b
 Actual loading is expressed as amount of RhDex encapsulated per 100 mg of nanocapsules. 
c
 Ratio between actual and theoretical loading x 100. Theoretical loading was 2%. 
 
Nanocapsules were spherical and not-aggregated, as demonstrated by TEM 
(Figure 4), showing a capsular structure consistent with the presence of an 
inner core surrounded by an external polymer wall.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Transmission electron microscopy images of nanocapsules prepared according to 
compositions reported in Table 3. 
 
 
DH evaluated by PCS were in the range100−250 nm, in agreement with TEM, 
which is a size interval suitable for administration also via intravenous 
injection. Theformation of a PEO coating at the surface of nanocapsules was 
confirmed by analyzing 1H NMR spectra of nanocapsules dispersed in D2O at 
25 °C (data not shown) that evidenced sharp resonances of PEO methylene 
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hydrogen atoms at 3.60 δ and broad resonances of low intensity relative to 
PCL units, indicating a reduced chain mobility of PCL segments in the 
nanocapsule wall. Encapsulation efficiency of RhDex was >50% and 
considered again to be satisfactory for a hydrophilic macromolecule in a 
nanosized system. Release rates of RhDex from nanocapsules (Figure 5) were 
characterized by an initialburst, followed by a slower diffusion/erosion phase. 
Burst effect and overall release trend for nanocapsules containing only water in 
the internal phase were similar. On the contrary, burst release strongly 
decreased as PEG400 was added in the internal aqueous phase, and release rate 
of RhDex was sustained for a time interval longer as compared with that 
observed for nanocapsules with a water core.  
 
 
Figure 5. Release profile of RhDex from nanocapsules as evaluated by dialysis in 10 mM 
phosphate buffer at pH 7.4 and 37 °C. Dialysis of free RhDex is reported as control. Each point is 
the mean of four measurements ± SD. 
 
 
This effect can be attributed to a lower molecule mobility in the hydrated core 
due to viscosizing properties of free PEG and its hindered diffusion in the 
external medium. The slowest release rate was observed for nanocapsules 
prepared with AB2-WP, probably due to their size being larger than that of 
AB-WP. As compared with release obtained for other macromolecules from 
polymersomes made of diblock PEO-PCL with similar composition,36 the 
delivery rate was very slow, which supports the hypothesis that no morphology 
transition occurs because of copolymer degradation. Hemolytic activity of 
nanocapsules on human RBC was investigated to verify their suitability via 
intravenous administration (Figure 6). A low hemolysis degree (<11%) was 
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observed with both AB-WP and AB2-WP formulations independently on the 
nanocapsule concentration. According to several studies,45 hemolysis values 
found for nanocapsules can be rated as “no concern” because they span in the 
5−25% range. Because of a better control of release rate, which presumably 
should occur also in vivo, we focused on AB2-WP formulations for further in 
vitro testing. To exclude a potential cytotoxic effect of nanocapsules, we 
investigated their activity on A375 proliferation. As shown in Figure 6, A375 
growth was not affected by any of the concentration of AB2-WP tested at all 
the time points considered. Similar results were obtained with the NHEM cell 
line (data not shown). 
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Figure 6. (A) Hemolytic activity of polysorbate 80 (positive control), AB-WP, and AB2-WP 
nanocapsules. Each point is the mean of four measurements ± SD. (B) Cytotoxicity of AB2-WP 
nanocapsules on A375 cell line. Each point is the mean of three measurements ± SD. 
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Conclusions 
A straightforward synthetic pathway based on a combination of segment 
coupling and ROP steps was developed to obtain amphiphilic Y-shaped 
miktoarm PEO-PCL block copolymers. Y-shaped copolymers demonstrated a 
high self-assembling tendency in water comparable to that of linear 
counterparts, which suggests their use as nanocontainers for lipophilic drugs. 
We showed that it is otherwise possible to obtain nanocapsules for the 
sustained release of hydrophilic macromolecules by processing PEO-PCL 
copolymers through an emulsion/melting-sonication technique. Nanocapsules 
showed an excellent cell toxicity profile and thus represent a nanosystem of 
great potential in several drug delivery applications. 
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Abstract 
Amphiphilic block copolymers of poly(-caprolactone) and poly(ethylene 
oxide) were assembled in core shell nanoparticles (NPs) by a melting-
sonication technique (MeSo). The entrapment of the poorly water-soluble 
anticancer drug docetaxel (DTX), nanocarrier cytotoxicity toward different 
cells and toxicity in mice were investigated. The encapsulation mechanism was 
rationalized and related to copolymer properties such as crystallinity and drug 
solubility in the copolymer phase. DTX release from NPs occurred in two drug 
pulses over 30 days. DTX entrapment in NPs strongly decreased haemolysis of 
erythrocytes in comparison with a commercial DTX formulation. In 
comparison with free DTX, NPs were both more efficient in inhibiting cell 
growth of breast and prostate cancer cells and less toxic in experimental 
animal models. The results of this study indicate that MeSo is an interesting 
technique for the achievement of peculiar core-shell nanocarriers for the 
passive targeting and sustained release of poorly water-soluble anticancer 
drugs. 
 
From the Clinical Editor: In this study, stealth nanoparticles of PEO/PCL 
block copolymers for passive targeting of docetaxel to solid tumors were 
developed using a novel technique. The studied properties of NPs suggest 
strong potential as anticancer drug-delivery system. 
 
Key words: Nanoparticles; Amphiphilic block copolymers; Anticancer drugs; 
Docetaxel 
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Introduction 
Nanotechnology offers a highly promising avenue in cancer treatment based 
on the concept that a drug formulated in nanoparticles (NPs) can alter its 
pharmacokinetics, enhancing the treatment ability to target and kill cells of 
diseased tissues or organs while negatively affecting as few healthy cells as 
possible1,2. Depending on the properties of the carrier, large variations in drug 
pharmacokinetics with major clinical implications may occur. Sterically 
stabilized nanocarriers with a biomimetic coating (stealth nanocarriers) show 
an increased longevity in the circulation and the potential to accumulate 
predominantly in pathological sites with compromised leaky vasculature, such 
as solid tumors. Direct correlations between the longevity of a nanocarrier in 
the circulation and its ability to reach the target have been observed on 
multiple occasions3. Furthermore, a number of reviews have amply illustrated 
how surface modification can be achieved by the use of poly(ethylene oxide) 
(PEO) to obtain longcirculating NPs4,5. It is established that PEO length and 
surface density can affect biomimetic properties of the nanocarrier, with 
special regard to opsonization process, and in vivo fate6,7. In recent years, the 
use of poly(ε-caprolactone) (PCL) has emerged overwhelmingly as the core 
material for NPs and micelles8,9. Due to its high hydrophobicity and 
crystallinity as well as low melting and glass transition temperatures, PCL is 
considered an excellent candidate to form the hydrophobic core of nanocarriers 
and deliver its drug cargo at controlled rates. In fact, it has been suggested that 
high core hydrophobicity can be of help in retaining the drug inside the carrier 
throughout circulation time, avoiding its premature release and erratic 
biodistribution10. Despite attractive properties, PEO/PCL NPs have been 
poorly investigated and never especially engineered (size, surface, drug 
release) for the purpose of passive targeting nor tested in depth for their 
biological potential9.The easiest way to obtain core-shell nanocarriers is to 
assemble PEO/PCL amphiphilic block copolymers in core-shell nanostructures 
with micellar or nanosphere structure. Among PEO/PCL copolymers, diblock 
architecture is generally preferred due to a very simple synthetic pathway of 
the amphiphilic copolymer. Examples of core-corona micelles/NPs made of 
PEO (A) and PCL (B) blocks with AB11 and BAB12-14 structure for the 
delivery of hydrophobic anticancer drugs have been published recently. 
However, very little is known about the applicability of novel polymer 
architectures in giving core-shell nanocarriers for passive targeting of 
anticancer drug delivery, where they have the potential to offer a superior 
degree of NP coating. Recently, we have demonstrated that depending on 
copolymer architecture, PEO-PCL micelles behave very differently in 
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biological environments despite sharing very similarsize, surface properties, 
and release rates15. The most widely employed “bottom-up” method to prepare 
nanocarriers from these copolymers, such as the solvent displacement method, 
makes use of a nanoemulsion template16,17. In this case the manufacture of NPs 
irremediably involves the removal of the volatile, occasionally toxic solvent 
from the formulation, which causes polymer precipitation within the organic 
phase. Solvent removal can be performed by evaporation or diffusion shock, 
and of course the presence of solvent traces represents a limitation in 
pharmaceutical manufacturing. Recently, we proposed a simple method named 
“melting-sonication” (MeSo) to produce coreshell NPs based on PEO-PCL 
block copolymers without the use of toxic organic solvents18. Working on 
copolymer amphiphilic properties and low melting temperature, we 
successfully produced nanoassemblies of copolymers with ABA triblock 
architectures, demonstrating stealth properties and the ability to entrap 
lipophilic molecules. In this article we propose MeSo as technique suitable to 
produce NPs made of (PEO-PCL) block copolymers for the passive targeting 
of docetaxel (DTX) in solid tumors. NPs were produced by two copolymers 
with ABA and simple AB architecture and sharing similar 
lipophilic/hydrophilic ratio. Relevant properties of NPs were explored and 
related to in vitro/in vivo biological profiles in view of their application as an 
anticancer drug-delivery system. 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                              Chapter 3 
110 
 
Methods 
Docetaxel (DTX) was purchased from Fluka (Sigma-Aldrich). Potassium 
phosphate dibasic and potassium phosphate monobasic, sodium azide and 
sodium chloride were from Sigma-Aldrich. Sodium hydroxide was from 
Delchimica Scientific Glassware. Ethanol 96°, phosphoric acid (85%) and 
acetonitrile were purchased from Carlo Erba Reagenti (Milan, Italy). α-
Methoxy,ω-hydroxy-poly(ethyleneoxide) (mPEO2000-OH) and α-methoxy,ω-
amino-poly(ethyleneoxide) (mPEO2000-NH2) (Aldrich), were dried by 
azeotropic distillation from toluene. ε-Caprolactone, (CL) (Aldrich), was 
distilled over CaH2 under vacuum before use. Tin(2-ethylhexanoate)2, Sn(Oct)2 
(Aldrich), 4 (dimethylamino)pyridine (DMAP) (Fluka), N,N'-
dicyclohexylcarbodiimide (DCCI) (Fluka), N-hydroxysuccinimide (NHS) 
(Fluka) and the sodium salt of 3-(trimethylsilyl)propionic- 2,2,3,3-d4 acid 
(TMSP) (Aldrich) were used as received. 
 
Preparation of DTX-loaded NPs 
PEO2000-PCL4100 diblock (AB) and PEO2000-PCL6800-PEO2000 triblock 
copolymers (see Supplementary Material) were employed to prepare unloaded 
and DTX-loaded NPs. NPs were prepared by MeSo according to the procedure 
that we previously developed18. In this study 10 mg of copolymer were added 
to 2 mL of filtered water in a vial and then poured into a water bath at 75 ± 
1°C to allow copolymer melting. DTX (0.5, 1 or 1.5 mg) was dissolved in 0.2 
mL of ethanol and added to filtered water in the presence of melted copolymer, 
sonicated for 10 minutes at 6W (Sonicator 3000, Misonix) by a microtip probe 
and finally cooled at around 22°C under magnetic stirring. NPs were filtered 
through 0.45 µm filters (RC, Phenomenex, Bologna, Italy), and freeze dried. 
The recovery yield of the production process was evaluated weighting the solid 
residue after freeze-drying. Results are expressed as the ratio between the 
weight of NPs obtained and the initial (drug + polymer) weight × 100. 
 
Characterization of NPs 
The hydrodynamic diameter (DH) and polydispersity index of NPs were 
determined by Photon Correlation Spectroscopy using a N5 Submicron 
Particle Size Analyzer (Beckman-Coulter Inc., Fullerton, California). A 
dispersion of NPs was diluted in Milli- Q water at an intensity between 104–
106 counts/s and measurements were performed at 25°C on a 90-degree angle. 
The morphology of NPs was assessed by TEM on a Leo 912AB microscope 
(Carl Zeiss S.p.a., Milano, Italy). A dispersion of NPs in water was placed on a 
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copper grid and stained with uranile acetate (2% w/v). The evaluation of the 
amount of hydrated PEO chains located in NP corona was performed by 1H-
NMR (400 MHz) in D2O at 25°C and 70°C, using TMSP as internal standard. 
NPs (4–5 mg) were suspended in 1 mL of a 1 × 10-5 M solution of TMSP in 
D2O. The intensity ratio of the PEO resonance at δ = 3.6–3.7 to the methyl 
resonance of TMSP at δ = 0 was compared with that obtained after the 
addition of 1 mL of chloroform-d, which allows a complete dissolution of the 
copolymer. Zeta potential was determined by analyzing a dispersion of NPs in 
water on a Zetasizer Nano Z (Malvern Instruments Ltd., Malvern, United 
Kingdom). Results are reported as the mean of three separate measurements on 
three different batches ± Standard Deviation (SD). Differential scanning 
calorimetry (DSC) analyses were performed on a Mettler-Toledo-30 
calorimeter under nitrogen using a 10°C/minute scan rate. 
 
DTX loading and release 
DTX loading was assessed by dissolving 1 mg of NPs in an acetonitrile-water 
mixture 50:50 (v/v). The sample was stirred overnight and filtered through a 
0.45 µm filter (RC, Phenomenex). The amount of DTX dissolved was 
measured by HPLC on a Shimadzu (Shimadzu Italia s.r.l., Milano, Italy) 
apparatus equipped with a LC-10ADvp pump, a SIL-10ADvp autoinjector, a 
SPD-10Avp UV-Vis detector and a C-R6 integrator. The analysis was 
performed on a Phenosphere-NEXT 5µ, C18column (250 × 4.6 mm, 100 Å) 
(Phenomenex). The mobile phase was a 40:60 (v/v) mixture of 20 mM 
phosphate buffer at pH 4.5 with acetonitrile pumped at a flow rate of 1 
mL/minute. The UV detector was set at 227 nm. A calibration curve for DTX 
in ethanol was constructed in the concentration range 0.820–82 µg/mL. The 
limits of quantitation (LOQ) and detection (LOD) were 0.105 and 0.0005 
mg/mL. Release of DTX from NPs was assessed by dialysis in 10 mM 
phosphate buffer at pH 7.4 (PBS). NPs (1 mg) were added to 0.5 mL PBS and 
placed in a dialysis bag (MWCO= 3500 Da, Spectra/Por). The sample was 
poured in 5 mL of PBS (sink condition) and kept at 37°C. At selected time 
intervals, 1 mL of release medium was withdrawn and replaced with an equal 
volume of fresh medium. The concentration of DTX was determined by HPLC 
as described above. The release profiles of the NPs were compared with that of 
the commercial formulation Taxotere. 
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Hemolysis of DTX-loaded NPs 
Human blood freshly collected in EDTA-containing tubes was washed 3 times 
with isotonic 10 mM phosphate buffer saline (PBS) solution (pH 7.4) by 
centrifugation at 880g for 5 minutes and the pellet, containing red blood cells 
(RBC), was finally diluted 1:10 v/v with 10 mM PBS. RBC suspension (0.1 
mL) was added to 0.9 mL of a NP dispersion at concentration ranging from 
0.01 to 2.0 mg/mL of DTX. After incubation at 37°C for 30 minutes, the 
sample was centrifuged at 1000g for 10 minutes to remove nonlysed RBC. The 
supernatant was collected and analyzed for hemoglobin release by 
spectrophotometric determinations at 416 nm. To obtain 0 and 100% 
hemolysis, 0.1 mL of RBC suspension were added to 0.9 mL of PBS and 
distilled water, respectively. The degree of hemolysis was determined by the 
following equation: Hemolysis (%) = (ABS-ABS0)/ (ABS100-ABS0) × 100, 
where ABS100, and ABS0 are the absorbances of the solution at 100% and 0% 
hemolysis, respectively. 
 
Cell cultures 
Our experimental models consist of human prostate carcinoma DU145 and 
LnCaP cell lines, human breast cancer MDA-MB 231 and MCF-7 cell lines 
(American Type Tissue culture Collection, Rockville, Maryland). DU145, 
LNCaP and MDA-MB231 cells were grown in DMEM, and MCF-7 cells were 
grown in RPMI 1640, both supplemented with heat-inactivated 10% FBS, 20 
mM HEPES, 100 µg/mL penicillin, 100 µg/mL streptomycin, 1% L-glutamine 
and 1% sodium pyruvate. Cells were grown in a humidified atmosphere of 
95% air/5% CO2 at 37°C. 
 
Cell proliferation assay 
Analysis of cell proliferation was performed in the presence of DTX, DTX-
loaded NPs and empty NPs on cell lines seeded in 96-well plates at the density 
of 1-2 × 103 cells/well in serum containing media. After 24 hours of incubation 
at 37°C, the cells were treated with increasing concentrations of DTX and 
DTX-NPs (0.78 to 100 ng/mL of DTX) as well as empty NPs. Cells were 
incubated under these conditions for a time-course spanning 72 hours. Cell 
viability was assessed with MTT method as previously described19. All data 
are expressed as mean ± SD. Statistical analysis was performed by analysis of 
variance (ANOVA) with Neumann-Keul's multiple comparison or 
Kolmogorov-Smirnov tests where appropriate. 
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In vivo toxicity 
Seven-week-old female BALB/c mice were obtained from Harlan (San Pietro 
al Natisone, Italy). Mice were housed 6 per cage and maintained on a 12-hours 
light :12-hours dark cycle (lights on at 7:00 a.m.) in a temperature-controlled 
room (22 ± 2°C) and with food and water ad libitum at all times. The 
experimental protocols were in compliance with the European Communities 
Council directive (86/609/EEC). After a 1-week acclimation to the housing 
conditions, maximum tolerated dose (MTD) was evaluated by lateral tail vein 
injection of DTX, DTX-loaded NPs and empty NPs. NPs were dispersed in a 
saline solution (0.9% NaCl). Survival experiments to define MTD were 
performed with 6 animals per group. Drug effects were determined by 
monitoring of body weight and survival. Mouse body weight was monitored 3 
times per week up to 28 days. MTD was defined as the maximum dose that 
caused no drug related lethality while producing an animal body weight loss of 
less than 20% of original weight. A fatality within 2 weeks after the first drug 
treatment was defined as a drug-related death. Body weight loss greater than 
30% was considered lethal. Statistical significance was calculated by ANOVA 
and Bonferroni-corrected P-value for multiple comparison tests. 
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Results 
Preparation and characterization of NPs 
Two amphiphilic block copolymers, a diblock PEO-PCL and a triblock PEO-
PCL-PEO, both designed to have a similar PCL/PEO weight ratio close to 2/1 
and PEO segments with the same length, were used to prepare AB and ABA 
based NPs by MeSo. Relevant properties of the synthesized copolymers are 
reported in Table 1, whereas overall characteristics of NPs are summarized in 
Table 2. 
 
Table 1. Molecular characterization and thermal data of PCL-PEO block copolymers. 
a
 Number average molecular weight evaluates by 1H-NMR.  
b Molecular weight polydispersity index obtained by SEC.  
c
 Melting temperature and enthalpy determined by DSC. 
d
 Crystallinity calculated from wide angle X-ray spectra. 
 
 
Table 2. Properties of unloaded and DTX-loaded NPs. 
NP 
code 
aDTX 
(mg) 
     DH 
(nm ± SD) 
 
PDI ZP 
 (mV ± SD) 
bActual  
loading 
EE 
(% ±SD) 
Yied 
(%) 
AB - 61 ± 4 0.174 −14.9 ± 2.5 
- 
- 72 ± 2 
AB5 5 56 ± 2 0.280 −14.5 ± 0.5 4.9 ± 0.3 85 ± 3 44 ± 1 
AB10 10 57 ± 2 0.213 −16.8 ± 2.0 8.7 ± 0.5 90 ± 5 79 ± 1 
AB15 15 53 ± 3 0.208 −18.6 ± 0.7 5.1 ± 0.1 41 ± 1 52 ± 6 
ABA - 93 ± 6 0.239 −12.2 ± 1.4 - - 89 ± 2 
ABA5 5 87 ± 3 0.308 −11.2 ± 3.0 4.9 ± 0.1 98 ± 2 48 ± 6 
ABA10 10 74 ± 7 0.254 −10.9 ± 0.9 8.1 ± 0.2 91 ± 1 70 ± 3 
ABA15 15 83 ± 9 0.331 −12.3 ± 1.0 4.8 ± 1.2 44 ± 8 52 ± 3 
aApproximate DTX amount per 100 mg of copolymer. 
bRatio between the actual amount of DTX entrapped and initial DTX amount employed × 100. 
cEncapsulation efficiency. 
 
 
Block 
copolymer 
Wt % 
of 
PCL 
Mn of blocks a) 
(kDa) 
 
PCL     PEO 
ηinh 
(dL/g) 
 
PDIb) Tmc) 
(°C) 
 
PEO    
PCL 
∆Hmc) 
(J/g) 
 
PEO   
PCL 
Xcd) 
(%) 
 
PEO   
PCL 
AB 67 4.1       2.0 0.28 1.16 41.3    
56.2 
10        
50 
12         
54 
ABA 63 6.8       2.0 0.38 1.27 39.0    
56.8 
11        
43 
13        
48 
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A temperature approximately 20°C higher than copolymer melting temperature 
was adequate to give NPs with good yields. The incorporation of DTX did not 
significantly affect DH, whereas a slight increase of PI was observed for NPs 
prepared from both copolymers. Both blank and loaded ABA NPs displayed 
greater DH than the corresponding AB ones. The nearly spherical morphology 
of the NPs was clearly observed by TEM (Figure 1), which also evidenced the 
absence of aggregation phenomena and a size close to that obtained by PCS.  
 
 
Figure 1. Transmission electron microscopy images of DTX-loaded AB10 (A) and ABA10 (B) NPs. 
 
The core-shell structure of the NPs was verified by 1H-NMR studies on 
unloaded NPs. Sharp peaks relative to PCL and PEO blocks were observed 
using chloroform-d as a solvent with high affinity with both segments. When 
NPs were dispersed in D2O at 25°C, their spectra showed only the sharp peak 
of the PEO methylene groups at δ=3.60-3.70, whereas resonances of PCL 
blocks were not observed even at high magnification. At 70°C, i.e., above 
melting temperature of the PCL, broad peaks attributed to PCL blocks were 
generated, in agreement with the formation of a viscous state of melted PCL 
chains in the core. To determine the amount of hydrated PEO chain located on 
the surface, a known amount of TMSP was used as internal standard in a D2O 
dispersion of NPs at 25°C. The comparison of these spectra with those 
obtained after the addition of chloroform-d, a good solvent for both blocks, 
allowed the partition of PEO between the hydrated shell and the core to be 
calculated. It was found that, at 25°C, 80–90% of PEO was actually present in 
the corona for AB NPs and that its amount was significantly lower (≈50%) in 
the case of ABA NPs. Zeta potential was slightly negative for both unloaded 
and DTX-loaded AB and ABA NPs. AB NPs were more negative than ABA 
NPs regardless of the amount of DTX loaded (Table 2). DTX encapsulation 
efficiency in NPs was the highest at intermediate amount of DTX used, 
whereas a decrease in entrapment efficiency occurred at higher DTX amounts 
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initially employed. The maximum amount of DTX entrapped inside NPs was 
around 8 mg/100 mg NPs for both AB and ABA NPs. An amount as low as ≈ 
5% of total DTX employed to prepare NPs was not entrapped in ABA10 NPs 
after MeSo, remaining free in the aqueous dispersion, whereas unencapsulated 
DTX increased to approximately 16% for AB10 NPs. DSC analysis evaluated 
the physical state of DTX inside NPs prepared at intermediate DTX loading, 
i.e., the highest DTX actual loading obtained. Figure 2 reports the heating 
thermograms of DTX-loaded AB10 and ABA10, collected at 10°/minute 
scanning rate and compares them with that of a DTX control treated by MeSo 
in the same experimental conditions as those employed to produce NPs.  
 
 
Figure 2. DSC thermograms of DTX treated by MeSo (a), AB10 NPs (b) and ABA10NPs (c). 
 
 
 
DTX curve showed a melting endotherm at about 186°C, in agreement with Tm 
of crystalline DTX, while a corresponding endotherm was not observed in the 
thermograms of loaded NPs. Moreover, the thermograms show melting 
endotherms of PCL and PEO blocks identical to those of unloaded systems and 
similar to DSC traces of copolymers, self-organized in bulk. Release profiles 
of DTX from NPs in PBS at pH 7.4 are reported in Figure 3. 
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Figure 3. Release profile of DTX from NPs in 10 mM phosphate buffer at pH 7.4 and 37 °C.Panel 
A. Release profile of DTX from AB5 (□) and ABA5 (▲) NPs. Release of DTX fromTaxotereR (×) 
is reported for comparison. Panel B. Release profile of DTX from AB10 (□) and ABA10 (▲) NPs. 
Inset in A and B show release profiles of DTX in the initial stage. Eachpoint is the mean of four 
measurements±SD. 
 
 
A two-pulse release was observed for both types of NPs and characterized by 
an initial fast release, a plateau and a second release stage. At the initial stage, 
drug release was dependent on copolymer type, due to a slower release rate for 
ABA NPs (see inset in Figure 3, A and B). Release profiles of DTX at low 
loadings show that control over DTX release rate in the initial stage is more 
efficient in the case of ABA NPs than for AB NPs. 
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In vitro cytotoxicity 
Hemolytic properties of DTX-loaded NPs were evaluated and compared with 
those of Taxotere (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hemolytic activity of TaxotereR, polysorbate 80, DTX-loaded AB10 and ABA10 NPs, 
unloaded AB and ABA NPs. Polysorbate 80 is the surfactant present in the TaxotereR vehicle. 
Each point is the mean of four measurements±SD. 
 
The results of the hemolysis test demonstrated that toxicity toward RBC of 
Taxotere could be mainly attributed to polysorbate 80, whereas DTX-loaded 
NPs were much less toxic to RBC at all concentrations tested. In vitro 
cytotoxicity of free DTX or DTX-loaded NPs was evaluated by incubating 5 
human tumor cell lines derived from breast (MCF-7 and MDA-MB231) and 
prostate (LnCaP and DU145) cancer with increasing concentrations of free 
DTX, DTX-loaded AB10 and ABA10 NPs (0.78 to 100 ng/mL), and empty AB 
and ABA NPs for 72 hours (Figure 5).  
                                                                                                                                              Chapter 3 
119 
 
 
 
Figure 5. Growth inhibition of cells treated with free DTX or DTX-loaded NPs for 72 h, evaluated 
by MTT assay and expressed as percentage of untreated cells. Data are reported as mean of three 
independent experiments ± SD. Key legend: free DTX (●), unloaded ABA ( ) and AB (▾) 
NPs,DTX-loaded ABA10 (▴) and AB10 NPs (  ). Each point is the mean of four measurements ± SD. 
 
 
Cell growth was then assessed by using the MTT assay as described in the 
Methods section. Empty NPs did not induce significant cell growth inhibition 
at every concentration and time interval tested. As expected, free DTX caused 
a significant cell growth inhibition after 72 hours of treatment in a range from 
10 to 90%, and both dose/effect curves of both DTX-loaded AB10 and ABA10 
NPs did not show a clear dose-dependent effect in all cell lines. Furthermore, 
we observed that both DTX-loaded AB10 and ABA10 NPs induced cell growth 
inhibition more forcefully than free DTX. In fact, the obtained data suggested 
that the DTX-loaded NPs caused a potent growth inhibition already at low 
DTX dosages, accounting for an anticancer activity ranging from 70 to 40% at 
                                                                                                                                              Chapter 3 
120 
 
a DTX concentration of 0.78 ng/mL depending on the cell line used for the 
assays (Figure 5). 
Moreover, the values of potentiating factor (PF) reported in Table 3 
demonstrate that both types of DTX-loaded NPs potentiated the growth 
inhibition induced by free DTX, reaching a PF higher than 1.0 in cancer cell 
lines of different histogenesis (Table 3). Specifically, PF values define the 
specific contribution of DTX-loaded NPs evaluated as the ratio of the IC50 or 
IC25 of encapsulated DTX to the IC50 or IC25 of free DTX. The PF was higher 
for the IC25 than for the IC50 values (Table 3); in fact, the encapsulation of 
DTX appeared to potentiate the antiproliferative activity of DTX at lower 
concentrations whereas the growth inhibitory activity of the NPs resembled 
that of free DTX for higher concentrations. 
 
Table 3. IC50/25 values (ng/ml) of free DTX or DTX-loaded NPs in different cell lines. 
 
 DTX ABA10 P.F. AB10 P.F. 
DU145 IC50 1.36 ± 0.04 <0.195 ± 0.003 >7 <0.195 ± 0.003 >7 
 
IC25 0.55 ± 0.04 <0.195 ± 0.003 >3 <0.195 ± 0.003 >3 
LNCaP IC50 0.700 ± 0.009 <0.19 ± 0.04 >4 <0.19 ± 0.06 >4 
 
IC25 0.28 ± 0.02 <0.19 ± 0.04 >1.5 <0.19 ± 0.06 >1.5 
MDA-
MB231 
IC50 
345.39 ± 0.04 164.60 ± 0.03 2.1 >184.85 ± 0.01 1.9 
 
IC25 1.413 ± 0.004 <0.19 ± 0.03 >7 <0.19 ± 0.01 >7 
MCF-7 IC50 0.35 ± 0.01 <0.04 ± 0.01 >9 <0.04 ± 0.01 >9 
 
IC25 0.09 ± 0.05 <0.04 ± 0.01 >2 <0.04 ± 0.01 >2 
 
 
In vivo toxicity 
MTD for intravenously administered free DTX, DTX-loaded AB10 and ABA10 
NPs (0.78 to 100 ng/ml) and empty AB and ABA NPs was determined in 
healthy 7-week-old BALB/c female mice. Survey experiments to define MTD 
were performed with 6 animals/group. DTX-loaded NPs were dispersed in a 
0.9% NaCl solution. No severe side effects, sudden deaths or mean loss of 
more than 20% or 30% of the initial body weight were observed up to 28 days 
after drug administration with free DTX or DTX-loaded NPs at every 
concentration tested suggesting that MTD was never achieved with any 
treatment (Figure 6). However, either 35 or 50 mg/m2 free DTX induced an 
about 25% decrease of the mean body weight of mice if compared with that of 
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the control group. This difference was statistically significant (*P<0.005) 
(Figure 6A). Lower dosages of free DTX did not cause any change in mean 
body weight compared with control mice. Similarly, at every used dosage, 
neither DBL-DTX nor TBL-DTX caused any significant change in the mean 
animal body weight compared with control mice (Figure 6B). These data 
suggested that neither NPs were toxic for mice and that they induced milder 
side effects than the highest dosage of free DTX induced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effects of free DTX and DTX-loaded NPs on the body weight changes of mice. Mice 
were randomized and treated with (A) different doses (from 10 to 50 mg/kg as indicated in the 
figure) of either free DTX (DTX) and (B) DTX-loaded ABA10 NPs by intravenously administered 
in the tail veins of the animals. The body weight was determined three times a week for 4 weeks 
and the results were expressed as means (n=6) + SD. *p<0.005. 
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Discussion 
MeSo is an interesting technique set up in our labs to produce core-shell NPs 
for drug delivery. The technique has been used here to prepare NPs from block 
copolymers of PCL and PEO with different architectures and to entrap the 
anticancer drug DTX. The formulation study aimed at understanding how 
copolymer physical-chemical properties affect those features of NPs that are 
relevant to the therapeutic response. Furthermore, the toxicity of NPs on RBC, 
different tumor cell lines and in mice was investigated to pinpoint the in vivo 
potential of the system. MeSo consists of the nanoemulsification of a fluid, 
nonwater-miscible copolymer at a temperature higher than Tm in water under 
sonication. The copolymer is then hardened by cooling at room temperature 
giving spherical nonaggregated NPs with a hydrophilic coating and a 
hydrophobic core. As indicated by the NMR results and zeta potential study, 
hydrated PEO segments with high chain mobility were located in the corona of 
NPs, and the PCL chains interact with each other, forming a solid-like compact 
semicrystalline core with strongly constrained motions. PEO was 
quantitatively distributed on the surface only for AB NPs, suggesting that a 
more regular core-shell structure was reached in the case of the diblock 
copolymer. This finding can be easily related to the structural differences 
between copolymers and especially to the presence of a single junction 
between PCL and PEO blocks in AB, which favors self-assembly in the MeSo 
process. Although the total amount of PEO found on the surface of ABA NPs 
was slightly lower than that found on AB NPs, zeta potential values suggested 
a different PEO organization with a more efficient shielding of the PCLcharge 
in the case of ABA NPs. It is conceivable that in the shell of ABA NPs, the 
presence of two PEO chains joined to the core by a single PCL chain ensures a 
higher surface density of PEO. Thus, PEO distribution on particle surface at a 
comparable hydrophilic/hydrophobic ratio might be modulated by chain 
flexibility of copolymers with different architectures. Nevertheless, such an 
organized PEO shell has previously been demonstrated to impart stealth 
properties to ABA NPs18. With regard to the drug-loading ability of NPs, the 
trend of actual loading at increasing DTX amount employed to obtain NPs 
suggests that the drug-to-copolymer ratio plays a key role in allowing efficient 
drug entrapment in the nano-structuring melted copolymer analogously to 
observations made for NPs prepared from other PCL copolymers by solvent 
displacement methods20,21. Behind the preparation of NPs by MeSo, complex 
multiple processes take place that strongly impact nanocarrier features. 
Nevertheless, some general indications on the process of nanocarrier formation 
can be affirmed based on our findings. Considering the very low solubility of 
                                                                                                                                              Chapter 3 
123 
 
DTX in water, it can be reasonably hypothesized that drug incorporation 
within PCL phase is promoted when the copolymer is in a melted state, 
because it is hindered in preformed core-shell NPs. Thus, loading efficiency is 
critically affected by the solubility profile of the drug in the dispersing medium 
(water), which has to be low, taking into account the great difference in the 
solubility parameters δ of water and DTX (47.9 and 25.5 MPa1/2, 
respectively), and in the melted copolymer (δ of PCL = 18.2 MPa1/2), which 
displays higher miscibility with the drug. It can be hypothesized that at drug 
loading higher than intermediate, in which a sharpdecrease of encapsulation 
efficiency is experienced, DTX rapidly precipitates in the water phase losing 
the possibility to partition in melted copolymer and remain entrapped in NPs. 
The absence of crystalline order of DTX in the solid NPs also suggests that an 
efficient drug dispersion in the polymer can be reached. On the other hand, the 
presence of crystalline PEO and PCL domains indicates that MeSo technique 
does not hinder efficient phase separations of immiscible separate copolymer 
segments. Due to the semicrystalline nature of both copolymers, it is 
reasonable to assume that the drug is entrapped in the amorphous regions of 
the PCL core of the NPs. Accordingly, actual loading of AB10 and ABA10 
seems to correlate well to copolymer crystallinity with the less crystalline 
ABA giving higher actual loading of DTX than AB bulk copolymer. DTX-
loaded AB10 and ABA10 NPs could be freeze-dried without the help of any 
cryoprotectant and redisperded in PBS, giving the original hydrodynamic 
diameter and without displaying any aggregation. This feature is important 
from a pharmaceutical perspective because it promises a good shelf life of the 
formulation. The size of DTX-loaded NPs below 100 nm can be considered a 
cut-off value to achieve long-circulating properties in vivo5. Thus, an 
advantage of MeSo technique is the possibility to finely control this feature 
without the help of any surfactant. This aspect is important when considering 
that carrier distribution in different body compartments as well as 
extravasation in solid tumors are strongly affected not only by size4,22 but also 
by the presence of surfactant on the surface23. 
Hemolytic potential is of critical importance for any intravenously 
administered drug because a negative interaction with blood components can 
strongly limit their applicability. This aspect is much more important when a 
hydrotropic vehicle is needed as in the case of Taxotere where polysorbate 80 
and ethanol are added to solubilize DTX. It is well known that surfactants at 
high concentrations are responsible for toxic effects due to membrane 
penetration and saturation of surfactant unimers which solubilize membrane 
lipids and proteins24,25. The lower toxicity of DTX-loaded ABA10 NPs in 
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comparison with AB10 NPs at concentrations higher than 0.05 mg/mL 
(P<0.001) could be due to the presence of perfect core-shell micelles prone to 
dissociate and release unimers. Because CMC for AB is lower than that of 
ABA, it can be hypothesized that the formation of core-shell AB micelles 
during the fabrication of NPs is higher for AB in comparison with ABA. The 
presence of a greater amount of AB micelles results in a greater presence of 
AB unimers, which could exert a certain toxicity on RBC. Both types of 
developed NPs were found to have very peculiar release trends with a two-
pulse profile. The finer control over DTX release rate in the initial stage in the 
case of ABA NPs can be reasonably ascribed to a lower PCL crystallinity in 
ABA, which promotes a more homogeneous distribution of DTX in the 
amorphous regions of NPs and its progressive delivery. At a higher DTX 
loading, an increased concentration gradient develops which increases delivery 
rate in the initial diffusive stage and speeds up release for both AB and ABA 
NPs. Again, the initial release of DTX was slower for ABA NPs, confirming 
the importance of reducing polymer crystallinity for an efficient modulation of 
release rate. In the plateau stage, which starts when all the diffusible drug 
molecules in the hydrating medium are over, DTX release stops; this is likely 
due to slow PCL degradation. The second drug pulse can be attributed to 
massive PCL degradation of the inner core allowing drug delivery from the 
polymer crystalline phase. Actually, drug pulse occurs at comparable times for 
both AB and ABA NPs, confirming that PCL degradation rate is the main 
determinant accounting for this effect and consistent with the two-step 
degradation mechanism, which has recently been suggested for PCL-PEO NPs 
in aqueous environment26. This release behavior could be of great interest in 
the treatment of solid tumors because it has been suggested that enhanced 
therapeutic efficacy of nanomedicines may be a function, in part, of this 
mechanism27. In fact, a controlled drug release rate in tumor interstitium can 
be of help in generating a drug concentration gradient in the tissue with major 
effects on the pharmacological effect of drugs and tumor resistance28. The 
experimental conditions realized in the in vitro release study could well 
simulate those induced in vivo by the dose-dense administration of DTX. The 
conventional high-dose chemotherapy is not very effective and is associated 
with high toxicity29. Dose-dense chemotherapy, in which one or more 
chemotherapeutic agent is administered at more frequent intervals, has shown 
efficacy in phase III RCTs30,31. It was, moreover, recently reported that the 
administration of paclitaxel (another taxane similar to DTX) on a weekly 
schedule (dosedense therapy), rather than the standard every-3-week schedule 
(conventional therapy), might produce greater tumor-cell death both in vitro 
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and in vivo32. It was reported that paclitaxel-induced apoptosis depends on the 
paclitaxel concentration and the duration of the exposure time. Therefore, it 
cannot be excluded that in our experimental conditions the continuous 
exposure of the tumor cells to DTX could elicit mechanisms of cell death (i.e., 
apoptosis) different from those caused by the addition of a single DTX pulse33. 
The different mechanisms of cell death induced by free Vs DTX-loaded NPs 
could account for the different antiproliferative effects observed in our 
experimental conditions. The different in vitro cytotoxicity of NPs versus free 
DTX was paralleled by a milder toxicity profile of DTX-loaded ABA10 NPs in 
an animal experimental model. Although the administration of scalar dosages 
of DTX both free or entrapped in NPs did not allow the achievement of a 
MTD, the highest dosages of free DTX caused a reduction in the body weight 
increase of the animals, whereas no effects were recorded with the 
corresponding dosages of DTX-loaded ABA10 NPs. This discrepancy could be 
due to the slow release of DTX in the blood circulation and the consequent 
elimination of the drug from the liver and kidney. These results strongly 
suggest the advisability of further development of these NP formulations in 
preclinical animal models of human cancers. 
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Abstract 
Combination therapies for cancer aim to exploit either additive or synergistic 
effects arising from the action of two species with the final goal to maximize 
the therapeutic efficacy. In this work, we develop  multifunctional 
nanoparticles (NPs) for co-delivery of the conventional anticancer drug 
docetaxel (DTX)  and the second generation photosensitizer zinc-
phthalocyanine (ZnPc) as potential dual carrier system for the combination of 
chemotherapy and photodynamic therapy (PDT). Biodegradable and 
amphiphilic block  copolymers based on poly(ε-caprolactone) (PCL=B) and 
poly(ethylene oxide) (PEO=A), with AB and ABA architectures, were 
assembled in “core-shell” NPs and loaded with both DTX and ZnPc employing 
the melting/sonication method. Hydrodynamic diameters within the range 60–
100 nm and low polydispersity  indexes were obtained. Zeta potential was 
negative for all the formulations and unaffected by drug encapsulation. 
Concerning drug loading ability of NPs, the entrapment efficiency was related 
to initial ZnPc/DTX ratio.  Steady-stationary and time-resolved emission 
fluorescence measurements pointed out the embedding of  monomeric ZnPc in 
the NPs, excluding the presence of ZnPc self-supramolecular oligomers. The 
release of  DTX was biphasic whereas ZnPc remained mainly associated with 
NPs. Singlet oxygen generation was observed when ZnPc-loaded NPs were 
irradiated at 610 nm within a 45 min time range, despite that ZnPc  was not 
released in the medium. Stability of NPs in the presence of serum proteins and 
plasma was excellent  and no toxicity toward red blood cells was found. NPs 
cytotoxicity was evaluated in HeLa cells irradiated for  30 min with a halogen 
lamp. After 72 h, viability of cells treated with ZnPc/DTX-loaded NPs strongly 
de-  creased as compared to NPs loaded only with DTX, thus showing a 
combined effect of both DTX and ZnPc. Superior antitumor activity of 
ZnPc/DTX-loaded NPs as compared to DTX-loaded NPs wasconfirmed in an 
animal model of orthotopic amelanotic melanoma, thus pointing to the 
application of PEO–PCL NPs in the combined chemo-photodynamic therapy 
of cancer.  
Keywords: Photodynamic therapy, Nanoparticles, Amphiphilic block 
copolymers, Poly(epsiloncaprolactone), Poly(ethyleneoxide), Docetaxel 
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Introduction 
The concept of combining different treatment modalities is widely employed 
in modern oncology to improve the therapeutic response. Photodynamic 
therapy (PDT) is a non-invasive clinical treatment based on the administration 
of a photosensitizer (PS) that, after irradiation by a non-thermal light, 
photochemically reacts with tissue components, causing the formation of 
cytotoxic species and the following cell death through the initiation of 
apoptosis and necrosis1. Anticancer effects of PDT are ascribed to direct 
cytotoxic effects on tumor cells, damage to tumor vasculature, and induction of 
a severe inflammatory action, all acting in cooperation2. Tumor selectivity of 
PDT is ensured by the application of localized light to neoplastic areawithout 
affecting healthy tissues Nevertheless, induction of a systemic immune 
response, is a key aspect  since it is foreseen as a strategy to treat metastatic 
cancer [2]. PDT has been combined with surgery, radiotherapy and 
chemotherapy and considered promising for the management of malignant and 
premalignant non-melanoma skin cancer, Barrett esophagus and non-
resectable cholangiocarcinoma whereas its role in managing other type of 
tumors has not been unequivocally proven2–5. Acting by different mechanisms, 
cytotoxic drugs can act in concert with PS for tumor killing, achieving 
potentiated therapeutic outcome through an anticancer synergistic effect6. 
Under irradiation with light of appropriate wavelength, PS is promoted from 
its ground state to the first excited single state which results in a chain of 
further electronic transitions. Due to intersystem crossing, PS in the triplet 
state can transfer energy to molecular oxygen and generate singlet oxygen. 
Short singlet oxygen lifetime (around 3 µs) and resulting diffusion distance (2–
4×10−6 cm2 s−1) make PDT a highly selective treatment7. Amid second 
generation PS, phthalocyanines have attracted attention over the past two 
decades as very promising candidates for tumor PDT7. Due to the presence of 
a suitable coordinating atom (zinc, aluminum, silicon), they exhibit long-lived 
triplet state with high singlet oxygen production. Nevertheless, poor water 
solubility of phthalocyanines is highly beneficial to increase tumor to normal 
tissue ratio8 but strongly limits intravenous administration, in analogy to highly 
lipophilic chemotherapeutic agents. To overcome these issues and alleviate PS 
accumulation in the body and post-PDT skin photosensitivity under exposure 
to environmental light, the so-called third generation of PS has been 
developed. It comprises second generation PS associated to a carrier able to 
promote PS accumulation at the target site as well as to minimize healthy cell 
localization and concomitant damage. On these bases, formulation of PS in 
different nanosized delivery systems has been attempted9–12. A variety of 
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photoactive NPs has been developed so far and found to alter PS 
pharmacokinetics as well as control side effects12,13. Research on third 
generation PS has been focused on uncoated biodegradable NPs made of 
PLGA10,12–14 or poly(ε-caprolactone)  (PCL)15 which, due to recognition by the 
host's immune system, are rapidly uptaken in MPS and cannot be considered 
highly efficient in altering PS biodistribution16. Nevertheless, from the early 
attempts of PS incorporation in biomimetic stealth biodegradable NPs17 to 
more recent findings18, an improvement of tumor selectivity as well as 
reduction of drug/light interval, treatment times, normal tissue damage, 
cutaneous sensitivity and dose required has been found when employing 
PEGylated nanocarriers as compared to free drug. The idea to combine two 
drugs with different pharmacokinetics in a nanocarrier with well-tailored 
properties can allow a control over anticancer drug/PS biological fate and 
promote co-localization in the same area of the body19. This approach is rather 
recent and demonstrated to be a promising strategy to overcome tumor drug 
resistance in a mouse tumor model treated with doxorubicin in combination 
with the PS methylene blue20. Furthermore, design of nanosystems being 
stable in vivo and able to release slowly their drug cargo in the body can 
strongly resemble metronomic chemotherapy and allow chronic administration 
of chemotherapeutics at relatively low, minimally toxic doses, and with no 
prolonged drug-free breaks. The potential of this approach has been recently 
revised on the basis of clinical trials21 and considered a very promising novel 
strategy also in cancer PDT2. On these basis and our previous experience in the 
delivery of the antimitotic lipophilic drug docetaxel (DTX) through core-shell 
biodegradable NPs22,23, here we develop NPs of amphiphilic block copolymers 
of PCL and poly(ethylene oxide) (PEO) for co-delivery of DTX and zinc-
phthalocyanine (ZnPc). NPs were made from PCL/PEO block copolymers 
with simple diblock (AB) and triblock (ABA) structure to highlight the role of 
copolymer architecture on NP overall properties. The combination of steady-
stationary and time-resolved emission fluorescence measurements gave 
insights into the entrapment process of ZnPc in the NPs, pointing out the 
crucial function of its monomeric form in the generation of singlet oxygen. 
The chemo-phototherapeutic dual effect of DTX and ZnPc was investigated on 
cancer cells, providing also data to understand the real mechanism in which the 
apoptotic cell death constitutes the ultimate effect. Finally, the synergic effect 
of DTX and ZnPc was preliminarily evaluated after NP injection in an 
orthotopic mouse model of amelanotic melanoma so as to reinforce the 
translational potential of the NP-based combined approach in clinical practice. 
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Experimental part 
Materials  
Docetaxel (DTX, MW=807.88) was purchased from LC laboratories (USA). 
Zinc(II) phthalocyanine (ZnPc, MW=577.91), (2-hydroxypropyl)-β-
cyclodextrin (DS 0.6), threalose, human serum albumin, Polysorbate 80, 
anthracene-9,10-dipropionic acid, potassium phosphate dibasic and potassium 
phosphate monobasic, sodium azide and sodium chloride were purchased from 
Sigma-Aldrich. Sodium hydroxide was provided from Delchimica Scientific 
Glassware. Ethanol 96°, phosphoric acid (85%), acetonitrile and 
tetrahydrofuran were purchased from Carlo Erba Reagenti (Milan, Italy). α-
Methoxy,ω-hydroxy poly(ethylene oxide) with Mn=2.0 kDa, mPEO2000-OH, 
(Aldrich) was dried by azeotropic distillation from toluene. ε-Caprolactone, 
CL, (Aldrich) was distilled over CaH2 under vacuum before use. Tin(2-
ethylhexanoate)2, Sn(Oct)2, (Aldrich), 4-(dimethylamino) pyridine,DMAP 
(Fluka), 1,3-dicyclohehylcarbodiimide, DCCI (Fluka), and N-
hydroxysuccinimide, NHS (Fluka) were used as received.  
 
Synthesis and characterization of block copolymers 
A PEO2000–PCL4300 diblock copolymer (AB) was prepared as previously 
described23. Briefly, mPEO2000-OH and Sn(Oct)2 were used as initiator and 
catalyst, respectively, in the bulk ring-opening polymerization (ROP) of CL at 
120 °C; CL/initiator molar ratio=38 (ηinh= 0.28 dL×g−1 at 25 °C in 
chloroform; Mw/Mn=1.16). A PEO2000–PCL6800–PEO2000 triblock copolymer 
(ABA) was synthesized by a two-step procedure23. Briefly, α,ω-dihydroxy-
PCL6800, obtained by ROP of CL initiated by 1,4-butanediol under the 
experimental conditions above reported, was coupled in the second step with 
two mPEO2000-COOH segments after activation of the carboxyl group with 
NHS. DCCI, as condensing agent, and DMAP as catalyst were used in the 
coupling step (ηinh=0.39 dL×g−1 at 25 °C in chloroform; Mw/Mn=1.32).  
 
Preparation of NPs  
AB and ABA copolymers were employed to prepare unloaded, DTX-loaded, 
ZnPc-loaded and ZnPc/DTX-loaded NPs by a slightly modified 
melting/sonication procedure (MeSo) previously described23. Ten mg of 
copolymer were added to 1.8 mL of filtered water in a vial that was poured in a 
water bath heated at 72±2 °C to allow copolymer melting. For ZnPc/DTX-
loaded NPs, DTX (5% or 10% of copolymer weight) and ZnPc (0.2% of 
copolymer weight) were dissolved in 0.1 mL of ethanol or THF, respectively. 
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Drug solutions were mixed and added to water containing melted copolymer. 
The mixture was sonicated for 10 min at 3 W (Sonicator 3000, Misonix, USA) 
by a microtip probe and finally cooled at room temperature. The organic 
solvent was then completely removed by vacuum distillation using a rotary 
evaporator for 30 min. For NPs loaded with a single drug, the same procedure 
was employed (drug was dissolved in the correspondent solvent and the other 
solvent added to give a 1:1 ethanol/THF volume ratio). NPs were filtered 
through 0.45 µm filters (RC, Chemtek, Italy), freeze-dried for 24 h and kept at 
4 °C. When needed, threalose or HPβCD were added as cryoprotectants at 
different mass ratio with NPs. Recovery yield of production process was 
evaluated on an aliquot of NP dispersion (without cryoprotectant) by 
weighting the solid residue after freeze-drying. Results are expressed as the 
ratio of the actual NPs weight to the theoretical polymer weight×100. 
 
Size and zeta potential of NPs 
The hydrodynamic diameter (DH) and polydispersity index (PI) of NPs were 
determined by Photon Correlation Spectroscopy (PCS) using an N5 Submicron 
Particle Size Analyzer (Beckman-Coulter). An NP dispersion was diluted in 
Milli-Q water at intensity in the range 104–106 counts/s and measurements 
were performed at 25°C on 90° angle. Results are reported as mean DH of three 
separate measurements of three different batches (n=9)±standard deviation 
(SD). Size of NPs stored in the dark at 4°C for 3 months was monitored too. 
The morphology of the NPs was examined by transmission electron 
microscopy (CM 12 Philips, Eindhoven, The Netherlands) using samples 
stained with a 2% phosphotungstic acid solution. Zeta potential was 
determined by analyzing a NP dispersion in water on a Zetasizer Nano Z 
(Malvern Instruments Ltd.). Results are reported as mean of three separate 
measurements of three different batches (n=9)±SD. 
 
Steady State and Time-resolved Fluorescence Spectroscopy 
Fluorescence emission spectra were carried out on ZnPc-loaded NPs and 
ZnPc/DTX-loaded NPs based on AB and ABA copolymers dispersed in ultra 
pure water (Galenica Senese, V=20 mL) and sonicated for 10 min. In all the 
experiments ZnPc was set at 0.07 µg/mL. Steady-state fluorescence 
measurements were performed on Jasco model FP-750 spectrofluorimeter with 
an excitation wavelength of 600 nm and using 1 cm path length quartz. 
Fluorescence spectra are not corrected for the absorbance of the samples. 
Depolarized fluorescence spectra were measured by using Equation (1)24: 
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 (1) 
where r is the anisotropy and IVV, IHH, IVH, and IHV are the fluorescence 
intensities registered with different polarizer orientations (V=vertical, 
H=horizontal). 
Time-resolved fluorescence measurements were carried out by a time-
correlated-single-photon-counting (TCSPC) home-made apparatus25. The 
excitation source was a synchronously mode-locked rhodamine 6G dye laser 
(Spectra Physics 375B) which provided excitation pulses of about 2 ps full 
width at half-maximum at a repetition rate of 82 MHz. An excitation 
wavelength of 570 nm was used. The fluorescence pulses were detected with a 
microchannel-plate photomultiplier (Hamamatsu R1645U-01, about 200 ps 
rising-time) and the decay profiles were collected with a computer-controlled 
multichannel analyzer card (EG&G Ortec Trump-8k/2k). The collected data 
were then analyzed using the nonlinear least-squares iterative reconvolution 
procedures based on the Marquardt algorithm26. In the case of total 
fluorescence decay curves, the fitting was performed on the basis of the 
multiexponential decay law24, 
 
∑ −=
i
ii tI )/exp(0 ταI(t)  (2)   
where I(t) is the total fluorescence decay curve, I0 is the intensity at time zero, 
and αi and τi are, respectively, the relative amplitudes and lifetimes of the ith 
component (the normalization condition is ∑ =
i
i 1α ). In the case of time-
resolved anisotropy measurements, the reconvolution fitting procedure was 
based on two steps. Fluorescence anisotropy r(t) is defined using the following 
expression:  
( ) ( ) ( )( ) ( ) )(
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tD
=
+
−
=
t2ItI
tItI
tr
VHVV
VHVV
    (3) 
where the sum data, S(t), must be equal to the total intensity I(t). In some 
cases, an additive constant r∞ to r(t) was introduced to take into account a long 
decay contribution due to static interaction with large clusters. In the simple 
case of spherical molecules, each rotational correlation time, τRj, is related to 
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the volume (Vj) of the rotating unit (or of the equivalent sphere) by the 
following equation [27]: 
 
Tk
V
B
j
Rj
η
τ =
    (4) 
where η is the microviscosity of the medium, T is the temperature in kelvin, 
and kB is the Boltzmann constant. 
 
DTX analysis  
DTX was analyzed by HPLC on a Shimadzu apparatus equipped with a LC-
10ADvp pump, a SIL-10ADvp autoinjector, a SPD-10Avp UV–Vis detector 
and a C-R6 integrator. The analysis was performed on a Phenosphere-NEXT 5 
µm, C18 column (250×4.6 mm, Å) (Phenomenex, USA). The mobile phase 
was a 40:60 (v/v) mixture of  20 mM phosphate buffer at pH 4.5 and 
acetonitrile pumped at a flow rate of 1 mL/min. The UV detector was set at 
227 nm. A calibration curve for DTX in ethanol was constructed in the 
concentration range 0.980–196 µg/mL. The limits of quantification (LOQ) and 
detection (LOD) were 1.29 and 0.39 µg/mL.  
 
ZnPc analysis  
ZnPc quantification was carried out by spectrofluorimetry on a Shimadzu RF-
1501 at EX=610 nm and EM=668 nm. The concentration of ZnPc was 
calculated by means of a standard calibration curve derived for THF solutions 
of ZnPc at known concentrations (7.2–720 ng/mL). The limits of 
quantification (LOQ) and detection  (LOD) in THF were 3.70 and 1.11 ng/mL. 
Potential interference of DTX on ZnPc emission was preliminarily assessed 
spiking a ZnPc solution in THF with different amount of DTX.  
 
DTX and ZnPc entrapment efficiency  
DTX loading inside NPs was assessed by dissolving 1 mg of NPs in 500 µL of 
acetonitrile under stirring for 1 h. Thereafter, 500 µL of water was added and 
the sample stirred for 1 h further and analyzed as reported above. The sample 
was filtered through a 0.45 µm filter (RC, Chemtek, Italy). ZnPc encapsulation 
efficiency was evaluated by dissolving a known amount of freeze-dried NPs (1 
mg) in 1 mL of THF under magnetic stirring for 1 h and analyzing the solution 
as described above. To verify a possible interference of copolymers on ZnPc 
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quantitative analysis, an amount of DTX-loaded NPs was dissolved in THF 
and analyzed in the same conditions reported for ZnPc.  
 
In vitro release studies  
In vitro release of DTX from NPs was assessed in 10 mM phosphate buffer 
containing NaCl (137 mM) and KCl (2.7 mM) at pH 7.4 (PBS) by a dialysis 
method. A known amount of NPs (2 mg) was dispersed in 0.5 mL of PBS and 
placed in a dialysis bag (MWCO=3500 Da, Spectra/Por®). The sample was 
plunged in 5 mL of PBS (sink condition) and kept at 37 °C. In vitro release of 
ZnPc from NPs was evaluated as described above in 3 mL of PBS containing 
10% v/v of polysorbate 80 in order to ensure sink conditions and to avoid 
ZnPc aggregation. In both cases, at selected time intervals, 1 mL of release 
medium was withdrawn and replaced with an equal volume of fresh medium. 
DTX or ZnPc quantitative analysis was performed as described above. Release 
profile of free DTX and ZnPc (76 µg and 3.6 µg, respectively dissolved in 0.1 
mL of 1:1 ethanol/THF) is reported for comparison. Results are expressed as 
release % over time±SD of three experiments. 
 
Singlet oxygen generation from NPs 
The capacity of NPs to generate singlet oxygen was monitored over time by 
measuring photobleaching of the radical quencher ADPA28. Briefly, 40 µl of a 
5 mM ADPA solution in NaOH 0.01 M was added to 2 mL of a ZnPc solution 
in water/THF 100:1 v/v or a NP water dispersion ([ZnPc]=2 µg/mL; [NPs]=1 
mg/mL). The sample was irradiated at 610 nm using a 150 W ozone-free 
xenon-arc lamp (JobinYvon) with a slit width of 10 nm for different times (15, 
30 and 45 min). Sample containing NPs was centrifuged at 16,090 ×g (Mikro 
20, Hettich) for 30 min. The supernatant was collected and analyzed by 
spectrophotometry at 400 nm to evaluate ADPA absorption. Singlet oxygen 
generation was monitored by the decrease of OD at 400 nm as a function of the 
irradiation time. 
 
Hemolytic activity of NPs 
Hemolysis studies were carried out on unloaded NPs, ZnPc/DTX-loaded NPs 
and HPβCD as control. After centrifugation of EDTA-treated human blood at 
880 ×g for 5 min, a red blood cells (RBC) dispersion was obtained and diluted 
with 0.1 M PBS up to a concentration of 10% v/v. The RBC dispersion (0.1 
mL) was added to 0.9 mL of a NP dispersion, with NP concentrations ranging 
from 0.01 to 2.0 mg/mL. The sample was incubated at 37 °C for 30 min and 
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centrifuged at 1000 ×g for 10 min. The supernatant was collected and analyzed 
for hemoglobin release by spectrophotometry at 416 nm. To obtain 0 and 
100% hemolysis, 0.1 mL of RBC dispersion was added to 0.9 mL of PBS and 
distilled water, respectively. The degree of hemolysis was determined by the 
following equation: Hemolysis (%)=(ABS–ABS0)/(ABS100–ABS0)×100, where 
ABS100 and ABS0 are the absorbance of the solution at 100% and 0% 
hemolysis, respectively. 
 
NP stability in the presence of blood components 
To determine the stability of NPs under physiologically relevant conditions, a 
known amount of freeze-dried NPs was dispersed in PBS containing 2% w/v 
of human serum albumin (HSA) or in human plasma (NP concentration was 
4.5 and 1.3 mg/mL, respectively) and incubated at 37 °C for different times. 
Human plasma was obtained by centrifugation of EDTA-treated human blood 
at 880 ×g for 5 min. Size measurements of the samples were taken by PCS 
after 24, 48 and 72 h of incubation. The stability of NPs was demonstrated by 
the absence of macroscopic aggregates and unchanged of initial particle size. 
 
NP behavior in cell culture medium 
The behavior of NPs prepared from AB copolymer in the medium employed 
for in vitro PDT studies (RPMI with 10% FBS) was evaluated by different 
methods. DTX concentration in NP dispersions was measured according to a 
method described elsewhere29. Briefly, 2.5 mg of ZnPc/DTX-loaded NPs were 
dispersed in 1.5 mL of RPMI enriched with FBS 10% v/v and incubated at 37 
°C. At 24 h the samples were treated with 1.5 mL of acetonitrile and stirred 
overnight to promote protein precipitation. Then, the samples were centrifuged 
at 1000 ×g and 4 °C for 15 min. Supernatant was filtered through a 0.45 µm 
RC filter and dried under a nitrogen stream at 40 °C. After complete solvent 
evaporation, the sample was reconstituted in 1 mL of acetonitrile–water 50:50 
v/v and analyzed by HPLC for DTX content. Recovery of DTX in the 
extraction process was 95±1%. Decrease of DTX concentration along time was 
considered indicative of NP aggregation and precipitation. Results are 
expressed as % decrease of DTX concentration as compared to the initial DTX 
content of the samples. For release studies, 2.5 mg of NPs were dispersed in 
RPMI with10% FBS (0.5 mL) and placed in a dialysis bag. The sample was 
plunged in 5 mL of PBS (sink condition) and kept at 37 °C up to 72 h. At 
selected time intervals, 1 mL of release medium was withdrawn and replaced 
with an equal volume of fresh medium. DTX analysis was performed as 
described above. Results are expressed as release % over time±SD of three 
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experiments. Absorption spectra of ZnPc/DTX-loaded and ZnPc-loaded NPs 
dispersed in PBS or RPMI ([ZnPc]=0.4 µg/mL, [NPs]=0.2 mg/mL) were 
collected on a Shimadzu UV-1800 spectrophotometer using a 1 cm path length 
quartz cuvette. As control, a solution of ZnPc in DMSO or diluted in RPMI 
(1:50 v/v, [ZnPc]=0.4 µg/mL) was analyzed.  
 
In vitro PDT  
HeLa cells were obtained from the American Type Culture Collection and 
propagated at 1:6 ratio in RPMI supplemented with 100 units/mL of penicillin 
and 10% fetal bovine serum. Cells were grown to confluence in 6 well plates 
and after 24 h they were treated with free drugs and drug-loaded NPs based on 
AB copolymer up to 72 h at 37 °C. Free DTX and ZnPc were in DMSO 
respectively ([DTX]=1 µg/mL, [ZnPc]=0.054 µg/mL). ZnPc/DTX-loaded NPs, 
DTX-loaded NPs, ZnPc-loaded NPs, unloaded NPs were all dispersed in water 
([NPs]=10 µg/mL). The cells were subsequently detached from the substrate 
using trypsin, transferred in polystyrene tubes and centrifuged. After washing 
in PBS, cell pellets were resuspended in PBS and placed separately in a 
spectrophotometric cuvette to be irradiated with a halogen lamp for 30 min. 
The irradiating beam was filtered through an UV filter (Hoya glass type UV-
34, cut-off: 340 nm) in order to cut the UV component and through a 1-cm cell 
filled with water, to remove the IR-component. A light dose of 5 joule/cm2 was 
estimated. 
 
Cell viability assay  
Cells (6×104) were placed in 96-well plates with 100-µL RPMI-1640 medium. 
After 24 h cells were treated with free drugs and drug-loaded NPs at the 
correspondent final concentration (as above reported). Cells were incubated 
and collected at 24 and 72 h, before the addition of the presence of tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-
sulfophenyl)-2H-tetrazolium, inner salt;MTS, Promega] and an electron 
coupling reagent phenazine methosulfate (PMS) dye (MTS 20 µL per well). 
As a control, the same cells were exposed to the vehicle alone (DMSO), in 
amounts corresponding to those employed for dissolving the compounds. After 
further incubation (1 h), the absorbance was read at 490 nm in a microplate 
reader (Labsystem Multiskan Bichromatic). The percentage of cell viability 
(%) was calculated according to the equation: 
Cell viability (%) = [(OD before lamp-OD after lamp)/OD before lamp]x100 
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Immunofluorescence assay  
To analyze nuclear morphology and the distribution of structural protein 
tubulin immunofluorescence assay was performed. Non-irradiated and 
irradiated samples were collected at 24 and 72 h post-treatment, layered on 
slides treated with polylysine. After fixing in PBS (pH 7.4) with 4% 
paraformaldehyde (pH 7.4) for 15 min at room temperature, a volume of 0.1% 
Triton X-100 in PBS was added and left for 15 min. After washing three times 
in PBS, permeabilized cells were incubated with a fluorescein-conjugated 
monoclonal anti- body against human tubulin for 1 h at room temperature, 
followed by FITC-conjugated goat anti-mouse IgG. The cells were than 
stained with Hoechst 33342 fluorescent DNA-binding dye. Samples were 
analyzed on a Biomed Fluorescence microscope (Letiz,Wetzlar, Germany; 
magnification 63×) by using a DAPI (blue emission) and FITC filter (green 
emission), respectively. 
 
Evaluation of apoptosis 
Analysis of apoptosis was carried out at single cell level using the TUNEL 
technique. Labeling of DNA strand breaks with fluorescein-dUTP by terminal 
deoxynucleotidyl transferase was performed using a commercial kit (“In situ 
cell death detection kit, fluorescein”, Boehringer Mannheim, Mannheim, 
Germany) according to the manufacturer's instructions. To evaluate DNA 
fragmentation (Ladder), treated cells were washed in PBS and then lysed in 0.5 
ml of lysis buffer (10 mM Tris, pH 7.4, 1 mM EDTA, pH 8.0, 0.2% Triton X-
100) containing proteinase K (100 mg/ml) for 1 h at room temperature. 
Samples were then centrifuged at 16,000 ×g for 15 min. DNA in the 
supernatants was precipitated with 5 N NaCl in 1 volume of isopropanol for 1 
h at −20 °C. DNA precipitates were recovered by centrifugation at 16,000 × g, 
air dried for 15 min at room temperature, resuspended in TE buffer (10 mM 
Tris, pH 7.4, 1 mM EDTA, pH 8.0) containing RNase (100 mg/ml) and 
incubated for 1 h at 37 °C. Before electrophoresis, loading buffer (2% SDS, 15 
mM EDTA, 0.25% w/v bromophenol blue, 50% v/v glycerol) was added to 
each sample. DNA was electrophoresed on 1.5% agarose gel stained with Gel 
Star (Lonza Rockland, Inc.) and visualized by UV light transillumination. 
 
In vivo antitumor activity 
The antitumor effects of NPs containing both DTX and ZnPc were tested in an 
orthotopic mouse model of amelanotic melanoma. The experimental 
procedures performed in this study followed the specific guidelines of the 
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Italian (N. 116/1992) and European Council law (N.86/609/CEE) for animal 
care. Eight-week old female athymic Nu/Nu nude mice were purchased from 
Harlan, Italy. Mice were housed 5 for cages and maintained on a light/dark 
cycle in a temperature-controlled room. To produce tumor, A375 cell line 
(human amelanotic melanoma cells) were harvested from subconfluent 
cultures. A375 human amelanotic melanoma cells were obtained from the 
American Type Culture Collection. A375 cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) (Invitrogen, San Diego, CA) at pH 7.4, 
supplemented with 10% FCS (Gibco, UE), 100 units/ml penicillin and 100 
µg/ml streptomycin. Cultures were maintained at 37 °C in a humidified 
atmosphere with 5% CO2. Only cells with 90% viability were used for the 
injections. Each mouse underwent subcutaneous injections of 2×106 cells, 
suspendedin a volume of 100 µl of PBS, directly into the right-side flank area. 
When tumor volume was around 100 mm 465 3, mice were randomizedinto 5 
different groups and treated by injection into the caudal vein (5 mice per 
group) with: saline alone, empty NPAB, free DTX (Polysorbate 80: EtOH: 
water, 20:13:67), DTX5-NPAB, ZnPc/DTX5-NPAB. DTX dose was 3.5 mg/kg 
whereas ZnPc dose was 0.2 mg/kg. After 24 h mice were anesthetized and 
exposed to 15 min (149 J) of 172 mW/cm2 light from a PDT-CLD100 system 
emitting red light at 618 nm ±5% (EPEM, Greece). Surrounding skin tissue 
was protected from light using a light impenetrable fabric. The day of NP 
treatment was designated as day 0 and observation continued until day 21. The 
size of tumors was measured along time by using a digital caliper. Normally 
distributed data were represented as mean±S.E.M. Two-way ANOVA and 
Bonferroni post-hoc analysis were used to examine the significance of 
differences among groups (Graph pad Prism 5.0). A probability value with 
*P<0.05 and **P<0.01 was considered to be statistically significant. 
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Results 
Properties of NPs  
PEO2000–PCL4300 diblock (AB) and PEO2000–PCL6800–PEO2000 triblock (ABA) 
copolymers with unimodal and narrow molecular weight distributions 
(PI=1.16, AB, and 1.32, ABA) were employed to prepare unloaded, DTX-
loaded, ZnPc-loaded and ZnPc/DTX-loaded NPs (Table 1). The recovery yield 
for all the formulations was very high highlighting that neither drug 
precipitation nor NP aggregation occurred during MeSo. Hydrodynamic 
diameters of NPs were below 100 nm. All formulations showed a negative zeta 
potential, slightly more negative for AB NPs. Entrapment of both drugs did not 
influence significantly surface properties and zeta potential of AB and ABA 
NPs, whereas a slight increase of polydispersity index was observed when 
ZnPc was loaded. The addition of trehalose at different mass ratio with 
copolymer (10–40:1) did not prevent the aggregation of NPs after freeze-
drying, while the presence of HPβCD at 10:1 mass ratio with ZnPc-loaded NPs 
allowed no collapsing of NPs during freeze-drying and storage at 4 °C up to 
three months (supplementary material, Table S1 and Fig. S1). 
The spherical morphology and the absence of aggregation of freeze-dried 
ZnPc/DTX-loaded NPs were confirmed by TEM (Fig. 1). Also NP size was in 
line with the data obtained by PCS.  
 
 
Figure 1. TEM images of ZnPc/DTX5-NPAB (A-B) and ZnPc/DTX5-NPABA (C-D). 
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Table 1. Composition and properties of NPs produced. SD were calculated on three 
different batches. 
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The entrapment efficiencies of DTX and ZnPc inside both formulations are 
summarized in Table 1. When NPs were loaded with a single drug, entrapment 
efficiency was higher than 70% independently of the drug employed and type 
of copolymer used. When DTX and ZnPc were loaded simultaneously, at 10 
and 0.2% theoretical loading respectively, a significant decrease in entrapment 
efficiencies was observed for NPs prepared with both copolymers. When the 
theoretical loading of DTX was reduced at 5%, the entrapment efficiency of 
NPs for both drugs increased. 
Release profiles of drugs from ZnPc/DTX-loaded AB and ABA NPs in PBS at 
pH 7.4 and 37 °C were evaluated up to 70 days and compared with free drugs 
in combination. In Fig. 2, it is possible to note that both AB and ABA NPs 
assure a sustained release pattern of DTX characterized by two phases, an 
initial burst followed by a much slower diffusion-erosion phase, completed in 
around 70 days, compared with the free drug in the same conditions (inset). In 
these conditions, no ZnPc release was found. To observe a ZnPc release, it was 
necessary to enrich the phosphate buffer with Polysorbate 80 as surfactant 
which ensured both sink conditions in the release medium and prevented ZnPc 
aggregation. Nevertheless, ZnPc precipitation occurred in the dialysis bag 
resulting in an incomplete release of the PS (Supplementary material, Fig. S2). 
 
 
Figure 2. Release profile of DTX from ZnPc/DTX-loaded NPs in 10 mM phosphate buffer at pH 
7.4 and 37°C. Release profile of DTX is reported for comparison (inset). Data are reported as 
mean of three independent experiments ± SD. For key legend see table 1. 
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Fluorescence properties and singlet oxygen generation of NPs 
The interaction of ZnPc with the copolymers inside NPs was investigated by 
steady-state and time-resolved fluorescence emission. Fluorescence emission 
spectra were carried out on samples prepared by dispersing an appropriate 
amount of powder tominimize the scattering contribute. ZnPc is poorly soluble 
in aqueous solution and needed DMSO to be solubilized. The spectrum in 
aqueous solution of ZnPc-loaded NPs exhibits bands centered at 680, 710 and 
740 nm (type AB copolymer is reported as representative) both in the absence 
(curve a) and in the presence (curve b) of DTX. The fluorescence bands are 
characteristic of metal – phthalocyanines dispersed in aqueous solution. The 
anisotropy value, which is around zero for free ZnPc (see inset of Fig. 3, trace 
c), is increasing at around 0.2–0.3 in ZnPc-NPAB (trace a) and in ZnPc/DTX5-
NPAB (trace b). ZnPc entrapped in NPs based on ABA copolymers both alone 
or in combination with DTX showed similar results (data not shown).  
 
 
 
 
Figure 3. Steady-state fluorescence emission spectra and, in the inset, correspondent anisotropy of 
ZnPc in ZnPc-NPAB (traces a) and ZnPc/DTX5-NPAB (traces b) dispersed in water ([ZnPc]=0.07 
µg/mL, λex=600 nm). Trace c in the inset is the anisotropy of free ZnPc in DMSO. 
 
From fluorescence time decay (Fig. 4A), it results that free ZnPc in DMSO has 
a lifetime of 3±0.4 ns, and this value remains unaffected when ZnPc is 
entrapped in NPs based on AB and ABA copolymers both in absence and in 
combination with DTX. To focus on the dynamic interaction between ZnPc 
and polymeric NPs, time-resolved fluorescence anisotropy experiments were 
carried out. These investigations provide detailed information on 
photosensitizer structural changes in the colloidal microenvironment.  
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Figure 4. Fluorescence time decay (A), and time-resolved fluorescence anisotropy (B): ZnPc in 
DMSO (a); ZnPc-loaded NPs (b,d), ZnPc/DTX5-loaded NPs (c, e) water dispersion (b and c traces 
refer to NPs of AB copolymer, d and e to NPs of ABA copolymer). In A the decays are scaled for 
a multiplicative factor in order to make easier the visualization. The continuous curves are the fit 
resulting from the convolution of the fluorescence decay and the excitation. In B the continuous 
curve is the best fit according to an exponential law. 
 
Anisotropy fluorescence time decay (Fig. 4B) established a rotational 
correlation time of τR ≅0.6 ns and a limiting anisotropy of 0.05, whereas in the 
aqueous dispersion of ZnPc-loaded NPs, r(t) of ZnPc appears as a plateau, 
indicating a much longer rotational correlation time (>20 ns).The generation of 
singlet oxygen from free ZnPc or ZnPc-loaded NPs dispersed in water was 
evaluated by monitoring the photobleaching of ADPA, a singlet oxygen 
quencher, occurring along time (Fig. 5). Comparable time-dependent 
production of singlet oxygen by ZnPc was found for free drug and ZnPc-
loaded NPs also when DTX was co-entrapped, suggesting that the presence of 
DTX did not interfere with the photochemical properties of ZnPc. 
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Figure 5. Photobleaching of ADPA by singlet oxygen generated from AB (A) and ABA (B)NPs. 
Data are reported as mean of three independente xperiments±SD. For key legend see Table 1. 
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Hemolytic activity of NPs 
To investigate cytotoxicity toward red blood cells, hemolysis studies were 
carried out ondeveloped NPs (Fig. 6). Hemolysis was assessed in the NP 
concentration range from 0.01 to  2.0 mg/mL, with and without HPβCD as 
cryoprotector. As shown in Fig. 6A, NPs did not display significant hemolysis 
whereas hemolysis up to 70% occurred for NPs cryoprotected by HPβCD (Fig. 
6B). This effect was related to HPβCD which, as such, showed a dose-
dependent cytotoxicity.  
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Figure 6. Haemolysis of red blood cells after incubation with NPs at different concentrations. NPs 
were tested immediately after preparation (A) or after freeze-drying with HPβCD (B). Free 
HPβCD was used at the same concentration present in the NPs formulations as control. Data are 
reported as mean of three independent experiments ± SD. For key legend see table 1. 
 
Stability of NPs in the presence of serum proteins  
In order to verify the absence of aggregation due to eventual interactions of 
NPs with serum proteins, NPs were incubated in PBS supplemented with 2% 
(w/v) of human serum albumin or in human plasma (Fig. 7). Hydrodynamic 
diameters of NP dispersions were monitored up to 72 h of incubation by PCS. 
Both ZnPc/DTX-loaded AB and ABA NPs displayed a comparable behavior in 
the presence of proteins and serum components, showing a slight increase of 
their size, which remained still lower than 200 nm. On the other hand, these 
results suggest that NPs do not undergo disassembly in biologically- relevant 
conditions. It is likely that protein-repelling properties of NPs were imparted 
by the presence of an external hydrophilic PEG shell with a thickness around 2 
nm (Supplementary material, Fig. S3). 
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Figure 7. Stability of NPs in the presence of 2% w/v Human Serum Albumin and human plasma. 
Data are reported as mean of three independent experiments ± SD. For key legend see table 1. 
 
NP behavior in cell culture medium  
Behavior of AB NPs in RPMI culture medium was assessed by different 
methods (Fig. 8). Stability of NPs in RPMI culture medium was monitored 
analyzing DTX content in the supernatant of NP dispersions after 
centrifugation to eliminate eventual aggregates (Fig. 8A). After 24 h of 
incubation, DTX amount in the supernatant was kept around 100%, which 
corresponded to the actual DTX loaded in the NPs, suggesting that both 
formulations displayed no tendency to aggregation. Release of DTX from NPs 
dispersed in RPMI (Fig. 8B) occurred at a rate slower than both NPs and free 
DTX dispersed in PBS. Finally, UV spectra of free ZnPc in DMSO showed a 
Q band centered at 674 nm which is both blue-and hypocromically shifted in 
the spectra of ZnPc-NPs and ZnPc/DTX-NPs dispersion in PBS. The spectra 
of all the dispersions in RPMI remained almost unaltered as compared to PBS. 
A fair red-shift and hypochromicity of Q band was only registered for 
ZnPc/DTX-NPs dispersion in RPMI.  
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Figure 8. Behavior of AB NPs in RPMI with FBS 10%. (A) Decrease of DTX concentration in
NP dispersions (1.6 mg/mL) prepared in RPMI+FBS 10% after 24 h of incubation. (B) Release of 
DTX from NPs dispersed in RPMI with FBS 10% at 37 °C. The external medium
was PBS at pH 7.4. Release of DTX from NPs dispersed in PBS at 
comparison purpose. (C) UV spectra of ZnPc dissolved in
([ZnPc]=0.4 µg/mL), ZnPc-NPs and ZnPc/DTX
µg/mL, [NPs]=0.2 mg/mL, 1 cm path length).
experiments±SD. For key legend see Table 1.
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In vitro PDT  
To evaluate cytotoxicity, the percentage of viable HeLa cells at 24 and 72 h of 
treatment was measured (Fig. 9). Experiments were performed on NPs made of 
AB copolymer. No reduction in terms of vitality was detected in samples 
incubated with unloaded NPs at all experimental times tested. In addition no 
significant reduction in cells viability was detected in cells treated with DTX-
loaded NPs and free DTX at 24 h after treatment, respectively (Fig. 9A). On 
the contrary the percentage of mortality was significantly higher in cells 
treated with DTX-loaded NPs at 72 h of treatment, as compared to those 
treated with free DTX. At 24 h and upon irradiation, a marked decline in cell 
viability was evident in samples treated with ZnPc-loaded and ZnPc/DTX-
loaded NPs. No relevant variation in terms of cell viability before and after 
irradiation was found at 72 h after treatment with free ZnPc and ZnPc-loaded 
NPs (Fig. 9B).  
 
Figure 9. Effects of different NPs on cell viability in HeLa cells after 24 h (A) and 72 h (B) 
treatment (“irrad” refers to samples irradiated as described above). HeLa cells were treated with a 
control vehicle (DMSO) or with drug-loaded and unloaded NPs. Data are reported as mean of 
three separate experiments ± SD. Free ZnPc and DTX were used at the same concentration present 
in the NPs ([ZnPc]= 0.054 µg/mL, [DTX]= 1 µg/mL). Cell viability was quantified using MTT 
assay. * p <0.0003. 
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At 72 h, the cells treated with both DTX-loaded NPs and ZnPc/DTX-loaded 
NPs showed a higher percentage of mortality before irradiation as compared to 
those observed after 24 h treatment. However, cytotoxic activity related to the 
presence of ZnPc was observed in cells treated with ZnPc/DTX-loaded NPs, 
after irradiation. 
In order to establish the effect of DTX on cellular DNA and detect 
modifications at nuclear level, cells were stained with the fluorescent DNA 
binding dye Hoechst 33342. Fig. 10 shows microscopy images from HeLa 
cells mock-treated or treated with NPs. Staining with Hoechst 33342 allowed 
us to identify cells undergoing aberrant mitosis. At 24 h, cells treated with 
DTX-loaded NPs and ZnPc/DTX-loaded NPs show morphological 
characteristics of mitotic catastrophe. No nuclear damage was detected in cells 
treated with ZnPc-loaded NPs. At 72 h the DNA damage initiated by DTX 
revealed the presence of apoptotic nuclei after staining with Hoechst 
fluorescent DNA-binding dye.  
 
 
 
Figure 10. Microscopy analysis of HeLa treated with DTX-, ZnPc- and ZnPc/DTX-loaded NPs 
and analyzed at 24 h and 72 h post exposure. To distinguish the subcellular location, dual staining 
for simultaneous detection of chromatin and cellular protein-positive cells was performed with 
Hoechst 33342 fluorescent DNA-binding dye and a fluorescein-conjugated monoclonal antibody 
against human tubulin, respectively. Cells were analyzed by DAPI filter and FITC filter to detect 
chromatin and tubulin respectively, and the images obtained were merged (63× objective). 
 
 
This occurrence was more marked in cells treated with ZnPc/DTX-loaded NPs 
as compared with those treated with DTX-loaded NPs. Due to the affinity of 
DTX for cellular tubulin, distribution of tubulin was also assessed by staining 
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treated samples with an antibody against human tubulin. In addition, apoptosis 
was monitored by detection of apoptotic bodies at single cell level using the 
TUNEL technique or at culture level by DNA gel electrophoresis (Ladder). As 
shown in Fig. 11A, a higher numbers of HeLa cells in apoptotic stage was 
found following treatment for 72 h with ZnPc/DTX5-NPAB or DTX-NPAB 
when compared to the mock cells. As can be seen in Fig. 11B, the presence of 
the typical apoptotic DNA ladder was found in cells treated with ZnPc/DTX5-
NPAB or DTX-NPAB, whereas it was absent in control sample. 
 
 
Figure 11. Analysis of cell death in HeLa cells after 72 h of treatment. (A) HeLa cells were 
incubated with DTX-NPAB (image III), ZnPc/DTX5-NPAB (image IV) or mock treated (image I) 
and analyzed by labeling of DNA strand breaks with fluorescein-dUTP TUNEL assay at single 
cell level. Positive control consisted of HeLa treated with DNase 1 (2U samples, Ambion Life 
Technology) for 1 h at 37 °C (image II). Analysis of labeled cells was performed by fluorescence 
microscopy (63× objective). (B) Analysis of DNA fragmentation by gel electrophoresis after HeLa 
cells treatment with DTX-NPAB (lane 1), ZnPc/DTX5-NPAB (lane 2) or mock treated (lane 3). Lane 
4: 1-Kb Plus DNA ladder (Invitrogen). 
 
 
 
In vivo antitumor activity 
In vivo experiment was carried out by xenografting nu/nu mice with the 
human amelanotic melanoma cell line A375. Results are reported in Fig. 12 as 
tumor growth along time and survival. At 17 days post NPs injection, tumor 
growth in animals that received free DTX was significantly slower than that in 
control group (*P<0.05). DTX-NPs displayed tumor growth inhibition similar 
to thatof DTX at the same drug dose (CTR vs DTX5-NPAB, *P<0.05). Tumor 
growth in the group treated with the combination of DTX/ZnPc in NPs and 
PDT was significantly slower than that in animals that received other 
treatments (CTR vs ZnPc/DTX5-NPAB**P<0.01). Group treated with empty 
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NPs did not show statistically different effects as compared with the control 
group. Survival of animals closely followed the tumor growth profile. Mice 
treated with combined NPs under light exposure survived longer compared to 
those that received other treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 12. (A) Tumor growth inhibition and (B) Kaplan–Meier survival plot of female athymic 
Nu/Nu nude mice bearing subcutaneous A375 tumor. Mice received an i.v. injection of saline 
(CTR), free DTX, empty NPs (NPAB), DTX5-NPAB, ZnPc/DTX5-NPAB. DTX dose was 3.5 mg/kg 
whereas ZnPc dose was 0.2 mg/kg After 24 h mice were anesthetized and exposed to 15 min (149 
J) of 172 mW/cm2 light. *P<0.05 DTX5NPAB vs ZnPc/DTX5-NPAB at 17 days post injection; 
**P<0.01 CTR vs ZnPc/DTX5-NPAB at 17 days post injection; **P<0.01 NPAB vs ZnPc/DTX5-
NPAB at 17 days post injection. Kaplan–Meier results showed an increased median survival for the 
ZnPc/DTX5-NPAB treated mice with respect to the control groups (CTR and NPAB) at 17 days 
(P=0.008 determined using log-rank test). 
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Discussion 
An emerging concept in modern oncology relies on combination of different 
therapeutic strategies. A great advantage of associating PDT to conventional 
chemotherapy is the synergic PDT cytotoxicity that can be elicited at 
pathological site, without risking non-target effects. On the other hand, it has 
been demonstrated that sustained release of chemotherapeutics (sustained 
chemotherapy), offers superior antitumor efficacy and prevents induction of 
MDR in chemosensitive and chemoresistant diseases30,31. With this idea in 
mind, in this study we have developed a biodegradable system for the 
combined photo- and chemo-therapy of cancer. In the effort to develop a 
translational system, we focused on two types of core-shell NPs made of 
amphiphilic biodegradable block copolymers of PEO–PCL able to deliver a 
taxan and a cyanine at sustained rates in the body. PEO–PCL of specific 
composition was selected on the basis of recent evidences highlighting that 
PEO:PCL molecular weight ratio is a key determinant for stability in 
biologically relevant media32. Furthermore, we have recently demonstrated 
that entrapment of DTX in NPs of PEO–PCL preserves DTX cytotoxicity 
while attenuating drug toxicity in vivo, in analogy to similar PEO–PLA block 
copolymer micelles33. Nevertheless, this last type of micelles has shown 
disassembly in the bloodstream34 which could explain an activity profile of 
DTX-loaded PEO-b-PLA micelles similar to free drug33. Making advantage of 
the low melting temperature and amphiphilic properties of PEO–PCL 
copolymers, the formation of a solid-like semicrystalline structure23 with 
potentially high stability in biologically relevant conditions, we combined 
DTX with ZnPc in PEO–PCL NPs to obtain a multifunctional system for 
cancer therapy. 
A preliminary formulation study was devoted to evaluate the best conditions to 
obtain NPs i) with a suitable size for i.v. injections; ii) able to entrap both 
molecules with high efficiency; iii) stable in different complex media; iv)with 
a good storage stability; v) able to preserve PS photobiological activity; vi) 
releasing chemotherapeutic agent at a controlled rate. Results highlight the 
formation of spherical, non-aggregated NPs with a quite small size useful to 
escape RES and kidney excretion35,36. Dual molecules entrapment is feasible 
and controlled by the total amount of the most abundant drug i.e. DTX. In fact, 
lipophilic molecules accommodate between polymeric chains in the 
amorphous regions of PCL and once these domains are saturated, drug 
crystallizes  outside polymeric NPs and a decrease of entrapment efficiency is 
experienced23. Considering the very low solubility of ZnPc in water, it can be 
reasonably hypothesized that when entrapping both drugs a mutual impairment 
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of drug solubilization in the melted copolymer may occur at high DTX 
theoretical loading. Thus, this effect is attenuated by decreasing the loading of 
the most abundant DTX at 5%. In analogy to previous papers drug-copolymer 
ratio is found again a critical parameter to control encapsulation efficiency37. 
For all the formulations tested, both DTX and ZnPc loadings are considered 
suitable for a therapeutically relevant system. Dual release of drugs from NPs 
show that while DTX was released from the carrier, ZnPc remains 
substantially entrapped along time. Different release rates are clearly attributed 
to different aqueous solubility of ZnPc and DTX. In fact, release from PEO–
PCL-based systems is activated by drug dissolution in the medium diffusing 
inside the polymer. Due to the fact that ZnPc is practically insoluble in water, 
it remains entrapped in both NP types while DTX is released at a sustained 
rate. It is worth of note that sink conditions realized by adding a surfactant in 
the release medium allow ZnPc release but induce also its precipitation during 
release. In order to avoid NP aggregation phenomena during freeze-drying, 
HPβCD was selected as cryoprotector and added to NP dispersion before 
freeze-drying. As demonstrated in the literature, HPβCD is able to increase 
collapse temperature during freeze-drying process, preventing aggregation of 
different nanocarriers based on PCL polymers38,39. NP formulations exhibit 
excellent long-term size stability upon storage at 4 °C and allow efficient NP 
dispersion in aqueous phase. 
The proof that the fluorophore is intercalated in the polymeric matrix is the 
significant change both in the steady-state and time-resolved fluorescence 
anisotropy of ZnPc-loaded NPs. In particular the longer rotational correlation 
time (longer than 20 ns) in ZnPc-loaded NPs as compared to ZnPc is due to the 
fact that the dye is rotating together with larger particles. The presence of DTX 
does not cause further changes in the fluorescence anisotropy decay. It is worth 
noting that there is a significant background in the fluorescence decay profile 
of ZnPc free in DMSO, mainly due to much longer lifetime of the triplet state 
emission. This background is still present for all the samples investigated, 
indicating that, despite being embedded in the polymer matrix, ZnPc maintains 
its phosphorescence properties useful for applications in PDT. The similar 
fluorescence lifetime of ZnPc (3±0.4 ns) in organic solvents (i.e., both in 
DMSO and in THF used in the preparation) and when PS is incorporated in 
NPs suggests that clusters of residual organic solvent could remain entangled 
in the mesoporous structure of NPs forming nanodomains able to host and 
stabilize both drugs39,40. On the other hand, steady-state fluorescence emission 
spectra and the correspondent anisotropy values suggest the strong interaction 
between ZnPc and NPs. While free ZnPc in aqueous solution is poorly soluble 
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(no emission spectra was observed), ZnPc-NPs and ZnPc/DTX-NPs exhibit 
emission fluorescence bands which are characteristic of ZnPc fluorophore 
highly dispersed in an aqueous solution, confirming the increased solubility of  
ZnPc incorporated in NPs. The similar amount of singlet oxygen generated 
from ZnPc-loaded NPs, alone or in combination with DTX, as compared to 
free ZnPc highlights that ZnPc generates singlet oxygen inside the polymeric 
matrix and suggests that, unlike conventional drug delivery systems, PS does 
not require to be released from PEO–PCL NPs to induce a photodynamic 
reaction28. This result is in line with previous findings where PCL was 
demonstrated to be permeable to singlet oxygen41. Photophysical 
investigations have shown also that association of ZnPc to NPs does not 
necessarily alter its excited-state properties nor its singlet oxygen generation. 
Presumably, a similar yield of singlet oxygen demonstrates also that NPs 
prevent ZnPc aggregation phenomena in water42.  
NP interaction with plasma proteins and blood components can be responsible 
of aggregation, charge neutralization, dissociation and, in some cases, may 
trigger clearance mechanisms in the body16. Several efforts have been devoted 
to understand how NP surface features drive protein-NPs interactions which, if 
properly handled, can be regarded as a very simple tool to control NP 
biodistribution16. Our results suggest that the steric hindrance conferred by a 
PEO corona on NPs offers efficient protection against NP aggregation in both 
HSA and plasma making the system suitable for intravenous injection. On the 
other hand, the fact that NP size is kept in the presence of serum suggests also 
that this type of NPs is not prone to dissociation once in the blood circulation, 
a phenomenon that has been demonstrated recently for PEO-polylactide NPs34. 
Interaction of NPs with proteins is regarded as a critical factor also in cell 
culture studies since it has been demonstrated that NPs can 
aggregate/dissociate in complex media altering photobiological results32. 
Combination of DTX with ZnPc inside NPs does not affect stability profile of 
NPs in RPMI, the medium employed for cell studies, and allow ZnPc to 
maintain its monomeric form. Furthermore, since amount of drugs free to pass 
through cell membranes cannot be derived directly from release studies in 
PBS43, release rate in RPMI highlights a sustained DTX release from NPs 
whereas ZnPc remains substantially entrapped in NPs and maintains its 
monomeric form. Since we experienced no relevant difference in the behavior 
of AB and ABA NPs, we decided to focus on AB copolymer due to its simpler 
architecture as compared to ABA copolymer. 
On a biological standpoint, in vitro results obtained here on HeLa cells 
highlight that DTX can benefit from the combined action of ZnPc in inducing 
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cell mortality. The results show firstly that unloaded NPs are highly 
biocompatible in the in vitro model. Furthermore, they indicate that upon 
photo-activation there is an immediate action (within 24 h) of ZnPc in ZnPc-
loaded NPs with or without DTX. On the contrary, along the time of treatment 
and upon irradiation ZnPc efficacy decreases and DTX starts evidencing 
severe cytotoxicity. The increase of cell mortality observed after 72 h of 
treatment suggests that ZnPc/DTX-loaded NPs are exerting a combined action 
under irradiation. The higher phototoxicity displayed by ZnPc-NPs as 
compared to free ZnPc well correlates with a significant aggregation of free 
ZnPc in RPMI, likely contributed by its very poor aqueous solubility. 
Conversely, the insufficient activity of ZnPc-NPAB at 72 h in the absence of 
DTX can be related to a decreased phototoxicity typical of lipophilic 
phthalocyanines such as ZnPc which, even if entrapped in NPs, could 
aggregate along time44. However these mechanistic aspects are still under 
investigation. 
DTX cytotoxic activity is exerted by promoting and stabilizing microtubule 
assembly, causing the inhibition of mitotic cancer cell division. It is 
noteworthy that in specific cancer cells microtubules do not disassemble in the 
presence of DTX, and accumulate inside cells causing initiation of apoptosis45. 
Apoptotic cell death was unequivocally shown by using different techniques 
and here it is proven that most of the cells treated with DTX-NPs, as well as 
with ZnPc/DTX-loaded NPs, display chromatin condensation, apoptotic body 
formation and DNA ladder. Nevertheless it is notable that only DTX-loaded 
NPs display a significant reduction in term of cell viability. Thus, association 
of DTX and ZnPc, both entrapped in polymeric NPs, should be required to 
improve the therapy effectiveness at all the stage of treatment. However 
further investigation are needed to understand the mechanisms involved in the 
compartmentalization of drugs and the induction of cytotoxicity by apoptosis. 
The encouraging findings obtained in a conventional cell line used for testing 
photodynamic effects were validated in an orthotopic mouse model of 
amelanotic melanoma to reinforce their translational potential in clinical 
practice. Results show again no cytotoxic effect of empty NPs and a slower 
tumor growth for DTX-loaded NPs in the presence of ZnPc. This effect is 
shown in the case of combined NPs, suggesting that alteration of drug 
biodistribution exerted by NPs does not impair pharmacological effect. It is 
worth noting that schedule of photodynamic treatment as well as dose regimen 
can be further revised to optimize treatment. 
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Conclusions 
This study has demonstrated that it is possible to construct a nanoassembly for 
combining sustained release chemotherapywith photodynamic therapy. NPs 
are especially useful to compatibilize the lipophilic ZnPc with an aqueous 
environment without altering photophysic properties. Under photoirradiation, 
NPs generate singlet oxygen and in parallel sustain the release of the 
chemotherapeutic resulting in dual cytotoxic effects,with ZnPc playing a 
fundamental role in the early stage of the treatment, followed by a delayed 
DTX action. On the basis of the preliminary in vivo data, this type of approach 
may be of clinical interest for the treatment of accessible solid tumors. 
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The journey of a NP from injection to the site of action is often fraught with a 
sequence of substantial obstacles that adversely impact therapeutic indices in 
cancer. A translational anticancer nanomedicine intended for iv administration 
of anticancer drugs should: 
 be not toxic and biocompatible; 
 encapsulate a variety of therapeutic agents, improving their solubility 
and  stability; 
 release the entrapped drug in a controlled manner over time to 
maintain a drug concentration within the therapeutic window; 
 offer a prolonged blood circulation half-life and a limited clearance 
by RES; 
 overcome biological barriers and reach selectively tumor sites, 
reducing the systemic toxicity of the therapeutic agent as well as 
increasing its concentration in the area of interest; 
 achieve cellular uptake by targeted tissues. 
To fulfill all these requirements is a demanding task and several approaches 
with specific advantages/disadvantages have been devoped. 
As base material for biomimetic core-shell nanomedicines, the use of 
amphiphilic materials, especially amphiphilic block copolymers, which 
spontaneously organize in supramolecular highly ordered core-shell systems, 
has received increasing interest. This special arrangement makes them suitable 
as long-circulating drug nanocontainers able to deliver drugs in different body 
compartments. Being loaded in the hydrophobic core, the drug is well 
protected from biological inactivation of surroundings and is distributed 
according to the pharmacokinetics of the carrier system. Furthermore, the 
external flexible fringe of hydrophilic blocks allows a steric stabilization 
against the opsonisation by RES, thus prolonging the in vivo fate into the 
bloodstream of the entrapped drugs. In spite of these advantages, a great 
drawback associated to these kind of systems widely discussed in the 
literature, resides in the poor stability they often show in biological 
environment. To this respect, properties of the hydrophobic core are of utmost 
importance in controlling precocious nanocarrier disassembly in the blood 
stream. 
On this rationale, we focused our work on the development of core-shell 
nanoassemblies based on PCL–PEO copolymers for the iv administration of 
small lipophilic and hydrophilic anticancer drugs, testing also the possibility to 
further combine different chemotherapeutics and obtain a synergic antitumor 
effect. 
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At a polymer level, results of this research project highlight that PCL–PEO are 
very promising materials to be used in iv delivery of anticancer drugs. Since 
copolymer architecture is critical in driving self-assembly properties, in the 
first part of this work, we investigated the ability of PCL–PEO block 
copolymers to assemble in nanocarriers with different structures 
(nanocapsules, NPs) to be used in the delivery of both lipophilic and 
hydrophilic molecules. In particular, we pointed at studying the impact of 
architecture rather than hydrophobic-hydrophilic balance indriving the 
organization and morphology of corresponding nanostructures and in 
controlling their stability, size, drug-loading capacity and release rate. 
Independently of the structure (micelle, NP, nanocapsule) the hydrophilic 
blocks of PEO impart steric stability and biomimetic properties to 
nanoassemblies, providing them with all the features for prolonged blood 
circulation. 
To produce nanocapsules with a aqueous core, which is in theory very 
challenging, we set up an emulsion/melting-sonication (EMeSo) technique 
forming nanocapsules with an inner aqueous core on an emulsion template. 
Novel amphiphilic Y-shaped miktoarm PCL–PEO block copolymers gave 
nanocapsules with size around 150 nm, low polydispersity index, high 
encapsulation efficiency and release rate. These properties together with an 
excellent toxicity profile suggest their potential use for further application as iv 
carrier.  
On the other hand, linear PCL–PEO triblock and PCL–PEO diblock 
copolymers formed, besides micelles, NPs in the range 50-80 nm which can be 
used as carriers for lipophilic drugs. NPs of PCL–PEO block copolymers 
entrapping the lipophilic drug DTX could be obtained by a MeSo method set 
up in our labs. Experimental conditions for MeSo had to be adapted when 
ZnPc was co-encapsulated inside NPs. In particular drug loading of both drugs 
was greatly affected by DTX to polymer and drug to drug ratio. A core-shell 
structure with highly mobile hydrated PEO segments forming the corona 
(around 2 nm), conferring stealth properties of the system, and PCL segments 
forming a solid-like core, was evidenced. Concerning a possible 
pharmaceutical application, PCL–PEO NPs could be freeze-dried giving 
powders with good stability along time. The use of cryoprotectants was needed 
depending on the entrapped drug. Thus, a stable formulation with a good shelf 
life to reconstitute in an aqueous medium before administration was obtained.  
PCL-PEO core-shell NPs with different architectures were found to be stable 
in complex protein-rich environments such as cell culture media and plasma. 
Furthermore, PCL-PEO NPs showed no toxicity toward human blood cells, 
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thus highlighting the suitability of these system as translational iv 
nanoplatform. 
Cytotoxicity studies on DTX-loaded PCL-PEO NPs in several human cancer 
cell lines (prostate carcinoma DU145 and LnCaP and breast cancer MDA-
MB231 and MCF-7) have demonstrated that entrapment in nanocarriers results 
in an improvement of DTX activity which is very relevant at low drug doses. 
Potentiation of drug activity was mainly related to slow extracellular drug 
release. When ZnPc was combined to DTX, interpretation of cytotoxicity 
results was much more complicate. Indeed, ZnPc/DTX-NPs gave severe 
activity on HeLa cells upon irradiation as compared to DTX-NPs highlighting 
that ZnPc/DTX-loaded NPs are exerting a combined action in inducing cell 
mortality. 
Some tasks of this research aimed to clarify the cellular biofate encompassing 
mechanisms involved in the molecular events controlling cellular response, 
focusing on apoptosis and/or autophagy. It is well know that the type and dose 
of stress within the cellular context after a pharmacological treatment dictate 
the cellular outcome, which is intimately converted to complex pathways 
mediating control of cell-cycle and cell death. Cells treated with DTX-loaded 
NPs showed a highly condensed chromatin, which was also, marginated or 
fragmented. These data were confirmed by ladder analysis. It is possible that 
prolonged mitotic arrest triggered by DTX can lead to activation of apoptotic 
cell death. Nevertheless, initiation of autophagic pathway by accumulation of 
p62 protein was assessed. Data obtained in our experimental model showed 
that a consistent generation of autophagosome in HeLa cells treated with 
nanoparticles, was observed. Thus, autophagy dysfunction is recognized as a 
potential mechanism of cell death which accompains apoptosis. However, 
further studies should be addressed to understanding in depth these 
mechanisms also in light of a proper safety assessment of nanoassemblies. 
Finally, from a preclinical point of view, the in vivo antitumor activity of NPs 
as carrier for DTX was tested in different animal models. First of all, the 
empty carrier did not show toxicity, suggesting the possibility of employment 
as safe parenteral formulation. Studies are in progress to assess 
pharmacokinetics of PCL-PEO NPs in healthy mice as well as in a breast 
cancer orthotopic model.  
Combined effect of DTX and ZnPc was demonstrated also in vivo in a 
ortotopic model of amelanotic melanoma. The ability to sustain the release of 
DTX along time and to induce singlet oxygen generation under PDT treatment 
generate a better antitumor response of PCL-PEO NPs as compared to free 
drugs at the same doses. 
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The experimental work enclosed in this manuscript was aimed to design novel 
PCL-PEO nanocarriers for the iv administration of anticancer drugs. 
 
The conclusions extracted from the results were the following:  
 
CHAPTER 2: Nanocapsules Based on Linear and Y Shaped 3-
Miktoarm Star Block PEO-PCL Copolymers as Sustained Delivery 
System for Hydrophilic Molecules: 
1. Nanocapsules with an aqueous core can be obtained by a novel 
emulsion-melting-sonication techniques employing novel amphiphilic 
Y-shaped miktoarm PCL-PEO block copolymers. 
2. Nanocapsules showed high entrapment efficiency of hydrophilic 
macromolecules and their controlled release was realized.  
3. An excellent cell toxicity profile makes these stealth nanocapsules 
very promising as iv nanoplatform for passive delivery of 
hydrophiphilic drugs  in solid tumors. 
 
CHAPTER 3: Core-shell biodegradable nanoassemblies for the 
passive targeting of docetaxel: features, antiproliferative activity and 
in vivo toxicity: 
1. Core-shell PCL-PEO NPs for the delivery of highly lipophilic 
anticancer drugs can be obtained by the novel MeSo technique. 
2. NPs were able to entrap high amounts of DTX related to copolymer 
properties, thus sustaining its release along time and not toxicity 
toward red blood cells was evidenced. 
3. A strong efficiency in inhibiting cell growth of breast and prostate 
cancer cells and not toxicity in experimental animal models were 
highlighed. 
4. These nanocarriers are attractive carriers for the passive targeting and 
sustained release of different lipophilic drugs in solid tumors  able to 
maintain activity and strongly decrease treatment toxicity linked to 
free drugs. 
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CHAPTER 4: Biodegradable core-shell nanoassemblies for the 
delivery of docetaxel and Zn(II)-phthalocyanine inspired by 
combination therapy for cancer: 
1. Biodegradable PCL-PEO block copolymers gave a nanoassembly for 
combining sustained release chemotherapy with PDT.  
2. NPs provided high DTX and ZnPc loadings, a slow release of the 
chemotherapeutic drug and high efficacy of the PS in the singlet 
oxygen generation. 
3. Their high stability in biological environments and the encouraging 
results obtained by the in vivo data suggested the possibility to 
employ this system as a translational injactable nanomedicine for the 
synergistic combination of chemotherapy and PDT. 
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Abstract 
The aim of this work was to evaluate if small pegylated biodegradable 
nanoparticles (NPs) can be a possible carrier for skin delivery of  lipophilic 
drugs. An amphiphilic and biodegradable diblock copolymer of poly(ε-
caprolactone) (PCL= 4.2 kDa) and poly(ethylene oxide)(PEO=2 kDa) (PEO-b-
PCL) was employed to produce NPs entrapping Zinc(II)phtalocyanine (ZnPc), 
a highly lipophilic photosensitizer, by using the melting/sonication technique. 
NPs displayed a hydrodynamic diameter around 60 nm, a slightly negative zeta 
potential and a high ZnPc entrapment efficiency (0.2 mg/100 mg NPs). ZnPc-
loaded NPs or free ZnPc was then incorporated in Sepigel 305. To evaluate 
skin transport of ZnPc, in vitro permeation studies on porcine skin were carried 
out in non-occlusive conditions through porcine ear skin on Franz-type 
diffusion cells. In all cases, no permeation of ZnPc in the receptor 
compartment was observed despite its solubility in the filling medium. Since 
ZnPc was not released from NPs, permeation of NPs should be followed. 
Results showed that ZnPc dissolved in PEG400 (which acts also as permeation 
enhancer) was retained mainly in stratum corneum likely due to high affinity 
of ZnPc for SC lipids. In the case of ZnPc-loaded NPs, ZnPc reached dermis in 
an extent depending on the type of  dispersing medium (water, PEG400, Sepigel 
305).  
Taken together, these results highlight PEO-b-PCL NPs as a novel vehicle for 
the skin delivery of highly lipophilic compounds, such as photosensitizing 
agents, with potential in photodynamic therapy as well as in other different 
applications. 
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Introduction 
Due to its peculiar composition, stratum corneum (SC) represents the main 
barrier limiting percutaneous transport of chemical species [1]. Recently, 
research has been focused on the design of strategic approaches to improve 
topical delivery of different drugs, in order to propose innovative and non-
invasive treatment modalities for several skin diseases. It is well recognized 
that small and highly lipophilic molecules are unable to cross SC and reach the 
water-rich viable epidermis. On these bases, several chemical and physical 
strategies have been proposed so far to improve drugs transport encompassing 
the use of permeation enhancers [2;3], surfactants and organic solvents, as well 
as the application of iontophoresis [4] and electroporation [5].  
Novel drug delivery strategies aimed at increasing the topical permeation of 
lipophilic drugs, without injuring or modifying the physiological skin 
composition have been recently proposed with particular emphasis on 
nanosized carriers [6;7][8]. Vesicular systems (liposomes, surfactant), lipid-
based colloidal carriers (lipid nanocapsules and solid lipid nanoparticles), 
micelles and microemulsion are currently investigated for their potential in 
driving a drug through the skin [9;10]. The masking of a drug in a nanosized 
carrier allows effective hindering of the interactions with biological 
environment, thus overcoming intrinsic unfavorable properties of the drug 
(molecular weight, lipophilicity, ionization). If suitably engineered, 
nanocarrier properties such as size, surface charge and structure can be a 
valuable tool to control drug distribution in the skin layers [11]. As compared 
to other nanocarriers, nanoparticles based on biodegradable polymers, such as 
poly(lactic-co-glycolic acid) (PLGA) [12;13], polylactic acid (PLA)[14] and 
poly(ε-caprolactone) (PCL) [15-17] could offer a further advantage of 
sustained drug release in the skin.  
Recent studies have shown that polymeric nanocapsules or nanoparticles with 
a core-shell structure, based on amphiphilic block copolymers of  PLA, PLGA 
and PCL with various architectures, can assemble in nanostructures able to 
entrap hydrophilic and lipophilic molecules with different molecular weight. 
These NPs have been found to drive DNA and minoxidil to the viable 
epidermis and oridonin even the intravascular sites [18-20], pointing to their 
possible application as transdermal delivery platforms. This special behaviour 
is ascribed to the presence of the hydrophilic external shell with deformable 
characteristics [21], that allows overcoming of the stratum corneum barrier. It 
has been reported, in fact, that elastic particles, for example with an external 
hydrophilic PEG shell are able to distribute through the epidermis faster, while 
rigid particles were found to remain on the surface of the upper stratum 
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corneum [22]. However, it has been highlighted also that the composition and 
the molecular weight of the base copolymer, as well as the number of 
amphiphilic arms or the ratio between the blocks, can strongly modify the 
behavior and the fate of a nanocarrier through the skin [23;24]. 
The aim of this work was to highlight the potential of core-shell NPs based on 
a diblock PCL-PEO copolymer in skin delivery of drugs. To this purpose, NPs 
entrapping the second generation photosensitizer Zn(II)-phthalocyanine (ZnPc) 
as a model of highly lipophilic drug were developed. ZnPc is an active drug, 
mainly investigated for its possible application in photodynamic therapy, for 
both systemic and topical diseases [25;26]. Up to now, due its high 
lipophilicity and its disadvantageous chemical profile, no strategy has been 
still selected to allow its clinical administration. For these reasons, many 
studies have been focus on more hydrophilic phthalocyanine derivates and on 
the design of different delivery devices to achieve their possible application, 
especially in the treatment of topical lesions [27-31]. NPs were prepared by 
melting/sonication (MeSo), characterized and their distribution in the skin 
assessed on porcine skin. 
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Experimental part 
Materials 
Sepigel 305 (polyacrylamide, C13-14 isoparaffin, laureth-7) was purchased 
from Farmalabor, sodium propyl parahydroxybenzoate and 
methylparahydroxybenzoate sodium were provided from New Fa.Dem. 
Zinc(II) phthalocyanine (ZnPc, MW= 577.91), (2-hydroxypropyl)-β-
cyclodextrin (DS 0.6) (HPβCD), polysorbate 80, polyethylene glycol 400 
(PEG), potassium phosphate dibasic and potassium phosphate monobasic, 
sodium azide and sodium chloride were purchased from Sigma-Aldrich. 
Potassium hydroxide was provided from Delchimica Scientific Glassware. 
Ethanol 96°, phosphoric acid (85%), acetonitrile and tetrahydrofuran were 
purchased from Carlo ErbaReagenti (Milan, Italy). α-Methoxy,ω-hydroxy 
poly(ethyleneoxide) with Mn = 2.0 kDa, mPEO2000-OH, (Aldrich) was dried by 
azeotropic distillation from toluene. ε-Caprolactone, CL, (Aldrich) was 
distilled over CaH2 under vacuum before use. Tin(2-ethylhexanoate)2, 
Sn(Oct)2, (Aldrich), 4-(dimethylamino) pyridine, DMAP (Fluka), 1,3-
dicyclohehylcarbodiimide, DCCI (Fluka), and N-hydroxysuccinimide, NHS 
(Fluka) were used as received. 
 
Synthesis and characterization of block copolymers 
A PEO2000-PCL4300 diblock copolymer was prepared [32]. Briefly, mPEO2000-
OH and Sn(Oct)2 were used as initiator and catalyst, respectively, in the bulk 
ring-opening polymerization (ROP) of CL at 120 °C; CL/initiator molar ratio = 
38 (ηinh.= 0.28 dL xg-1 ; Mw /Mn = 1.16). 
 
ZnPc quantitative analysis 
ZnPc quantification was carried out by spectrofluorimetry on a Shimadzu RF-
1501 at EX= 610 nm and EM=668 nm.  The concentration of ZnPc was 
calculated by means of a standard calibration curve obtained on THF solutions 
of known ZnPc concentrations (7.2–720 ng/ml). The limits of quantification 
(LOQ) and detection (LOD) in THF were 3.70 and 1.11 ng/mL, respectively. 
 
Solubility determination of ZnPc 
Saturated solution of ZnPc were prepared by stirring an excess of ZnPc in PBS 
at pH 7.4 with different amounts of Polysorbate 80 and in PEG400 at room 
temperature for 72 h. The samples were then filtered through a RC (Chemtek, 
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Italy) membrane (pore size 0.22 µm) and analyzed by UV spectrophotometry 
at 666 nm. 
 
Preparation of NPs 
NPs were prepared by a slightly modified melting/sonication procedure 
previously described. Ten mg of copolymer were added to 1.8 mL of filtered 
water in a vial and poured in a water bath heated at 72±2°C to allow 
copolymer melting. ZnPc (0.2% of copolymer weight) was dissolved in 0.2 
mL of ethanol/THF 1:1 volume ratio and the solution obtained added to water 
containing melted copolymer. The mixture was sonicated for 10 min at 3 W 
(Sonicator 3000, Misonix, USA) by a microtip probe and finally cooled at 
room temperature. The organic solvent was removed under vacuum by a rotary 
evaporator for 30 min and NPs were finally collected (ZnPc-NPs). The same 
procedure was employed to prepare unloaded NPs as control. NPs were 
filtered through 0.45 µm filters (RC, Chemtek, Italy), freeze-dried for 24 h and 
kept at 4°C. HPβCD was added as excipient (10:1 mass ratio with NPs) to 
yield ZnPc/CD-NPs in powder. Recovery yield of production process was 
evaluated on an aliquot of NP dispersion (without cryoprotectant) by 
weighting the solid residue after freeze-drying. Results are expressed as the 
ratio of the actual NPs weight to the theoretical polymer weight x 100. 
 
Characterization of NPs 
Hydrodynamic diameter (DH) and polydispersity index (PI) of NPs were 
determined by Photon Correlation Spectroscopy (PCS) using a N5 Submicron 
Particle Size Analyzer (Beckman-Coulter). An NP dispersion was diluted in 
Milli-Q water at intensities in the range 104-106 counts/s and measurements 
were performed at 25°C on 90° angle. Results are reported as mean DH of three 
separate measurements of three different batches (n=9) ± standard deviation 
(SD). Size of NPs stored in the dark at 4 °C for 3 months was monitored too.  
The morphology of the nanoparticles was examined by transmission electron 
microscopy (CM 12 Philips, Eindhoven, The Netherlands) using samples 
stained with a 2% phosphotungstic acid solution. 
Zeta potential was determined by analysing a NP dispersion in water on a 
Zetasizer Nano Z (Malvern Instruments Ltd). Results are reported as mean of 
three separate measurements on three different batches (n=9) ± SD. 
ZnPc encapsulation efficiency was evaluated by dissolving a known amount of 
freeze-dried NPs (1 mg) in 1 mL of THF under magnetic stirring for 1 hour. 
Results are reported as actual loading, i.e. the amount (mg) of drug 
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encapsulated per 100 mg of nanoparticles, and entrapment efficiency, i.e. the 
ratio between actual and theoretical loading x 100 ± SD (n=6)  
 
Singlet oxygen generation 
The capacity of NPs to generate singlet oxygen was monitored over time by 
measuring photobleaching of the radical quencher ADPA [33]. Briefly, 40 µl 
of a 5 mM ADPA solution in NaOH 0.01 M was added to 2 mL of a ZnPc 
solution in water/THF 100:1 v/v, in water/PEG400 10:1 or a NP water 
dispersion ([ZnPc]=2 µg/mL; [NPs]=1 mg/mL). The sample was irradiated at 
610 nm using a 150 W ozone-free xenon-arc lamp (JobinYvon) with a slit 
width of 10 nm for different times (15, 30 and 45 min). Sample containing NPs 
was centrifuged at 16,090 ×g (Mikro 20, Hettich) for 30 min. The supernatant 
was collected and analyzed by spectrophotometry at 400 nm to evaluate ADPA 
absorption. Singlet oxygen generation was monitored by the decrease of OD at 
400 nm as a function of the irradiation time. 
Preparation of ZnPc-NPs dispersions in PEG 
A known amount of ZnPc-loaded NP water dispersion ([NPs] = 3.75 mg 
[ZnPc] = 7.5 µg) was centrifuged at 573340 xg for 40 minutes and dispersed in 
PEG400 (0.2 mL). As control, a PEG400 stock solution containing the same 
amount of ZnPc was prepared.  
Preparation of ZnPc-loaded NPs in Sepigel 305  
Sepigel 305 of medium viscosity (3% w/v) was prepared by adding preserved 
water containing sodium propyl parahydroxybenzoate (0.14% w/w) and 
sodium methyl parahydroxybenzoate (0.06% w/w) to Sepigel 305 (30 mg) 
under gentle stirring until gel formation. A known amount of ZnPc-NPs water 
dispersion obtained by MeSo ([NPs] = 3.75 mg, [ZnPc] = 7.5 µg) was mixed 
with preserved water and then added to Sepigel under gentle stirring. Another 
gel was prepared by dispersing freeze dried ZnPc/CD-NPs in preserved water 
and adding Sepigel. The control formulations with free ZnPc were prepared by 
adding 0.35 mL of PEG400 stock solution containing the same amount of ZnPc 
in the preserved water employed for Sepigel preparation.  
 
In vitro release studies 
In vitro release of ZnPc from NPs was assessed in 10 mM phosphate buffer 
containing NaCl (137 mM) and KCl (2.7 mM) at pH 7.4 (PBS) or in PEG400 by 
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a dialysis method. A known amount of NP water dispersion (corresponding to 
2.5 mg of NPs) was centrifuged at 573340 xg for 40 minutes, redispersed in 
0.5 mL of PBS or PEG400 and placed in a dialysis bag (MWCO=3500 Da, 
Spectra/Por®). The sample was plunged in 3 mL of PBS containing 10 % v/v 
of polysorbate 80 or in 5 mL of PEG400 respectively, in order to ensure sink 
conditions and to avoid ZnPc aggregation. At selected time intervals, 1 mL of 
release medium was withdrawn and replaced with an equal volume of fresh 
medium. ZnPc quantitative analysis in the sample was performed as described 
above. To understand the contribution of HPβCD on ZnPc release profile, the 
experiment was repeated on freeze dried ZnPc/CD-NPs (25 mg) dispersed in 
0.5 mL of PBS according to the above reported method.  
Release from Sepigel 305 containing ZnPc-NPs was performed on modified 
Franz diffusion cells using regenerated cellulose membranes (MWCO=3500 
Da, Spectra/Por®). A weighted amount of gel (0.5 g) was applied in the donor 
compartment. At predetermined time intervals, 1 mL of release medium in the 
receptor phase (PBS enriched with 10 % v/v of polysorbate 80) was withdrawn 
and replaced with an equal volume of fresh medium. Results are expressed as 
release % over time ± SD of three experiments.  
 
Permeation studies 
Permeation studies were carried out on free ZnPc dissolved in PEG400 or in 
Sepigel, and on ZnPc-NPs dispersed in water, with or without the addition of 
HPβCD (10:1 mass ratio with copolymer), in PEG400 or incorporated in 
Sepigel 305.  
Drug transport through porcine ear skin was assessed on Franz-type diffusion 
cells (diffusion area 0.785 cm2). Porcine ear skin was obtained from a freshly 
killed pig weighing about 100 kg slaughtered on the day of the experiment. 
After removal, the tissue was stored at 4°C and used within 2 h. The skin was 
separated from the underlying tissue using surgical scissors and mounted 
between the donor and receiver chambers of diffusion cell with stratum 
corneum (SC) facing the formulation tested. Non-occlusive conditions were 
adopted for all samples whereas for ZnPc/CD-NPs the experiment was carried 
out also in occlusive conditions. The receptor compartment was filled with a 
10 mM PBS at pH 7.4 containing 10% v/v of polysorbate 80 maintained at 32 
± 1 °C under gentle stirring. At predetermined times, 1 mL of receiving 
medium was sampled and replaced by an equivalent volume of fresh medium. 
ZnPc concentration in the receiving medium was evaluated as described above. 
Results are reported as µg/cm2 of permeated ZnPc ± SD of three experiments.  
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Skin distribution of ZnPc 
At the end of the permeation experiment (24 h), skin was collected, washed 
with a NaCl solution 0.9% w/v to eliminate any residue of the formulation and 
tape-stripped by applying a 3M-Scotch magicTM tape roll (1.5 cm × 1.5 cm). 
Complete removal of SC from the viable epidermis was indicated by the 
appearance of a white and shiny surface. First strip was separately analysed 
whereas the other 15 samples were pooled. ZnPc was extracted from the tape 
by treating the sample with 3 mL THF under magnetic stirring overnight. After 
centrifugation at 16090 xg for 30 minutes, the sample was filtered through 
0.22 µm filters (PTFE, Chemtek, Italy), and analysed for ZnPc content as 
reported above. 
The remaining skin membrane (epidermis without SC) was treated under a hot 
air flow for 60 sec. Through a surgical blade, epidermis and derma were 
separated by aid of a surgical blade and placed in separate vials. Tissues were 
hydrolyzed in KOH 1 M (2 mL) under stirring at 37°C, and then ZnPc was 
extracted in THF (2 mL) for 2 hours. Samples were centrifuged at 224 xg for 
30 minutes, and the supernatant filtered through a 0.45 µm filter before ZnPc 
quantitative analysis. Extraction technique was validated by placing known 
amounts of drug solubilized in THF in contact with tape, epidermis and derma, 
and extracting the drug. Recovery higher than 85% was always obtained. 
 
Fluorescence microscopy 
At the end of the permeation experiments, the excess formulation was removed 
from the skin surface. The skin was then washed three times with saline and 
dried gently with a cotton swab. The skin samples were fixed in 4% 
paraformaldehyde and examined without additional tissue processing. Sections 
of 20µm thickness were prepared from each sample using a microtome 
(ACCU-CUT®SRM™200 rotary microtome, Sakura Finetek, USA). Cutting 
was performed with fresh blades from the dermis side towards the epidermis in 
order to avoid dislocation of NPs from the skin surface on the section. Sections 
were finally observed by fluorescence microscopy (Leica DMRB) and a Leica 
application suite program v 2.8.1. was used for imaging. 
To ensure proper visual comparison, the exposure time was the same for all 
samples examined, including the control samples. 
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Results 
NPs based on biodegradable amphiphilic block copolymers of poly(ε-
caprolactone) (PCL) and poly(ethyleneoxide) (PEO) were prepared by a 
modified MeSo technique previously described.[32] In particular, we selected 
as base material a simple linear diblock copolymer (PEO2000-PCL4300) with 
unimodal and narrow molecular weight distribution (PI = 1.16). The second 
generation photosensitizer ZnPc was selected as fluorescence lipophilic probe 
and incorporated in NPs at 0.2% theoretical loading.  
In table 1, composition and overall properties of NPs are summarized. 
Significant differences between unloaded and ZnPc-loaded NPs were not 
observed. NPs displayed a hydrodynamic diameter around 60 nm with a low 
polydispersity index and a slightly negative zeta potential.  
 
Table 1. Composition and properties of NPs produced. 
Code Unloaded NPs ZnPc-NPs 
ZnPc (% w/w) 
- 0.2 
Yield (%) 93 86 
Mean DH (nm ± SD) 57.8 ±6.1 67.4 ±5.7 
P.I. 0.217 0.279 
Zeta Potential(mV ± SD) 
-10.3±3.3 -11.7±4.6 
ZnPc Actual loadinga 
(EE b) 
- 
0.172 ± 0.01 
(98.1 ± 1.9) 
 
aActual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of 
nanoparticles 
b
 EE (entrapment efficiency) is calculated from the ratio between actual and theoretical 
loading x 100.  
 
In the case of nanoparticles, their storage stability is a key parameters to 
consider, in order to ensure that native technological properties are maintained 
along time. Strong aggregation of ZnPc-NPs occurred after freeze-drying 
which needed a cryoprotector to be stored in solid form. The addition of 
HPβCD to NP dispersion was effective to avoid NP collapsing and to give 
original NP size after sample dispersion in an queous phase [34]. It is possible 
to note from TEM image (fig. 1) the spherical and non-aggregated morphology 
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of freeze-dried ZnPc/CD-NPs dispersed in filtered water Also the sizes of NPs 
found in TEM was in line with PCS measurements acquired immediately after 
MeSo. 
 
 
 
 
 
 
Figure 1. TEM image of freeze-dried ZnPc-NPs in HPβCD.  
 
Concerning drug loading properties of NPs, PEO-b-PCL NPs well adapt to the 
entrapment of highly lipophilic molecules giving encapsulation efficiency of 
the initial ZnPc amount around 100%.  
Due the poorly water solubility of ZnPc, we preliminarly assessed its solubility 
in different media with the final aim to find the optimized conditions to 
monitor release and carry out transport studies. The solubility of  ZnPc in 
PEG400 was high whereas in PBS at pH 7.4 containing Polysorbate 80 
depended on surfactant concentration. In particular, as evident in fig. 2, UV 
spectra of ZnPc in  polysorbate 80 showed an intense and sharp Q-band in the 
red visible region between 678 and 710 nm highlighting the absence of ZnPc 
aggregation, thus promoting its solubilization, as demonstrated for other 
cyanines [35]. 
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Figure 2. (A) Solubility of ZnPc in PBS enriched with different amounts of Polysorbate 80 and in 
PEG400. (B) UV spectra of ZnPc in THF, in PEG400 (diluition factor 5X) and PBS pH 7.4 enriched 
with different amounts of Polysorbate 80. ZnPc concentration in THF was 4 µg/mL. 
 
 
On the bases of our previous findings about the ability of PEO-PCL diblock 
NPs to slowly release poorly water soluble drugs, we performed several in 
vitro experiments to assess ZnPc release from formulations assigned to skin 
application. First of all, we monitored ZnPc release from NPs in PBS at pH 7.4 
enriched with Polysorbate 80 at 10% v/v to ensure sink conditions, thus 
Medium Solubility (µg/ml) 
PEG400 22.71 
PBS+Polysorbate 80 1% v/v 0.54 
PBS+Polysorbate 80 5% v/v 1.25 
PBS+Polysorbate 80 10% v/v 2.64 
A 
B 
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avoiding ZnPc precipitation. No detectable amount of ZnPc was found in the 
release medium after 24 hours (data not shown) thus suggesting that ZnPc was 
strongly fixed to NPs. Afterwards the experiment was repeated employing NPs 
freeze-dried with HPβCD to find out a possible influence of the excipient on 
NP release properties. Nevertheless, no ZnPc was released in the medium (data 
not shown). When incorporated in Sepigel, ZnPc was not released from NPs 
(data not shown).  Conversely, when NPs were dispersed in PEG400, about 
10% of entrapped drug was released after 24 hours (time-frame of transport 
experiment), as shown in figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Release profile of ZnPc from NPs dispersed in PEG400. Results are the mean of three 
experiments ± SD. 
 
In order to test the photodynamic activity of ZnPc dissolved in THF or PEG400 
or entrapped in NPs, singlet oxygen studies were carried out. As evidenced in 
figure 4, comparable time-dependent production of singlet oxygen was found 
for free drug both in THF (employed as control) and in PEG400 whereas for 
ZnPc-NPs, a faster ADPA bleaching was observed.  
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Figure 4. Photobleaching of ADPA by singlet oxygen generated from ZnPc-NPs and ZnPc free in 
THF or in PEG400 after photoirradiation at 610 nm ([ZnPc]=2 µg/mL). Data are reported as mean 
of three independent experiments±SD. 
To analyze the potential of core-shell PEO-b-PCL nanoparticles in skin 
trasport of ZnPc, in vitro permeation studies were carried out in non-occlusive 
conditions through porcine ear skin on Franz-type diffusion cells. Furthermore, 
ZnPc skin distribution was then evaluated in SC and skin layers (epidermis and 
dermis) after 24 h of permeation. In particular, we monitored the variation of 
NP deposition across the skin depending on the NP vehicle employed for the 
experiment (water, gel) or the presence of some permeation enhancers 
(PEG400, HPβCD).  
The composition of all formulations tested is reported in table 2. 
 
Table 2. Composition of formulations tested.  
Formulation code ZnPc (µg) PEG400 (µl) Water (µl) 
Sepigel 
(g) 
NPs 
(mg) 
ZnPc-PEG 7.5 720 - - - 
ZnPc-gel 7.5 375 - 1 - 
ZnPc-NPs/W 7.5 - 800 - 3.75 
ZnPc/CD-NPs/W 7.5 - 100 - 3.75 
ZnPc-NPs/PEG 7.5 200 - - 3.75 
ZnPc-NPs/gel 7.5 - - 1 3.75 
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In all the transport experiments, ZnPc was not detected in the receptor 
compartment despite its solubility in the receptor filling medium. Concerning 
ZnPc deposition through the skin, different results were obtained depending on 
the formulation type. 
Skin distribution of  ZnPc-NPs dispersed in water or PEG400 was compared 
with that obtained from ZnPc dissolved in PEG400 at same concentration. As 
reported in figure 5, when ZnPc was dissolved in PEG400, a similar drug 
amount was extracted by SC and E/D. Dipersion of ZnPc-NPs in PEG, instead 
gave higher accumulation in SC. In the case of ZnPc-NPs dispersed in water 
the lowest accumulation of the drug both in the SC and in E/D was detected 
after 24 h of permeation. Finally, skin permeation from ZnPc/CD-NPs resulted 
in a total skin accumulation of ZnPc even higher as compared to ZnPc 
dissolved in PEG, especially when occlusive conditions were adopted. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. ZnPc amount found in porcine ear skin after 24 h of ex vivo permeation experiment. 
ZnPc amounts in stratum corneum (SC) and in skin layers (epidermis (E) and derma (D)). Results 
are the mean of three experiments ± SD. 
 
In a second step, ZnPc accumulation in the skin after gel application was 
assessed (figure 6). ZnPc-NPs incorporated in Sepigel 305 at medium viscosity 
allowed a strong accumulation of ZnPc in the stratum corneum, which was 
similar to that observed for gel loaded with free ZnPc. The accumulation of 
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ZnPc in deeper skin layer was not very different as compared to the control, 
thus suggesting that Sepigel did not modify NPs transport through the skin.   
 
 
Figure 6. ZnPc amount found in porcine ear skin after 24 h of ex vivo permeation experiment. 
ZnPc amounts in stratum corneum (SC) and in skin deeper layers (epidermis (E) and derma (D)). 
Results are the mean of three experiments ± SD. 
 
To confirm the data obtained in the permeation studies, fluorescence 
microscopy studies of skin sections treated with the different formulations for 
24 hours were carried out. As reported in figure 7, a more marked fluorescence 
in the deeper skin layers was evident in the case of ZnPc-NPs dispersed in 
PEG400 and in a HPβCD-containing medium, whereas conversely the 
permeation of NPs dispersed in water did not induce a high skin deposition of 
the fluorescent drug. 
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Figure 7. Fluorescence microscopy of sections of in porcine ear skin treated with ZnPc-NP 
formulations after 24 h of ex vivo permeation experiment.  
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Discussion 
In this study, we investigated the suitability of small core/shell nanoparticles 
based on a linear amphiphilic diblock copolymer (PEO-b-PCL) as carrier 
system of lipophilic drugs in the skin. The second generation photosensitizer 
Zn(II)-phthalocyanine (ZnPc) was selected as model lipophilic drug  and 
fluorescent tag. In fact, ZnPc has been proposed for the photodynamic 
treatment of skin diseases, such as for example cancerous lesions. 
It is generally accepted that highly lipophilic drugs are unable to cross the 
stratum corneum due to therir high affinity with lipids. As a consequence, to 
date several technological approaches encompassing also nanotechnologies 
have emerged in order to promote skin penetration of different molecules with 
the aim to reach deeper layers. Since skin turn-over is around 30 days, NPs 
with sustained release properties can be also beneficial to exert long-term 
effect, which is useful in long-term therapies. In this scenario, biodegradable 
polymeric nanoparticles received remarkable attention as potential drug 
vehicle through the skin, recognizing their ability to protect the drugs, sustain 
its release and eventually reach also deeper skin layers, depending on 
compositions and properties.  
Spherical PEO-b-PCL core-shell nanoparticles with a small size were formed 
by the melting/sonication technique, exploiting the amphiphilic profile of 
PEO–PCL block copolymer. On the basis of our recent findings, ZnPc remains 
substantially intercalated in the polymeric matrix of NPs in monomeric form 
which is a key feature to maintain its photophysical and photodynamic 
properties. Furthermore, the addition of  HPβCD  to NP dispersion before 
freeze-drying, allowed to obtain a good storage stability of NPs, preventing 
their aggregation. [36] 
Since it was demonstrated  that the ZnPc was not released from NPs after 24 
hours, it was assumed that the drug coul act as probe of NP transport in the 
skin.[36] Furthermore, the effect of aqueous vehicles containing different 
excipients, namely HPβCD, PEG400 and Sepigel 305, and used to disperse NPs 
was evaluated. In particular, HPβCD and PEG400 were selected for their ability 
to act as permeation enhancers, whereas Sepigel 305 was chosen for its well 
known ability to incorporate lipophilic components. In all cases, no permeation 
of ZnPc occurred, in line with previous results [16] whereas a significantly 
different distribution in skin layers was evident, depending of the dispersing 
vehicle used. In particular, the accumulation of NPs dispersed in water soon 
after MeSo in the skin was very poor. This result can be easy explained by the 
continuous Brownian motion of NPs in water resulting in their weak transport 
through the skin. On the contrary, when using PEG400 as dispersing medium 
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for ZnPc-NPs, ZnPc was found in SC, viable epidermis and dermis likely due 
to transport of both free ZnPc released from NPs and ZnPc-NPs by themselves. 
This observation is in line with previous findings highlighting the permeation 
enhancing activity of PEG400 in the skin for several lipophilic drugs, including 
photosensitizing agents and phthalocyanines[37]. The comparable UV spectra 
of ZnPc in THF and in PEG400, in fact, highlight the absence of aggregation 
phenomena and the preservation of its monomeric form, suggesting the 
suitability of this medium for topical administration. Furthermore, PEG400 did 
not alter the photophysical properties of ZnPc which produced a similar yield 
of singlet oxygen as compared to an aqueous monomeric formulation. At the 
same time, previous photophysical investigations and a similar yield of singlet 
oxygen demonstrate also that NPs prevent ZnPc aggregation phenomena in 
water [36]. In spite of these advantages, the ZnPc amount that can be apply in 
a topical formulation employing PEG400 is strongly limited by its restricted 
solubility profile in this medium, thus reducing the dose that can be 
administered. 
The most remarkable result of this study  refers to the role played by HPβCD. 
In fact dispersion of ZnPc-NPs in a medium containing HPβCD, allowed a 
very high accumulation of ZnPc in the deeper skin layers. Since ZnPc as not 
released from NPs, it is likely that this accumulation refers to actual NP 
penetration in the skin. This permeation enhancer activity of HPβCD on NPs is 
presumably related to HPβCD ability to extract SC lipids, behaving as 
classical chemical permeation enhancer [38;39]. To our knowledge, this is the 
first time that HPβCD is found to promote also nanocarrier transport through 
the skin. 
To improve the applicability of NPs to skin surface, we decided to incorporate 
this nanosystem in a gel, commonly employed in pharmaceutical and cosmetic 
topical formulations. In this way, a higher accumulation of the drug in the 
external stratum corneum was detected, due to the longer residence time of the 
formulation to the shin surface, without modifying the transport of NPs 
through the skin deep layers.  
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Conclusion 
In light of our results, we can suppose that PEO-PCL NPs can be a promising 
alternative for topical application of ZnPc, especially if dispersed in HPβCD 
carrier. First of all, we can apply high amounts of NPs on skin surface 
(corresponding to higher ZnPc dosages) for their inert character. The addition 
of HPβCD can then improve the carrier permeation containing the active 
molecule, without increasing its release from NPs.  Finally Sepigel could be 
easy used to disperser NPs and to achieve a longer residence time on skin 
surface than an aqueous vehicle, due its stronger viscosity.    
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Introduction 
Gene therapy has been regarded as a promising and the ultimate cure for many 
acquired and inherited life-threatening diseases, such as cancer, genetic 
disorders, etc [1]. Despite the obvious promise shown by nucleic acids as 
therapeutic agents for cancer, such as small interfering RNA (siRNA), plasmid 
DNA (pDNA) and oligonucleotides (ODN), a number of problems need to be 
solved before their use can become commercial therapies. These are essentially 
their instability in biological media and their poor penetration into cells [2;2-4]. 
Their mechanism of action, in fact, requires that they reach the cytoplasm, but 
also on a cellular level, these molecules suffer of a strong degradation by 
lysosomal hydrolytic enzymes. Lysosomal escape is therefore an important 
factor for therapeutic effect [5]. Extensive efforts have been focused on 
overcoming these barriers, and some strategies have been reviewed lately. One 
approach is a chemical strategy that consists in synthesizing nucleic acids with 
variations in the natural structure, which give them better resistance in 
physiological media while conserving the specificity of binding to the target 
[6;7]. The second is a pharmaceutical technology approach that aims to 
associate the nucleic acid with appropriate delivery systems, which can protect 
it from degradation and modify its tissue and cellular distribution to reach the 
target [8-10]. The vectors for gene delivery are usually divided into two 
categories: viral and non-viral (or synthetic) vectors. Viruses offer greater 
efficiency of gene delivery; however, non-viral vectors are preferred due to 
safety concerns with the viral vectors [11-13]. DNA/cationic lipid (lipoplexes), 
DNA/cationic polymer (polyplexes) and DNA/cationic polymer/cationic lipid 
(lipopolyplexes) electrostatic complexes were proposed as non-viral nucleic 
acids delivery systems [14-16]. The complexes protect the genetic material 
from degradation by nucleases. Moreover, cellular and local delivery strategies 
have to deal with the need for internalization, release, and distribution in the 
proper subcellular compartment. Nevertheless, they have had limited success 
for in vivo gene downregulation, they have also exhibited a dose-dependent 
toxicity, and a low colloidal stability under physiological conditions with poor 
intracellular release of the oligonucleotides. 
On these bases, the aim of this work was to design a delivery system with a 
low toxicity profile that could be applied for a broad range of gene delivery 
applications, such as pDNA or siRNA delivery. For this purpose, we chose 
specific biomaterials, which have shown beneficial properties not only from 
the biocompatibility point of view, but also from the perspective of their 
efficacy for pDNA delivery.  
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Lecithin is a mixture of phospholipids with phosphatidylcholine (PC) as a 
main component (up to 98% w/w). Egg or soy lecithin as well as purified 
phospholipids aroused for pharmaceutical purposes as components of 
liposomes, mixed micelles and submicron emulsions [17-19]. Cui et al have 
proposed the use of lecithin for the design of nucleic acid delivery systems; 
they have achieved a significant improvement in the stability of a previously 
reported nanoparticle-based DNA delivery system using the cationic 
tensioactive CTAB (Cetyltrimethylammonium bromide). A plasmid was 
adsorbed onto the surface of the lecithin nanoparticles and was successfully 
transfected to cultured cells; however, this formulation resulted very toxic for 
the presence of the cationic surfactant [20]. The idea of the present work was 
to take advantage of lecithin’s biocompatibility along with its physicochemical 
properties for the preparation of lecithin nanoemulsions; these dispersions 
would be used then as nanocarriers for pDNA and siRNA delivery.  
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Methods 
Preparation of blank nanoemulsion 
Blank nanoemulsions were obtained by a modification of the solvent 
displacement technique. Briefly, an organic phase was formed by dissolving 2 
mg of Epikuron 80 (PC 80) or a synthetic lysophospholipid (SLP-1-octadecyl-
2-O-methyl-glycero-3-phosphocholine) in 3.2 mL of ethanol, followed by 84 
µL of Mygliol 812 with or without the addition of different amounts of 
Cholesterol and/or DC-cholesterol. This organic phase was added drop by drop 
to 10 mL of water under magnetic stirring. After 30 minutes of agitation, 
nanoemulsions were evaporated under vacuum to a final constant volume of 10 
mL. 
 
Characterization of nanoemulsion 
The hydrodynamic diameter (DH) and polydispersity index (PI) of 
nanoemulsions were determined by Photon Correlation Spectroscopy (PCS) 
using Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). A 
nanoemulsion dispersion was diluted in Milli-Q water at intensity in the range 
104-106 counts/s and measurements were performed at 25°C on 173° angle. 
Results are reported as mean DH of three separate measurements of three 
different batches (n=9) ± standard deviation (SD). Size of nanoemulsions 
stored in the dark at 4 °C for 15 days was monitored too. 
Zeta potential was determined by analysing NP dispersion in water on a 
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Results are reported 
as mean of three separate measurements of three different batches (n=3) ± SD. 
 
Haemolysis studies 
Haemolysis studies were carried out on blank nanoemulsions based on PC 80 
and SLP with or without the presence of Cholesterol and/or DC-cholesterol. 
After centrifugation of EDTA-treated human blood at 880 xg for 5 min, a red 
blood cells (RBC) dispersion was obtained and diluted with 0.1 M PBS up to a 
concentration of 10% v/v. The RBC dispersion (0.1 mL) was added to 0.9 mL 
of the nanoemulsion suspension. The concentrations of the nanoemulsion 
suspensions varied from 0.01 to 0.7 mg/mL. The sample was incubated at 37 
°C for 30 minutes and centrifuged at 1000 xg for 10 minutes. The supernatant 
was collected and analysed for haemoglobin release by spectrophotometry at 
416 nm. To obtain 0 and 100% haemolysis, 0.1 mL of RBC dispersion was 
added to 0.9 mL of PBS and distilled water, respectively. The degree of 
haemolysis was determined according to the following equation: Haemolysis 
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(%)= (ABS-ABS0)/(ABS100-ABS0) x 100, where ABS100 and ABS0 are the 
absorbance of the solution at 100% and 0% haemolysis, respectively. Results 
are reported as mean of three separate measurements of three different batches 
(n=9) ± SD. 
 
Nanoemulsion stability in human plasma 
To determine the stability of nanoemulsion under physiologically relevant 
conditions, a known amount of nanoemulsion (0.15 mL) was dispersed in 0.5 
mL of human plasma and incubated at 37 °C up to 48 hours. Human plasma 
was obtained by centrifugation of EDTA-treated human blood at 880 xg for 5 
min. Size measurements of the samples were taken by PCS. The stability of 
nanoemulsion was demonstrated by the absence of macroscopic aggregates 
and unchanged of initial particle size. 
 
pDNA and siRNA Association Efficiency 
Plasmid DNA (pDNA) or small interfering DNA (siRNA) was adsorbed on the 
surface of nanoemulsions at 1%, 2.5%,5%, 7.5% or 10% loadings, defined as 
the percentage between the mass of pDNA and the total mass of lipids 
(Epikuron 80 and Cholesterol and/or DC-cholesterol) in the formulation (mg 
of pDNA /100 mg of lipids). For the adsorption procedure, a pDNA solution 
was added to an isolated nanoemulsion suspension (200 µl) and subsequently 
vortexed for 30 seconds. Eventually, nanoemulsions were concentrated by 
vacuum evaporation. Formulations were left at room temperature under 
magnetic stirring for 1 hour to achieve an optimal interaction of the pDNA 
with the nanoemulsions.  
pDNA- and siRNA-associated nanoemulsions were characterized according to 
size and zeta potential as detailed previously. Additionally, the association of 
pDNA to the nanoemulsions was studied by a conventional agarose gel 
electrophoresis assay (1% agarose, 50 V, 120 min, Sub-Cell GT 96/192, Bio-
Rad Laboratories Ltd., England). In order to displace the pDNA adsorbed to 
the nanoemulsions, a far excess of heparin (12.5 mg/mL) was added to the 
suspension and the mixture was incubated for 2 hours. pDNA was stained with 
SYBR Gold by adding 2 µL.  
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Results and discussion 
Preparation and characterization of nanoemulsions 
In the last few years, research on the field of gene therapy has focused on the 
design of several safe non-viral vectors, which are typically based on cationic 
lipids or polymers, in order to improve the delivery efficiency and therapeutic 
effect of different nucleic acids. With this idea in mind, in this work we 
developed a lipidic nanoemulsion intended for intravenous administration, thus 
testing its properties as potential carrier system of plasmid DNA and small 
interfering RNA.  
For the preparation of nanoemulsions we employed as base materials two 
different lipids, the amphiphilic phospholipid lecithin (PC 80), widely 
employed as carrier system, and a synthetic lysophospholipid (SLP) in order to 
investigate first of all their differences concerning the toxicity profile. 
Furthermore, we incorporated in the system different amounts of Cholesterol 
or/and a cationic cholesterol (DC-Chol) in order to obtain formulations with 
different surface properties. The employment of Chol is due to the recent 
findings about its ability to enhance the serum stability of lipidic formulations, 
thus improving resistance to aggregation after intravenous administration [21]. 
DC-Chol, indeed, is the most widely used cationic lipid in liposome 
preparation and has been classified as one of the most efficient vectors for the 
transfection of pDNA into cells and in clinical trials [22;23]. It was widely 
note, in fact, that  the inclusion of cationic lipids in lipid formulations 
improves the association with polyanionic nucleic acids. Moreover, the 
presence of a positive surface charge on nucleic acid/lipid particles facilitates 
binding and uptake by cells in vitro [24;25]. However, in using cationic lipids 
it is often not clear whether all of the nucleic acid is encapsulated inside a 
bilayer envelope or whether small complexes of cationic liposome/nucleic acid 
are formed. Furthermore,when delivery systems bearing a net cationic charge 
are administered intravenously (i.v.), they exhibit rapid plasma clearance, 
distribute into lung, liver and spleen [26], and often exhibit liver and 
hemodynamic toxicities, such as activation of complement and prolongation of 
clotting times [27;28]. For these reasons, we decided to develop various 
nanoemulsions with different amounts of Chol and DC-Chol, thus 
understanding the optimized conditions for an efficient gene binding and 
delivery as well as a minimal toxicity profile.  
Unloaded nanoemulsions based on PC 80 or SLP were prepared by a modified 
solvent displacement technique, as previously described.  
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They were characterized for their size, polydispersity index and zeta potential 
(Table 1). 
 
Table 1. Composition and some properties of unloaded PC 80 and SLP nanoemulsions. 
Code PC 80 (mg) 
SLP 
(mg) 
Chol 
(mg) 
DC-
Chol 
(mg) 
Mean DH 
(nm ± a SD) P.I. 
ZP 
(mV ± a SD) 
CH: PC 1:5 2 - 0.4 - 191.9±3.9 0.1 -37.7±2.3 
CH+: PC 1:5 2 - - 0.4 192.2±5.0 0.1 +40.4±3.9 
CH+: PC 1:10 2 - - 0.2 259.8±63.9 0.2 +15.0±5.6 
CH/CH+: PC A 2 - 0.2 0.2 205.9±11.5 0.2 +19.5±4.7 
CH/CH+: PC B 2 - 0.3 0.1 precipitation - - 
CH/CH+: PC C 2 - 0.15 0.25 194.8±7.5 0.1 +25.6±5.3 
CH/CH+: PC D 2 - 0.25 0.15 232.7±5.3 0.2 +22.0±1.4 
CH/SLP 1:5 - 2 0.4 - 191.5±2.5 0.1 -26.2±4.5 
CH
+
:SLP 1:5 - 2 - 0.4 192.4±5.5 0.1 +26.6±3.2 
CH
+
:SLP 5:1 - 0.4 - 2 183.4±5.6 0.1 +24.1±1.8 
CH/CH
+
:SLP - 2 0.25 0.15 192.2±6.5 0.1 +19.7±1.5 
SLP - 2 - - 206.3±4.1 0.1 -20.5±3.3 
aSD calculated on three different batches 
 
All the formulations displayed monodispersed populations with a 
hydrodynamic diameter of around 200 nm. As expected, their zeta potential 
values were dependent on the type and the amount of Cholesterol used. The 
presence of Cholesterol induced the formation of an anionic nanoemulsion, 
whereas the addition of DC-Cholesterol allowed an inversion of the surface 
charge.  
 
Hemolysis studies 
Being designed as injectable nanomedicines, we investigated the cytotoxicity 
of developed nanoemulsions towards human red blood cells in order to 
evidence the different behavior of the two lipids. Hemolysis studies on 
developed unloaded PC and SLP with Cholesterol and/or DC-Cholesterol were 
carried out. Hemolysis was assessed in the NE concentration range from 0.01 
to 0.7 mg/mL. As shown in fig. 1, all the nanoemulsions based on PC did not 
display significant hemolysis, whereas, a strong hemolytic activity occurred 
for NE based on SLP.  In particular, it’s possible to note that the presence of 
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DC-Chol in the formulations, can control and reduce the toxicity of SLP, 
probably for the interaction of the cationic cholesterol with the phosphate 
groups of the synthetic lysophospholipid.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 . Hemolysis of red blood cells after incubation with different concentrations of NE based 
on Epikuron 80 (A) or a synthetic lysophospholipid (B). Data are reported as mean of three 
independent experiments ± SD.  
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Nanoemulsion stability  
On the bases of the results toxicity and the charge of the NEs we selected only 
formulations based on PC 80 with some specific compositions for evaluating 
the stability and later studying the association of both pDNA and siRNA. In 
particular, we selected only three formulations, CH: PC 1:5, CH+: PC 1:5 and 
CH/CH+: PC D. Their stability in the dark at 4 °C was analyzed. As shown in 
figure 2, all the formulations displayed a high stability concerning their size 
and surface  properties up to 15 days. 
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Figure 2. Stability of unloaded PC-nanoemulsions in terms of size (panel A) and zeta potential (B) 
in the dark at 4 °C.Data are reported as mean of three independent experiments ± SD.  
 
Nanoemulsion stability in human plasma  
One of the strongest drawback of a nanomedicine following intravenous 
administration, is the stability  in the biological fluids. In fact, nanocarriers  
tend to adsorb plasma components such as opsonins, which mediate 
nanoparticle recognition by monocytes and subsets of tissue macrophages  and 
opsonized nanoparticles tend to be rapidly cleared from the circulation by 
phagocytic cells of RES.  
For this reason, we investigated the stability of NE dispersions in human 
plasma monitoring the change of their hydrodinamic diameters up to 72 hours 
of incubation  by PCS. The experiment was carry out only on cationic 
nanoemulsions, being eventually employed in the adsorption of nucleic acids.  
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Figure 3. Stability of nanoemulsions in the presence in human plasma (70 µg/mL). Data are 
reported as mean of three independent experiments ± SD.  
 
As clearly shown in figure 3, both unloaded CH+:PC and  CH/CH+:PC D 
nanoemulsions displayed a comparable behavior  in the presence of proteins, 
showing a slight increase of their size, which remained always around 200 nm.  
On the other hand, results are suggestive that NE do not undergo aggregation 
or disassembly in biologically-relevant conditions. 
 
pDNA Association Efficiency 
Following, the ability of nanoemulsions to interact with plasmid DNA (pDNA) 
was tested. In particular, pDNA was adsorbed on the surface of the systems at 
different loadings. pDNA-associated nanoemulsions were then characterized in 
term of size and zeta potential, whereas the association of the pDNA was 
determined by gel electrophoresis assays.  
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Table 2.  Properties of pDNA-associated PC 80-nanoemulsions. 
Code pDNA 
 (% w/w) 
Mean DH 
(nm ± SD)       P.I. 
    Zeta Potential 
      (mV ± SD) 
CH: PC pDNA 5% 5 211.2±6.2 0.2 -27.0±3.5 
CH: PC pDNA 7.5% 7.5 215.4±7.1 0.1 -29.4±2.3 
CH: PC pDNA 10% 10 216.3±4.0 0.1 -31.4±6.4 
CH+: PC pDNA 5% 5 precipitation - - 
CH+: PC pDNA 7.5% 7.5 213.0±2.4 0.1 -11.9±4.3 
CH+: PC pDNA 10% 10 218.7±11.7 0.1 -16.8±5.4 
CH/CH+: PC D pDNA 5% 5 233.6±5.5 0.2 -14.2±0.1 
CH/CH+: PC D pDNA 7.5% 7.5 223.4±7.6 0.3 -15.4±7.2 
CH/CH+: PC D pDNA 10% 10 230.4±26.4 0.1 -19.4±3.0 
aSD calculated on three different batches 
 
Concerning PC-nanoemulsions containing only Cholesterol, the addition of 
pDNA did not modify the size and the polydispersity index of the 
nanodroplets, as shown in Table 2, whereas a strongly inversion of zeta 
potential was observed, depending of the amount of the pDNA added.  
Nevertheless, pDNA was not adsorbed on the surface of nanemulsion, as 
evidenced by gel electrophoresis assay (fig.4).  
 
 
 
 
Figure 4. Gel electrophoresis of naked pDNA, pDNA-loaded CH:PC nanoemulsions and at 5%, 
7.5% and 10% loading pDNA/nanoemulsions, without and after treatment with heparin. 
 
 1= Naked pDNA (0.5 µg) 
2= CH:PC pDNA 5% 
3= CH:PC pDNA 7.5% 
4= CH:PC pDNA 10% 
5= CH:PC 1:5 pDNA 5% +hep 
6= CH:PC 1:5 pDNA 7.5% +hep 
7= CH:PC 1:5 pDNA 10% +hep 
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On the contrast, the presence of cationic DC-Cholesterol, as shown in  the 
figure 5, allowed the interaction of pDNA: in particular a slight adsorption at 
7.5% theoretical loading, and a complete association at 5% theoretical loading 
on NE surface was observed, due to the electrostatic binding between the 
cationic charge of the DC-Chol and the negative charge of the phosphate group 
of the pDNA. In spite of these results, the addition of pDNA at 5% theoretical 
loading induced a strong precipitation of the system (table 2).  
 
 
 
 
 
 
Figure 5. Gel electrophoresis of naked pDNA, pDNA-loaded CH+:PC nanoemulsions and at 5%, 
7.5% and 10% loading pDNA/nanoemulsions, without and after treatment with heparin. 
 
Finally, we tested the nanoemulsion containing both Cholesterol and DC-
Cholesterol. In this case, we observed good properties in all cases (table 2) and 
some delay on the pDNA migration that suggest a slight but not complete 
association of pDNA at 5% theoretical loading (fig. 6). 
 
 
  
1= Naked pDNA (0.5 µg)  
2= CH+:PC pDNA 5%  
3= CH+:PC pDNA 7.5%  
4= CH+:PC pDNA 10%  
5= CH+:PCpDNA 5% +hep 
6= CH+:PCpDNA 7.5% +hep 
7= CH+:PCpDNA 10% +hep 
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Figure 6. Gel electrophoresis of naked pDNA, pDNA-loaded CH/CH+:PC D 
nanoemulsions and at 5%, 7.5% and 10% loading pDNA/nanoemulsions, without and 
after treatment with heparin. 
On the bases of these preliminary results, we selected the combined 
CH/CH+:PC D nanoemulsion as possible formulation to deliver nucleic acids. 
Then, we decided to analyze the stability of the pDNA-associated complex. It 
displayed a high stability in terms of size and zeta potential up to 15 days, as 
the unloaded formulation (fig. 7).  
 
 
 
 
1= ladder                                                 
2= Naked pDNA (0.5 mg)  
3= CH/CH+: PC D pDNA 5%  
4= CH/CH+: PC D pDNA 7.5% 
5= CH/CH+: PC D pDNA 10% 
6= Naked pDNA (0.5 mg) + hep 
7= CH/CH+: PC D pDNA 5% + hep 
8= CH/CH+: PC D pDNA 7.5% +hep 
9= CH/CH+: PC D pDNA 10%+ hep 
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Figure 7. Stability of unloaded CH/CH+:PC D pDNA 5% nanoemulsions in terms of size (panel 
A) and zeta potential (B) in the dark at 4 °C. Data are reported as mean of three independent 
experiments ± SD.  
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siRNA-associated nanoemulsions 
Small interfering RNAs face similar pharmacokinetic and cell penetration 
limitations of plasmid DNA. Besides the common delivery tasks, structural 
and chemical aspects of the pDNA and siRNA molecules also need to be 
considered. Both are double-stranded nucleic acids with anionic 
phosphodiester backbones. The negative charge allows electrostatic 
interactions with cationic polymers or lipids that condense the nucleic acids 
into polyplexes or lipoplexes with nanometric sizes. However, the ability to 
form these stable complexes differs greatly because of different properties 
regarding size, structure and chemistry of the pDNA and siRNA molecules. 
Plasmid DNA has a size of several kilobp, while siRNA has only about 21 to 
23 bp and consequently shows less electrostatic interactions with polycations 
[29]. Thus, a preliminary formulation study was devoted to test the association 
of siRNA on PC nanoemulsions and the technological properties of the 
complexes were evaluated. On the basis of results obtained by the association 
of pDNA, we selected only the formulations containing the cationic DC-
cholesterol, trying to adsorb five different amounts of siRNA. 
 
Table 3. Properties of siRNA-associated PC 80-nanoemulsions. 
Code 
 
pDNA (% 
w/w) 
Mean DH 
(nm ± aSD) P.I.
Zeta 
Potential 
(mV ± aSD) 
CH+: PC siRNA 1%  1 210.8±4.7 0.2 24.7±3.9 
CH+: PC siRNA2.5%  2.5 203.1±2.0 0.1 14.7±3.4 
CH+: PC siRNA 5%  5 precipitation - - 
CH+: PC siRNA 7.5%  7.5 precipitation - - 
CH+: PC siRNA 10%  10 precipitation - - 
CH/CH+: PC D siRNA 1%  1 precipitation - - 
CH/CH+: PC DsiRNA 2.5%  2.5 precipitation - - 
CH/CH+: PC D siRNA 5%  5 precipitation - - 
CH/CH+: PC DsiRNA 7.5%  7.5 precipitation - - 
CH/CH+: PC DsiRNA 10%  10 precipitation - - 
aSD calculated on three different batches 
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As evidenced in the table 4, only the CH+:PC nanoemulsion allowed the 
adsorption of siRNA but at low theoretical loading (1% and 2.5%). In the other 
cases, in fact, a fast precipitation of the nanoemulsions was observed.  
Conclusions 
We demonstrated that lipidic nanoemulsions based on the amphiphilic 
phospholipid lecithin are suitable for iv administration for their high stability 
in human plasma and the safe profile toward human red blood cells. However, 
in spite of the presence of a cationic surface, the association of plasmid DNA 
and small interfering RNA is not too high. Thus, for an eventual clinical 
application in gene therapy more work still needs to be done to optimize the 
formulations.   
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